

# CITATION REPORT

List of articles citing

**Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT**

**DOI: 10.1182/blood-2005-05-2004**  
**Blood, 2005, 106, 2912-9.**

**Source:** <https://exaly.com/paper-pdf/38008375/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2169	Non-HLA immunogenetics in hematopoietic stem cell transplantation. <b>2005</b> , 17, 517-25		75
2168	Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. <b>2006</b> , 43, 107-17		31
2167	Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?. <b>2006</b> , 3, 668-81		258
2166	Issues of aging and geriatric medicine: relevance to cancer treatment and hematopoietic reconstitution. <b>2006</b> , 12, 100-6		6
2165	Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. <b>2006</b> , 12, 573-84		75
2164	Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. <b>2006</b> , 12, 954-64		108
2163	Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. <b>2006</b> , 12, 1047-55		161
2162	Transplant strategies for patients with myelodysplastic syndromes. <b>2006</b> , 13, 61-6		10
2161	Optimizing conditioning regimens for autologous and allogeneic progenitor cell transplantation. <b>2006</b> , 11, 46-53		
2160	A risk score for mortality after allogeneic hematopoietic cell transplantation. <b>2006</b> , 144, 407-14		149
2159	Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. <b>2006</b> , 135, 201-9		48
2158	Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). <b>2006</b> , 37, 547-52		14
2157	Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?. <b>2006</b> , 38, 585-92		23
2156	Autologous hematopoietic stem cell transplants that utilize total body irradiation can safely be carried out entirely on an outpatient basis. <b>2006</b> , 38, 757-64		20
2155	Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. <b>2006</b> , 20, 128-35		202
2154	Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. <b>2006</b> , 20, 1661-72		105
2153	The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. <b>2006</b> , 20, 235-44		19

2152	Hematopoietic stem cell transplantation in autoimmune diseases: is the glass half full or half empty?. <b>2006</b> , 54, 3730-4		16
2151	Outcomes with myeloid malignancies. <b>2006</b> , 2006, 381-9		5
2150	Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. <b>2006</b> , 24, 4150-7		88
2149	Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. <b>2006</b> , 13, 26-41		57
2148	Treatment of acute myeloid leukemia in older patients. <b>2007</b> , 7, 285-95		20
2147	Bone Marrow and Peripheral Blood Stem Cell Transplantation. <b>2007</b> , 787-822		
2146	Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2. <b>2007</b> , 2007, 47-54		7
2145	Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. <b>2007</b> , 25, 25-31		64
2144	Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. <b>2007</b> , 92, 533-41		67
2143	Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. <i>Blood</i> , <b>2007</b> , 110, 3064-70	2.2	449
2142	Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. <i>Blood</i> , <b>2007</b> , 110, 4606-13	2.2	262
2141	Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. <b>2007</b> , 19, 660-6		13
2140	Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. <b>2007</b> , 14, 145-51		38
2139	Reduced-intensity stem cell transplantation for hematological malignancies: current status and the future. <b>2007</b> , 2, 149-62		6
2138	Measures of Morbidity: Functional Assessment and Cytokines. <b>2007</b> , 13, 98-102		3
2137	Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. <b>2007</b> , 13, 87-97		58
2136	Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. <b>2007</b> , 13, 355-65		155
2135	Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. <b>2007</b> , 13, 932-41		26

2134	Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. <b>2007</b> , 13, 1041-8	19
2133	Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. <b>2007</b> , 13, 1499-507	37
2132	Allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome (MDS). <b>2007</b> , 33, S6-S10	1
2131	Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. <b>2007</b> , 25, 4246-54	320
2130	Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. <b>2007</b> , 82, 867-72	46
2129	Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation. <b>2007</b> , 25, 170-7	7
2128	Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. <b>2007</b> , 109, 1376-83	129
2127	Modified Charlson comorbidity index for predicting survival after liver transplantation. <b>2007</b> , 13, 1515-20	110
2126	Predicting the future?. <b>2007</b> , 13, 1503-5	5
2125	Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. <b>2007</b> , 39, 279-83	35
2124	Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. <b>2007</b> , 40, 209-17	48
2123	The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. <b>2007</b> , 136, 624-7	187
2122	Expanding the role of umbilical cord blood transplantation. <b>2007</b> , 137, 20-35	112
2121	Allogreffe de cellules souches h�matopo�iques avec conditionnement �intensit�r�duite: situation en 2007 et perspectives. <b>2007</b> , 9, 842-847	
2120	Stem cell transplantation for myelodysplastic syndromes: the lure of a cure. <b>2007</b> , 2, 3-8	
2119	Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia. <b>2007</b> , 2, 34-42	1
2118	[Individualized management and therapy of myelodysplastic syndromes]. <b>2008</b> , 120, 523-37	5
2117	Symptom burden after autologous stem cell transplantation for multiple myeloma. <b>2008</b> , 112, 1617-24	33

2116	Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. <b>2008</b> , 112, 1992-2001	199
2115	Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. <b>2008</b> , 83, 717-20	18
2114	Prognostic relevance of anemia in myelodysplastic syndromes. <b>2008</b> , 83, 761-2	3
2113	Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach. <b>2008</b> , 22, 293-302	21
2112	Impact of comorbidity indexes on non-relapse mortality. <b>2008</b> , 22, 2062-9	50
2111	Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. <b>2008</b> , 22, 1377-86	71
2110	Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. <b>2008</b> , 41, 953-60	55
2109	Reduced-intensity umbilical cord blood transplant for older adult patients. <b>2008</b> , 42, 685-6	3
2108	Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. <b>2008</b> , 41, 33-8	52
2107	High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. <b>2008</b> , 41, 721-7	53
2106	Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. <b>2008</b> , 41, 425-37	12
2105	Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. <b>2008</b> , 41, 887-93	17
2104	Choosing between stem cell therapy and drugs in myelofibrosis. <b>2008</b> , 22, 474-86	49
2103	Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens. <b>2008</b> , 10, 252-9	20
2102	Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. <b>2008</b> , 141, 235-43	41
2101	Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. <b>2008</b> , 142, 11-26	101
2100	Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. <b>2008</b> , 143, 395-403	87
2099	Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. <b>2008</b> , 38, 945-52	40

2098	Acute myeloid leukemia in the elderly. <b>2008</b> , 35, 430-8	54
2097	Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality. <b>2008</b> , 35, 449-57	32
2096	Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?. <b>2008</b> , 21, 67-77	9
2095	What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?. <b>2008</b> , 21, 691-7	27
2094	Acute Myeloid Leukemia in Older Patients: Special Problems and Possible Solutions. <b>2008</b> , 2, 237-240	
2093	A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. <b>2008</b> , 14, 28-35	48
2092	Risk-adjusted outcome measurement in pediatric allogeneic stem cell transplantation. <b>2008</b> , 14, 335-43	19
2091	Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. <b>2008</b> , 14, 282-9	105
2090	Impact of acute kidney injury on long-term mortality after nonmyeloablative hematopoietic cell transplantation. <b>2008</b> , 14, 309-15	40
2089	Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. <b>2008</b> , 14, 538-45	45
2088	Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. <b>2008</b> , 14, 556-67	30
2087	Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. <b>2008</b> , 14, 583-90	77
2086	Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine. <b>2008</b> , 14, 651-7	17
2085	Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation. <b>2008</b> , 14, 658-63	25
2084	Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. <b>2008</b> , 14, 840-6	75
2083	Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. <b>2008</b> , 14, 985-992	57
2082	Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. <b>2008</b> , 14, 1039-1044	45
2081	Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. <b>2008</b> , 14, 1209-16	69

2080	Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). <b>2008</b> , 14, 1217-25	109
2079	Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. <b>2008</b> , 14, 1279-87	215
2078	Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction. <b>2008</b> , 14, 1312-6	14
2077	Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. <b>2008</b> , 14, 1401-7	36
2076	Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience. <b>2008</b> , 2, 198-204	9
2075	The origin of increasing utilization of hematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (SAD). Introduction. <b>2008</b> , 41, 556-62	4
2074	Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. <b>2008</b> , 8, 785-98	5
2073	Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. <b>2008</b> , 326-33	49
2072	The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. <b>2008</b> , 13, 119-27	21
2071	Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <b>2008</b> , 26, 4912-20	228
2070	Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. <b>2008</b> , 26, 211-7	172
2069	Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia. <b>2008</b> , 14, 5585-93	22
2068	High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. <b>2008</b> , 19, 1166-71	36
2067	Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. <i>Blood</i> , <b>2008</b> , 111, 446-52	2.2 165
2066	Impact of age and comorbidity in myelodysplastic syndromes. <b>2008</b> , 6, 927-34	26
2065	Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. <b>2008</b> , 93, 1806-13	113
2064	Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. <b>2008</b> , 93, 1837-42	79
2063	Myelodysplastic syndromes: diagnosis and staging. <b>2008</b> , 15 Suppl, 4-13	38

2062	Practical aspects and procedures, including conditioning protocols and haploidentical transplantation. 235-300	
2061	[Influence of comorbidities on decision caring of malignant haematological diseases]. <b>2009</b> , 96, 563-70	3
2060	Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. <b>2009</b> , 301, 2349-61	612
2059	The myelodysplastic syndromes. <b>2009</b> , 71-79	
2058	Allotransplantation for chronic lymphocytic leukemia. <b>2009</b> , 602-9	26
2057	Optimal sequencing of treatments for patients with myelodysplastic syndromes. <b>2009</b> , 16, 77-83	9
2056	Diabetes mellitus is associated with high early-mortality and poor prognosis in patients with autoimmune hemolytic anemia. <b>2009</b> , 14, 361-5	11
2055	Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. <b>2009</b> , 16, 140-6	13
2054	Role of hematopoietic stem cell transplant in the management of follicular lymphoma. <b>2009</b> , 14, 726-38	8
2053	Acute myeloid leukemia. <b>2009</b> , 25-33	
2052	Acquired aplastic anemia and Fanconi anemia. <b>2009</b> , 165-176	1
2051	Patient selection: preliminary interview, screening of patient and donor. <b>2009</b> , 213-220	
2050	Reduced-intensity conditioning for allogeneic stem cell transplantation. <b>2009</b> , 287-291	
2049	Management of the older patient. <b>2009</b> , 303-312	
2048	Acute myelogenous leukemia in older adults. <b>2009</b> , 14, 222-32	76
2047	Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. <b>2009</b> , 83, 519-27	57
2046	Mutation analysis of hepcidin and ferroportin genes in Italian prospective blood donors with iron overload. <b>2009</b> , 84, 592-3	6
2045	The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease. <b>2009</b> , 84, 594-6	15



2044	Identification of <i>Chlamydia trachomatis</i> in a patient with ocular lymphoma. <b>2009</b> , 84, 597-9	9
2043	Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. <b>2009</b> , 84, 599-600	34
2042	Progressive transition of Epstein-Barr virus associated lymphoproliferative disease subtypes with the development of lung cancer. <b>2009</b> , 84, 600-3	5
2041	Sickle cell disease caused by heterozygosity for Hb S and novel LCR deletion: Report of two patients. <b>2009</b> , 84, 603-6	15
2040	The clonality of CD3+ CD10+ T cells in angioimmunoblastic T cell lymphoma, B cell lymphoma, and reactive lymphoid hyperplasia. <b>2009</b> , 84, 606-8	8
2039	Impact of the basal metabolic ratio in predicting early deaths after allogeneic stem cell transplantation. <b>2009</b> , 84, 608-11	4
2038	Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. <b>2009</b> , 27, 148-53	37
2037	Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic models. <b>2009</b> , 115, 2472-81	20
2036	[Hematopoietic stem cell transplantation. Indications, foundations and perspective]. <b>2009</b> , 50, 572-80	5
2035	The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. <b>2009</b> , 145, 318-32	122
2034	The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. <b>2009</b> , 23, 1131-8	93
2033	Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. <b>2009</b> , 43, 133-9	62
2032	Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. <b>2009</b> , 43, 717-23	41
2031	In pursuit of the allo-immune response in multiple myeloma: where do we go from here?. <b>2009</b> , 43, 91-9	7
2030	Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. <b>2009</b> , 43, 839-43	63
2029	Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens. <b>2009</b> , 43, 949-51	9
2028	Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. <i>Blood</i> , <b>2009</b> , 114, 1429-36	2.2 67
2027	NanoLC-MS/MS analyses of urinary desmosine, hydroxylslylpyridinoline and lysylpyridinoline as biomarkers for chronic graft-versus-host disease. <b>2009</b> , 81, 9454-61	10

2026	Possible association between obesity and posttransplantation complications including infectious diseases and acute graft-versus-host disease. <b>2009</b> , 15, 73-82	42
2025	Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. <b>2009</b> , 15, 101-8	45
2024	Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. <b>2009</b> , 15, 195-204	100
2023	Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. <b>2009</b> , 15, 214-22	34
2022	Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. <b>2009</b> , 15, 223-30	37
2021	Impacts of pretransplant comorbidities on allogeneic hematopoietic cell transplantation (HCT) outcomes. <b>2009</b> , 15, 149-53	26
2020	Incidence and risk factors of early bacterial infections after unrelated cord blood transplantation. <b>2009</b> , 15, 439-46	34
2019	Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility?. <b>2009</b> , 15, 447-53	21
2018	What is the role for donor natural killer cells after nonmyeloablative conditioning?. <b>2009</b> , 15, 580-8	50
2017	Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences. <b>2009</b> , 15, 757-8	36
2016	Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT. <b>2009</b> , 15, 758-60	7
2015	Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. <b>2009</b> , 15, 1094-9	15
2014	Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. <b>2009</b> , 15, 1265-70	27
2013	Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts. <b>2009</b> , 15, 1314-22	25
2012	Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. <b>2009</b> , 15, 1394-9	44
2011	Non-myeloablative allogeneic hematopoietic stem cell transplantation. <b>2009</b> , 25, 120-8	7
2010	Acute complications of stem cell transplant. <b>2009</b> , 25, 129-38	14
2009	Principles and overview of allogeneic hematopoietic stem cell transplantation. <b>2009</b> , 144, 1-21	14

2008	Aging, acute myelogenous leukemia, and allogeneic transplantation: do they belong in the same sentence?. <b>2009</b> , 9, 289-97		5
2007	An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. <b>2009</b> , 2009, 704928		12
2006	The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia. <b>2009</b> , 3, 47-57		
2005	Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation. <b>2009</b> , 5, 559-68		8
2004	Umbilical cord blood transplantation for acute myeloid leukemia. <b>2009</b> , 16, 124-8		7
2003	New insights in the management of elderly patients with acute myeloid leukemia. <b>2009</b> , 21, 589-93		18
2002	The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. <b>2009</b> , 94, 729-32		75
2001	Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. <b>2009</b> , 94, 602-6		35
2000	Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. <i>Blood</i> , <b>2009</b> , 113, 4771-9	2.2	64
1999	Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. <i>Blood</i> , <b>2009</b> , 113, 1375-82	2.2	129
1998	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. <i>Blood</i> , <b>2009</b> , 113, 3383-91	2.2	87
1997	Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. <i>Blood</i> , <b>2009</b> , 113, 2902-5	2.2	96
1996	Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. <b>2010</b> , 95, 476-84		116
1995	Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions. <b>2010</b> , 22, 150-4		2
1994	Allogeneic transplantation for lymphoma: long-term outcome. <b>2010</b> , 17, 522-30		8
1993	Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents. <b>2010</b> , 17, 104-9		4
1992	Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care?. <b>2010</b> , 17, 133-8		15
1991	A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia. <b>2010</b> , 95, 810-8		54

1990	Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. <i>Blood</i> , <b>2010</b> , 115, 4018-20	2.2	52
1989	Who is fit for allogeneic transplantation?. <i>Blood</i> , <b>2010</b> , 116, 4762-70	2.2	71
1988	A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. <i>Blood</i> , <b>2010</b> , 116, 971-8	2.2	135
1987	Successful allogeneic bone marrow transplantation for diamond-blackfan anemia complicated by severe cardiac dysfunction due to transfusion-induced hemochromatosis. <b>2010</b> , 49, 453-6		1
1986	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , <b>2010</b> , 115, 453-74	2.2	2483
1985	[Comorbidity oriented oncology - an overview]. <b>2010</b> , 122, 203-18		2
1984	Impact of hospital volume on clinical outcomes of endoscopic biliary drainage for acute cholangitis based on the Japanese administrative database associated with the diagnosis procedure combination system. <b>2010</b> , 45, 1090-6		17
1983	Allogeneic stem cell transplantation (SCT) in Ph+ CML: still a therapeutic option?. <b>2010</b> , 3, 16-18		1
1982	Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation. <b>2010</b> , 91, 310-21		
1981	Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype. <b>2010</b> , 91, 436-45		14
1980	Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center. <b>2010</b> , 91, 661-9		19
1979	C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation. <b>2010</b> , 92, 161-7		13
1978	Facteurs psychosociaux: impact sur l'indication de greffe de moelle osseuse. <b>2010</b> , 4, 244-249		4
1977	Acute myeloid leukemia: when to transplant in first complete remission. <b>2010</b> , 5, 101-8		9
1976	Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. <b>2010</b> , 38, 1241-50		33
1975	Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. <b>2010</b> , 116, 852-62		10
1974	On estimating basal metabolic rate from body mass: a potential pitfall in predicting post operative survival. <b>2010</b> , 85, 829-30; author reply 830		1
1973	Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?. <b>2010</b> , 85, 829		1

1972	The basal metabolic ratio: A sensitive index for predicting early death after allogeneic stem cell transplantation. <b>2010</b> , 85, 830-830	
1971	Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. <b>2010</b> , 150, 170-8	36
1970	Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. <b>2010</b> , 24, 1276-82	81
1969	Eosinophilia predicts better overall survival after acute graft-versus-host-disease. <b>2010</b> , 45, 371-7	18
1968	Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. <b>2010</b> , 45, 450-7	29
1967	Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act. <b>2010</b> , 45, 419-21	8
1966	Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study. <b>2010</b> , 45, 513-20	23
1965	Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. <b>2010</b> , 45, 633-9	38
1964	Myeloablative hematopoietic stem cell transplantation for myelodysplastic syndrome in patients younger than 55 years: impact of comorbidity and disease burden on the long-term outcome. <b>2010</b> , 32, 222-9	18
1963	Hematopoietic cell transplantation in older adults. 260-273	4
1962	Hematopoietic stem cell transplantation. <b>2010</b> , 3, 105-17	44
1961	Role of comorbidities in optimizing decision-making for allogeneic hematopoietic cell transplantation. <b>2010</b> , 2, e2010015	1
1960	Allogeneic transplantation for chronic lymphocytic leukemia. <b>2010</b> , 2, e2010026	2
1959	Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. <b>2010</b> , 28, 2859-67	163
1958	Iron overload in patients undergoing hematopoietic stem cell transplantation. <b>2010</b> , 2010,	33
1957	Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. <b>2010</b> , 28, 405-11	238
1956	Older patients with acute myeloid leukemia. <b>2010</b> , 3, 755-74	2
1955	Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms. <b>2010</b> , 3, 23-33	2

1954	Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. <i>Blood</i> , <b>2010</b> , 116, 4439-43	2.2	190
1953	Acute Myelogenous Leukemia. <b>2010</b> ,		
1952	Single-agent larmustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. <b>2010</b> , 28, 815-21		60
1951	A modified comorbidity index for hematopoietic cell transplantation. <b>2010</b> , 45, 933-8		19
1950	Does location matter? Rural vs urban outcomes after blood and marrow transplantation in a population-based Canadian cohort. <b>2010</b> , 45, 1167-73		11
1949	How we approach patient evaluation for hematopoietic stem cell transplantation. <b>2010</b> , 45, 1259-68		59
1948	Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. <b>2010</b> , 21, 114-9		91
1947	Comorbidities and hematopoietic cell transplantation outcomes. <b>2010</b> , 2010, 237-47		40
1946	Hematopoietic stem cell transplantation in patients with chronic kidney disease. <b>2010</b> , 30, 602-14		22
1945	Hematopoietic stem cell transplantation for MDS. <b>2010</b> , 24, 407-22		27
1944	Prognostic classification and risk assessment in myelodysplastic syndromes. <b>2010</b> , 24, 459-68		34
1943	Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. <b>2010</b> , 16, 413-20		53
1942	Larmustine (cloretazine). <b>2010</b> , 11, 657-67		4
1941	Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome. <b>2010</b> , 2010, 325-9		17
1940	Dose intensity of preparative regimens for acute myeloid leukemia - one-size-fits-all or tailor-made?. <b>2010</b> , 23, 509-17		8
1939	Influence of pretransplantation restrictive lung disease on allogeneic hematopoietic cell transplantation outcomes. <b>2010</b> , 16, 199-206		16
1938	Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial. <b>2010</b> , 16, 384-94		38
1937	Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. <b>2010</b> , 16, 792-800		68

1936	Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. <b>2010</b> , 16, 838-47		170
1935	Prognostic factor and quality of life analysis in 160 patients aged > or =60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation. <b>2010</b> , 16, 967-75		36
1934	Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults. <b>2010</b> , 16, 1442-50		53
1933	Factors associated with self-reported physical and mental health after hematopoietic cell transplantation. <b>2010</b> , 16, 1682-92		34
1932	Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. <i>Blood</i> , <b>2010</b> , 116, 2438-47	2.2	240
1931	Reduced mortality after allogeneic hematopoietic-cell transplantation. <b>2010</b> , 363, 2091-101		1102
1930	Patient selection for transplantation in the myelodysplastic syndromes. <b>2010</b> , 24, 469-76		6
1929	Chronic lymphocytic leukemia: planning for an aging population. <b>2010</b> , 10, 1389-94		30
1928	Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. <b>2010</b> , 51, 1502-8		12
1927	Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. <b>2011</b> , 96, 441-9		180
1926	Therapeutic advances in acute myeloid leukemia. <b>2011</b> , 29, 487-94		581
1925	Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure?. <b>2011</b> , 11 Suppl 1, S46-8		4
1924	Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making?. <b>2011</b> , 11, 342-9		9
1923	Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency. <b>2011</b> , 128, 1371-1374.e2		31
1922	Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments. <b>2011</b> , 71, 155-77		14
1921	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. <i>Blood</i> , <b>2011</b> , 118, 6438-45	2.2	137
1920	Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. <b>2011</b> , 17, 341-50		80
1919	Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation. <b>2011</b> , 17, 394-400		27

1918	Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. <b>2011</b> , 17, 384-93	18
1917	Childhood obesity and outcomes after bone marrow transplantation for patients with severe aplastic anemia. <b>2011</b> , 17, 737-44	20
1916	Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. <b>2011</b> , 17, 831-40	49
1915	Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. <b>2011</b> , 17, 421-8	13
1914	Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. <b>2011</b> , 17, 908-15	91
1913	Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. <b>2011</b> , 17, 1250-4	62
1912	Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. <b>2011</b> , 17, 1327-34	47
1911	The prognostic value of YKL-40 concentrations in nonmyeloablative conditioning allogeneic hematopoietic cell transplantation. <b>2011</b> , 17, 1299-307	7
1910	Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: a study of 455 patients. <b>2011</b> , 17, 1653-61	13
1909	Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. <b>2011</b> , 17, 1114-20	50
1908	The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index. <b>2011</b> , 17, 1822-32	28
1907	Comorbidities and outcomes: advancing the field comes at a price. <b>2011</b> , 17, 1721-3	5
1906	[Allogeneic hematopoietic stem cell transplantations]. <b>2011</b> , 18, 235-45	2
1905	Immunophenotyping of the Blast Cells in Correlations with the Molecular Genetics Analyses for Diagnostic and Clinical Stratification of Patients with Acute Myeloid Leukemia: Single Center Experience. <b>2011</b> ,	
1904	Identifying older patients with acute myeloid leukemia who may be candidates for reduced-intensity hematopoietic cell transplantation. <b>2011</b> , 9, 319-29; quiz 330	3
1903	Effect of hospital volume on clinical outcome in patients with acute pancreatitis, based on a national administrative database. <b>2011</b> , 40, 1018-23	35
1902	An observational study using a national administrative database to determine the impact of hospital volume on compliance with clinical practice guidelines. <b>2011</b> , 49, 313-20	28
1901	Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). <b>2011</b> , 96, 1433-40	192



1900	The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. <i>Blood</i> , <b>2011</b> , 117, 2137-45	2.2	306
1899	Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. <i>Blood</i> , <b>2011</b> , 117, 2728-34	2.2	54
1898	Fluorouracil, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. <i>Blood</i> , <b>2011</b> , 118, 1132-9	2.2	56
1897	Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. <i>Blood</i> , <b>2011</b> , 118, 4258-64	2.2	48
1896	Insufficient recovery of thymopoiesis predicts for opportunistic infections in allogeneic hematopoietic stem cell transplant recipients. <b>2011</b> , 96, 1846-54		45
1895	Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. <b>2011</b> , 96, 1457-61		49
1894	Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. <b>2011</b> , 96, 349-52		17
1893	Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. <b>2011</b> , 18, 237-45		30
1892	Outcome of hematopoietic stem cell transplant in children with congenital heart disease. <b>2011</b> , 15, 75-80		3
1891	Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). <b>2011</b> , 152, 331-9		85
1890	Allogeneic transplantation for Hodgkin's lymphoma. <b>2011</b> , 152, 261-72		20
1889	Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. <b>2011</b> , 153, 76-82		43
1888	The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. <b>2011</b> , 59, 1837-46		92
1887	Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. <b>2011</b> , 25, 75-81		39
1886	Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia. <b>2011</b> , 25, 1548-54		16
1885	High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. <b>2011</b> , 46, 20-6		32
1884	Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia. <b>2011</b> , 86, 237-45		3
1883	A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants. <b>2011</b> , 86, 305-16		24

1882	Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine. <b>2011</b> , 35, e164-6		4
1881	Facteurs d'isessionnels dans l'indication d'allogreffe: la perception des infirmiers. <b>2011</b> , 5, 251-255		3
1880	Three decades of transplantation for chronic myeloid leukemia: what have we learned?. <i>Blood</i> , <b>2011</b> , 117, 755-63	2.2	80
1879	Successful allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia during respiratory failure and invasive mechanical ventilation. <b>2011</b> , 123, 354-8		2
1878	Evaluation of compliance with the Tokyo Guidelines for the management of acute cholangitis based on the Japanese administrative database associated with the Diagnosis Procedure Combination system. <b>2011</b> , 18, 53-9		22
1877	The search for better prognostic models in myelodysplastic syndromes. <b>2011</b> , 6, 13-21		9
1876	Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant. <b>2011</b> , 57, 499-505		7
1875	There's more to surviving transplant than remission. <b>2011</b> , 57, 359-60		
1874	Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience. <b>2011</b> , 29, 107-10		2
1873	Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. <b>2011</b> , 29, 202-10		12
1872	Controversies surrounding iron chelation therapy for MDS. <b>2011</b> , 25, 17-31		38
1871	Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. <b>2011</b> , 35, 159-62		33
1870	Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. <b>2011</b> , 35, 757-61		8
1869	[Allogeneic hematopoietic stem cell transplantation in elderly]. <b>2011</b> , 98, 915-25		3
1868	A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies. <b>2011</b> , 22, 1865-71		8
1867	What is the upper age limit for performing allo-SCT? Cord blood transplantation for an 82-year-old patient with AML. <b>2011</b> , 46, 619-20		2
1866	Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. <b>2011</b> , 46, 557-61		18
1865	Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4). <b>2011</b> , 46, 1326-30		8

1864	Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. <b>2011</b> , 46, 1418-25		14
1863	Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. <b>2011</b> , 1, e35		82
1862	Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends. <b>2011</b> , 49 Suppl 1, S13-6		11
1861	Aggressive disease, aggressive treatment: the adult hematopoietic stem cell transplant patient in the intensive care unit. <b>2011</b> , 22, 349-64		6
1860	Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?. <b>2011</b> , 29, 805-13		152
1859	The neuropsychological course of acute delirium in adult hematopoietic stem cell transplantation patients. <b>2011</b> , 26, 98-109		13
1858	Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. <i>Blood</i> , <b>2011</b> , 118, 2351-7	2.2	130
1857	Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <b>2011</b> , 126, 30-9		15
1856	Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. <b>2011</b> , 306, 1874-83		216
1855	Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. <b>2011</b> , 55, 1953-60		66
1854	Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. <b>2011</b> , 29, 2240-6		110
1853	Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. <b>2011</b> , 29, 1190-7		270
1852	The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. <b>2011</b> , 96, 1678-84		56
1851	Prognostic factors in allo-SCT of elderly patients with AML. <b>2011</b> , 46, 545-51		12
1850	The Myelodysplastic Syndromes. <b>2011</b> ,		
1849	Renal failure in multiple myeloma: a medical emergency. <b>2011</b> , 46, 771-83		21
1848	Assignment of scores for the hematopoietic cell transplantation comorbidity index: integer vs exact weights. <b>2011</b> , 46, 464-6		8
1847	Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation. <b>2011</b> , 46, 516-22		22

1846	Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma. <b>2011</b> , 46, 827-34	15
1845	Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT. <b>2011</b> , 46, 1000-5	29
1844	Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG. <b>2011</b> , 46, 1077-83	12
1843	Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution. <b>2011</b> , 46, 690-701	17
1842	Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over. <b>2011</b> , 46, 1219-25	23
1841	Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. <b>2012</b> , 47, 494-8	49
1840	A prognostic score with pretransplant serum ferritin and disease status predicts outcome following reduced-intensity SCT. <b>2012</b> , 47, 596-7	6
1839	Validation of pretransplantation assessment of mortality risk score in the outcome of hematopoietic SCT in non-Caucasians. <b>2012</b> , 47, 1075-81	9
1838	Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. <b>2012</b> , 47, 212-6	17
1837	Clinical significance of hemophagocytosis in BM clot sections during the peri-engraftment period following allogeneic hematopoietic SCT. <b>2012</b> , 47, 387-94	15
1836	Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning. <b>2012</b> , 47, 1343-9	8
1835	Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. <b>2012</b> , 367, 135-45	203
1834	The clinical role of procalcitonin in hematopoietic SCT. <b>2012</b> , 47, 1326-31	21
1833	Predictors of health-related quality of life in patients treated with auto- and allo-SCT for hematological malignancies. <b>2012</b> , 47, 757-69	59
1832	Are reduced-intensity transplants safe in older patients with hematologic malignancies?. <b>2012</b> , 5, 149-52	
1831	Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). <b>2012</b> , 23, 166-171	45
1830	A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. <b>2012</b> , 97, 393-401	188
1829	Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia. <b>2012</b> , 17, 53-8	23

1828	A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. <b>2012</b> , 97, 1882-9		72
1827	New treatment approaches in acute myeloid leukemia: review of recent clinical studies. <b>2012</b> , 7, 224-37		6
1826	Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. <b>2012</b> , 97, 423-7		17
1825	Hematopoietic stem cell and natural killer cell transplantation. 527-548		
1824	Should transplantation be an option in elderly patients with myelodysplastic syndromes?. <b>2012</b> , 1, 107-110		
1823	Acute myeloid leukemia in the elderly. <b>2012</b> , 1, 57-69		1
1822	The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. <i>Blood</i> , <b>2012</b> , 119, 2657-64	2.2	116
1821	Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. <i>Blood</i> , <b>2012</b> , 120, 1327-33	2.2	72
1820	A disease risk index for patients undergoing allogeneic stem cell transplantation. <i>Blood</i> , <b>2012</b> , 120, 905-13		259
1819	Risk assessment for acute kidney injury after allogeneic hematopoietic stem cell transplantation based on Acute Kidney Injury Network criteria. <b>2012</b> , 51, 2105-10		38
1818	Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?. <b>2012</b> , 26, 247-54		11
1817	Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia. <b>2012</b> , 159, 82-7		43
1816	Wczesna niehematologiczna toksyczność po chemioterapii w wysokich dawkach i autologicznym przeszczepieniu komórek krwiotwórczych u chorych na nowotwory limfoidalne powyżej 60. roku życia. <b>2012</b> , 43, 210-214		
1815	Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. <b>2012</b> , 18, 1600-7		21
1814	Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant. <b>2012</b> , 53, 96-102		17
1813	Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of <i>abnl(17p)</i> and <i>-5/5q-</i> . <i>Blood</i> , <b>2012</b> , 120, 2521-8	2.2	49
1812	Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoietic progenitor cell transplantation. <b>2012</b> , 47, 528-34		29
1811	Comorbidity and geriatric assessment for older patients with hematologic malignancies: A review of the evidence. <b>2012</b> , 3, 49-57		19

1810	A prospective study comparing the outcomes and health-related quality of life in adult patients with myeloid malignancies undergoing allogeneic transplantation using myeloablative or reduced-intensity conditioning. <b>2012</b> , 18, 113-24	28
1809	Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. <b>2012</b> , 18, 289-94	48
1808	Pretransplantation assessments and symptom profiles: predicting transplantation-related toxicity and improving patient-centered outcomes. <b>2012</b> , 18, 497-504	6
1807	From biology to clinical practice: aging and hematopoietic cell transplantation. <b>2012</b> , 18, S40-5	15
1806	T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. <b>2012</b> , 18, 937-43	21
1805	Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. <b>2012</b> , 18, 1099-107	44
1804	Prognostic factors for therapy-related acute myeloid leukaemia (t-AML)--a single centre experience. <b>2012</b> , 66, 285-92	5
1803	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. <b>2012</b> , 9, 579-90	303
1802	Outcome of therapy-related myeloid neoplasms treated with azacitidine. <b>2012</b> , 5, 44	37
1801	Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation. <b>2012</b> , 26, E513-21	15
1800	Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study. <b>2012</b> , 47, 46-53	26
1799	Myelofibrosis 2012: it's complicated. <b>2012</b> , 3, 131-46	4
1798	How to manage polycythemia vera. <b>2012</b> , 26, 870-4	7
1797	Overview of myelodysplastic syndromes. <b>2012</b> , 49, 287-94	6
1796	Allogeneic hematopoietic cell transplantation in mantle cell lymphoma. <b>2012</b> , 25, 165-74	4
1795	Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia. <b>2012</b> , 66, 578-82	8
1794	Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. <b>2012</b> , 12, 38-48	25
1793	Ruxolitinib treatment for myelofibrosis. <b>2012</b> , 9, 178-181	

1792	Nutrition chez le patient adulte atteint de cancer: place de la nutrition artificielle dans la prise en charge des patients atteints de cancer. <b>2012</b> , 26, 278-295		10
1791	Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. <b>2012</b> , 36, 1147-51		39
1790	[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations]. <b>2012</b> , 138, 119.e1-9		1
1789	Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?. <b>2012</b> , 5, 395-407		9
1788	Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I). <b>2012</b> , 8, 1254-64		8
1787	Stem Cells and Cancer Stem Cells, Volume 6. <b>2012</b> ,		2
1786	NT-pro-BNP: not the prognostic all-rounder in elderly patients undergoing allogeneic stem cell transplantation. <b>2012</b> , 91, 1929-35		4
1785	Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients. <b>2012</b> , 91, 1363-70		11
1784	Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL-positive ALL. <b>2012</b> , 2, e72		21
1783	Leukemia and Related Disorders. <b>2012</b> ,		3
1782	Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. <b>2012</b> , 47, 1552-7		4
1781	Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. <b>2012</b> , 47, 1274-82		36
1780	Discharge needs of allogeneic transplantation recipients. <b>2012</b> , 16, E142-9		16
1779	Chronic Lymphocytic Leukemia: Allogeneic Stem Cell Transplantation. <b>2012</b> , 353-364		
1778	The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. <i>Blood</i> , <b>2012</b> , 119, 5584-90	2.2	84
1777	Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. <b>2012</b> , 91, 1579-86		25
1776	Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia. <b>2012</b> , 29, 1077-81		22
1775	Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy. <b>2012</b> , 95, 291-8		9

1774	Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting. <b>2012</b> , 156, 273-5	10
1773	Single-institution long-term outcomes for patients receiving nonmyeloablative conditioning hematopoietic cell transplantation for chronic lymphocytic leukemia and follicular lymphoma. <b>2012</b> , 89, 151-9	6
1772	Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for Myelodysplastic Syndromes. <b>2012</b> , 36, 132-9	13
1771	The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients. <b>2012</b> , 36, 479-82	37
1770	Allogeneic stem cell transplantation for myelofibrosis in 2012. <b>2012</b> , 157, 413-25	43
1769	Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. <b>2012</b> , 158, 174-185	22
1768	Guideline for the diagnosis and management of myelofibrosis. <b>2012</b> , 158, 453-71	76
1767	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. <b>2012</b> , 158, 506-14	18
1766	A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group. <b>2012</b> , 14, 141-8	37
1765	A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. <b>2012</b> , 118, 410-7	19
1764	Pulmonary function testing prior to reduced intensity conditioning allogeneic stem cell transplantation in an unselected patient cohort predicts posttransplantation pulmonary complications and outcome. <b>2012</b> , 87, 9-14	15
1763	Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. <b>2012</b> , 87, 433-5	31
1762	Liver iron overload assessment by T *2 magnetic resonance imaging in pediatric patients: an accuracy and reproducibility study. <b>2012</b> , 87, 435-7	14
1761	Clinical impact of pre-transplant pulmonary impairment on survival after allogeneic hematopoietic stem cell transplantation. <b>2012</b> , 18, 11-6	
1760	Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status. <b>2012</b> , 60, 31-41	5
1759	Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. <b>2012</b> , 91, 47-55	20
1758	Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. <b>2013</b> , 6, 32	52
1757	Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. <b>2013</b> , 6, 29	45



1756	Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia. <b>2013</b> , 125, 50-3	2
1755	Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. <b>2013</b> , 48, 1415-20	24
1754	Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies. <b>2013</b> , 30, 373-81	9
1753	Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. <b>2013</b> , 92, 1397-403	15
1752	Allogeneic hematopoietic stem cell transplantation for patients with mildly reduced renal function as defined based on creatinine clearance before transplantation. <b>2013</b> , 92, 255-60	6
1751	Body mass index and bioelectrical impedance phase angle as potentially modifiable nutritional markers are independent risk factors for outcome in allogeneic hematopoietic cell transplantation. <b>2013</b> , 92, 111-9	39
1750	Myelodysplastic Syndromes. <b>2013</b> ,	
1749	Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. <b>2013</b> , 19, 429-34	88
1748	The impact of pretransplant hypoalbuminemia on survival in patients with leukemia who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT): a nutritional problem?. <b>2013</b> , 45, 3371-4	11
1747	Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. <b>2013</b> , 19, 973-80	31
1746	Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. <b>2013</b> , 13, 541-51	62
1745	Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch. <b>2013</b> , 19, 1167-74	13
1744	Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. <b>2013</b> , 19, 1374-80	64
1743	Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. <i>Blood</i> , <b>2013</b> , 122, 1678-84	2.2 54
1742	Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. <b>2013</b> , 6, 547-62	23
1741	Comorbidity burden in patients with chronic GVHD. <b>2013</b> , 48, 1429-36	15
1740	Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. <b>2013</b> , 37, 998-1003	67
1739	Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. <b>2013</b> , 31, 3883-8	35

1738	Feasibility of clofarabine cyto-reduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia. <b>2013</b> , 92, 1379-88	28
1737	Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis. <b>2013</b> , 27, E21-9	15
1736	Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index. <b>2013</b> , 48, 1253-6	12
1735	Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. <b>2013</b> , 48, 346-50	71
1734	The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. <b>2013</b> , 5, 13	41
1733	Comparison of characteristics of bacterial bloodstream infection between adult patients with allogeneic and autologous hematopoietic stem cell transplantation. <b>2013</b> , 19, 994-9	21
1732	Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status. <b>2013</b> , 88, 1074-81	17
1731	Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure. <b>2013</b> , 48, 678-83	14
1730	Hematopoietic stem cell transplantation practice variation among centers in the Eastern Mediterranean Region (EMRO): Eastern Mediterranean Bone Marrow Transplantation (EMBT) group survey. <b>2013</b> , 6, 14-9	20
1729	Ostra biańczka szpikowa u osó w wieku podeszłym. <b>2013</b> , 44, 75-84	1
1728	Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. <b>2013</b> , 19, 1340-7	20
1727	Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects. <b>2013</b> , 19, 792-8	22
1726	Single cord blood combined with HLA-mismatched third party donor cells: comparable results to matched unrelated donor transplantation in high-risk patients with hematologic disorders. <b>2013</b> , 19, 143-9	26
1725	Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. <b>2013</b> , 19, 82-6	5
1724	Outcome of allogeneic peripheral blood stem cell transplantation by donor graft CD3+/Tregs ratio: a single-center experience. <b>2013</b> , 19, 495-9	16
1723	Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation. <b>2013</b> , 19, 1361-7	22
1722	Biobehavioral influences on recovery following hematopoietic stem cell transplantation. <b>2013</b> , 30 Suppl, S68-74	44
1721	Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies. <b>2013</b> , 19, 597-601	6

1720	T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. <b>2013</b> , 31, 1310-6	387
1719	Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. <b>2013</b> , 31, 4431-7	46
1718	Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. <b>2013</b> , 19, 474-80	9
1717	Heart failure after allogeneic hematopoietic stem cell transplantation. <b>2013</b> , 167, 2502-6	8
1716	Feasibility of frequent patient-reported outcome surveillance in patients undergoing hematopoietic cell transplantation. <b>2013</b> , 19, 450-9	35
1715	The role of comorbidities in chronic myeloid leukemia. <b>2013</b> , 37, 729-30	7
1714	A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation. <b>2013</b> , 19, 799-803	58
1713	Impact of antithymocyte globulin on the need for platelet transfusions during reduced-intensity conditioning administration before allogeneic stem cell transplantation. <b>2013</b> , 41, 503-5	2
1712	Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. <b>2013</b> , 19, 1087-93	11
1711	Nonmalignant late effects in survivors of partially matched donor hematopoietic stem cell transplantation. <b>2013</b> , 19, 777-83	8
1710	Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. <b>2013</b> , 19, 1713-8	55
1709	The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation. <b>2013</b> , 37, 1052-6	6
1708	Allogeneic stem cell transplantation in MDS: how? When?. <b>2013</b> , 26, 421-9	9
1707	Prognostic risk score for the survival of elderly patients with acute myeloid leukaemia comprising comorbidities. <b>2013</b> , 30, 394	10
1706	Lymphodepletion chemotherapy followed by donor leukocytes for post-transplantation relapse of myelofibrosis after previous donor leukocyte infusion failure. <b>2013</b> , 90, 76-8	
1705	The Myelodysplastic Syndromes. <b>2013</b> , 487-518	1
1704	Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation. <b>2013</b> , 88, 477-84	24
1703	Consensus-based definition of unfitnes to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. <b>2013</b> , 27, 997-9	51

1702 Novel conditioning regimens for bone marrow transplantation. **2013**, 1

1701 The role of hematopoietic SCT in adult Burkitt lymphoma. **2013**, 48, 617-29

2

1700 Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation. **2013**, 19, 1029-34

21

1699 Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. **2013**, 6, 767-84

22

1698 To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. **2013**, 48, 1497-505

62

1697 Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age. **2013**, 13, 404-9

5

1696 A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. **2013**, 19, 1040-5

13

1695 Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation. **2013**, 19, 283-90

24

1694 «SI ne s'agissait que d'en mourir» Enjeux éthiques de l'indication d'allogreffe. **2013**, 10, 3-8

2

1693 Stem cell transplantation in non-Hodgkin lymphomas. **2013**, 182-195

1692 Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit. **2013**, 31, 4207-14

54

1691 Older patients/older donors: choosing wisely. **2013**, 2013, 70-5

7

1690 Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress?. **2013**, 38, 73-84

12

1689 Decitabine for the treatment of acute myeloid leukemia. **2013**, 1, 661-673

3

1688 Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry. **2013**, 48, 529-36

50

1687 Practice variation in physician referral for allogeneic hematopoietic cell transplantation. **2013**, 48, 63-7

50

1686 Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR. **2013**, 48, 1450-5

19

1685 The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. **2013**, 48, 1409-14

52

1684	Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation. <b>2013</b> , 2013, 565824	7
1683	Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study. <b>2013</b> , 48, 1342-9	57
1682	Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. <b>2013</b> , 2, 489	19
1681	Transplantation for myelodysplastic syndromes 2013. <b>2013</b> , 20, 494-500	8
1680	Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. <b>2013</b> , 20, 150-6	13
1679	When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome/acute myeloid leukemia. <b>2013</b> , 31, 822-3	10
1678	High-dose cyclophosphamide therapy associated with diffuse alveolar hemorrhage after allogeneic hematopoietic stem cell transplantation. <b>2013</b> , 86, 453-61	5
1677	Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. <b>2013</b> , 2013, 414959	8
1676	The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. <b>2013</b> , 88, 497-502	27
1675	Predictors of anxiety and depression in hematopoietic stem cell transplant patients during protective isolation. <b>2013</b> , 22, 1790-7	35
1674	Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. <b>2013</b> , 88, 642-6	46
1673	Improved outcomes using G-CSF-mobilized blood and bone marrow grafts as the source of stem cells compared with G-PB after HLA-identical sibling transplantation in patients with acute leukemia. <b>2013</b> , 27, 844-51	11
1672	Proposed score for survival of patients with myelodysplastic syndromes. <b>2013</b> , 43, 1120-8	10
1671	Longitudinal follow-up of nutritional status and its influencing factors in adults undergoing allogeneic hematopoietic cell transplantation. <b>2013</b> , 48, 446-51	39
1670	Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. <b>2013</b> , 27, 362-9	80
1669	Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia. <b>2013</b> , 27, 2068-72	18
1668	Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. <b>2013</b> , 31, 1530-8	164
1667	Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. <b>2013</b> , 52, 63-70	34

1666	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). <i>Blood</i> , <b>2013</b> , 122, 1974-82	2.2	69
1665	How I assess comorbidities before hematopoietic cell transplantation. <i>Blood</i> , <b>2013</b> , 121, 2854-63	2.2	153
1664	Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. <i>Blood</i> , <b>2013</b> , 121, 4287-94	2.2	258
1663	Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. <b>2013</b> , 98, 208-16		143
1662	Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society. <b>2013</b> , 68, 253-62		2
1661	Prognostic factors and treatment of acute myeloid leukemias in adults (except for APL). <b>2013</b> , 19, 69-77		
1660	[Leukemia: recent progress in diagnosis and treatment. Topics: III. Diagnosis and treatments; 7. Hematopoietic stem cell transplantation for leukemia: complications]. <b>2013</b> , 102, 1737-43		
1659	Practical aspects and procedures, including conditioning protocols and haploidentical transplantation. 235-287		
1658	Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms. <b>2013</b> , 48, 178-84		20
1657	Hematopoietic stem cells allogeneic transplant. <b>2013</b> , 19, 288-296		1
1656	Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy. <b>2014</b> , 7, 101-8		1
1655	Hematopoietic Cell Transplantation for Older Patients with MDS. <b>2014</b> , 6, e2014056		1
1654	Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation. <b>2014</b> , 3, 3		4
1653	Comparison of reduced conditionings combining fludarabine with melphalan or 3-day busulfan in patients allografted for myeloid neoplasms. <b>2014</b> , 100, 582-91		4
1652	Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa. <b>2014</b> , 49, 1193-7		3
1651	Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors. <b>2014</b> , 49, 185-9		13
1650	Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning. <b>2014</b> , 49, 1162-9		27
1649	Value of liver elastography and abdominal ultrasound for detection of complications of allogeneic hemopoietic SCT. <b>2014</b> , 49, 806-11		16

1648	The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma. <b>2014</b> , 49, 1323-9	19
1647	Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT. <b>2014</b> , 49, 332-7	62
1646	A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies. <b>2014</b> , 55, 2739-47	8
1645	Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia. <b>2014</b> , 55, 1274-80	3
1644	Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. <b>2014</b> , 49, 11-6	10
1643	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. <b>2014</b> , 2014, 21-33	29
1642	Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. <b>2014</b> , 49, 1505-12	53
1641	Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia. <b>2014</b> , 2014, 8-13	26
1640	Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. <b>2014</b> , 99, 1486-91	23
1639	Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia. <b>2014</b> , 55, 2211-2	4
1638	Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. <b>2014</b> , 99, 308-13	28
1637	Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation. <b>2014</b> , 49, 1310-6	44
1636	Donor T-cell chimerism and early post-transplant cytomegalovirus viremia in patients treated with myeloablative allogeneic hematopoietic stem cell transplant. <b>2014</b> , 16, 61-6	3
1635	Getting fit for allogeneic hematopoietic cell transplantation. <b>2014</b> , 49, 1249-50	1
1634	Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. <b>2014</b> , 49, 895-901	34
1633	Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. <b>2014</b> , 99, 1762-8	24
1632	Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease. <b>2014</b> , 28, 1023-35	5
1631	Transplants in myelodysplastic syndromes. <b>2014</b> , 28, 1011-22	3

1630	Validation of the European Group for Blood and Marrow Transplantation (EBMT) risk score in patients receiving allogeneic hematopoietic stem cell transplantation at a single center in Japan. <b>2014</b> , 28, 403-9	5
1629	Predictive value of risk assessment scores in patients with hematologic malignancies undergoing reduced-intensity conditioning allogeneic stem cell transplantation. <b>2014</b> , 89, E138-41	6
1628	Outcomes of allogeneic haemopoietic stem cell transplants at a small New Zealand centre: does size matter?. <b>2014</b> , 44, 683-9	
1627	Hematopoietic stem cell transplantation-50 years of evolution and future perspectives. <b>2014</b> , 5, e0028	89
1626	Allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes. <b>2014</b> , 26, 642-9	4
1625	Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?. <b>2014</b> , 21, 114-22	6
1624	A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic V $\beta$ V $\alpha$ T cells. <b>2014</b> , 37, 321-30	16
1623	Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution. <b>2014</b> , 2014, 853435	6
1622	Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis. <b>2014</b> , 9, e114735	25
1621	Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. <b>2014</b> , 25, 447-54	31
1620	The role of hypomethylating agents in the treatment of elderly patients with AML. <b>2014</b> , 5, 89-105	42
1619	Kidney Disease in Patients Undergoing Hematopoietic Cell Transplantation. <b>2014</b> , 73-104	0
1618	Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. <b>2014</b> , 20, 724-9	120
1617	A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. <b>2014</b> , 20, 354-60	28
1616	High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia. <b>2014</b> , 20, 801-5	20
1615	Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. <b>2014</b> , 20, 337-44	60
1614	"To combine or not to combine": optimizing risk assessment before allogeneic hematopoietic cell transplantation. <b>2014</b> , 20, 1455-6	9
1613	Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease. <b>2014</b> , 20, 1341-8	43



1612	Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial. <b>2014</b> , 89, 243-8	12
1611	Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. <b>2014</b> , 31, 869	24
1610	Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience. <b>2014</b> , 126, 23-9	3
1609	Guidelines for the diagnosis and management of adult myelodysplastic syndromes. <b>2014</b> , 164, 503-25	69
1608	First application of the EBMT risk score in double umbilical cord blood transplantation for hematologic malignancies: significant impact on different outcomes. <b>2014</b> , 42, 161-2	5
1607	High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells. <b>2014</b> , 14, 140-7	18
1606	Clinical nutrition guidelines of the French Speaking Society of Clinical Nutrition and Metabolism (SFNEP): Summary of recommendations for adults undergoing non-surgical anticancer treatment. <b>2014</b> , 46, 667-74	46
1605	Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. <b>2014</b> , 5, 299-306	17
1604	Having a sibling as donor: patients' experiences immediately before allogeneic hematopoietic stem cell transplantation. <b>2014</b> , 18, 436-42	5
1603	ACE deletion polymorphism is associated with a high risk of non-infectious pulmonary complications after stem cell transplantation. <b>2014</b> , 99, 175-83	2
1602	Solid organ transplantation following end-organ failure in recipients of hematopoietic stem cell transplantation in children. <b>2014</b> , 29, 1337-47	2
1601	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. <b>2014</b> , 15, 87-95	100
1600	Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. <b>2014</b> , 25, 171-6	42
1599	Chronic myeloid leukemia-transplantation in the tyrosine kinase era. <b>2014</b> , 28, 1037-53	11
1598	Hematopoietic stem cell transplantation for non-Hodgkin lymphoma. <b>2014</b> , 28, 1073-95	16
1597	Quality of life and outcomes in patients >60 years of age after allogeneic hematopoietic cell transplantation. <b>2014</b> , 49, 1426-31	14
1596	A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. <b>2014</b> , 89, 83-7	20
1595	Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. <b>2014</b> , 20, 2004-9	41

1594	Urinary liver-type fatty acid-binding protein linked with increased risk of acute kidney injury after allogeneic stem cell transplantation. <b>2014</b> , 20, 2010-4	14
1593	[Hematopoietic stem cell transplantation: bone marrow and blood stem cells]. <b>2014</b> , 55, 1306-12	
1592	Evaluation of the pretransplantation workup before allogeneic transplantation. <b>2014</b> , 20, 1852-6	6
1591	Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. <b>2014</b> , 20, 1975-81	167
1590	[Pulmonary alveolar proteinosis]. <b>2014</b> , 31, 975-91	15
1589	Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate-dose alemtuzumab-based conditioning. <b>2014</b> , 20, 1722-8	9
1588	The skinny on obesity and plasma cell myeloma: a review of the literature. <b>2014</b> , 49, 1009-15	26
1587	Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. <b>2014</b> , 49, 1475-80	38
1586	The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML. <b>2014</b> , 49, 1498-504	10
1585	Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning. <b>2014</b> , 20, 1758-66	39
1584	Clinical and genetic predictors of prognosis in myelodysplastic syndromes. <b>2014</b> , 99, 956-64	71
1583	A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies. <b>2014</b> , 49, 955-60	2
1582	Anti-HLA antibodies other than against HLA-A, -B, -DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies. <b>2014</b> , 20, 1634-40	28
1581	Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. <b>2014</b> , 32, 3249-56	273
1580	Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy. <b>2014</b> , 20, 1553-9	22
1579	Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. <b>2014</b> , 93, 1825-38	73
1578	High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. <b>2014</b> , 20, 684-9	29
1577	Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. <b>2014</b> , 20, 1864-8	49

1576	Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. <b>2014</b> , 28, 658-65	92
1575	The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). <b>2014</b> , 38, 1184-90	53
1574	Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. <b>2014</b> , 49, 1170-5	25
1573	Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation. <b>2014</b> , 20, 2062-6	8
1572	Results of allogeneic stem cell transplantation in the Spanish MDS registry: prognostic factors for low risk patients. <b>2014</b> , 38, 1199-206	6
1571	A pediatric prognostic score for patients undergoing allogeneic hematopoietic stem cell transplantation. <b>2014</b> , 93, 509-15	3
1570	Umbilical cord blood as an alternative source of reduced-intensity hematopoietic stem cell transplantation for chronic Epstein-Barr virus-associated T or natural killer cell lymphoproliferative diseases. <b>2014</b> , 20, 214-21	14
1569	Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. <b>2014</b> , 38, 1165-72	10
1568	Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. <b>2014</b> , 20, 1274-81	16
1567	Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations. <b>2014</b> , 20, 908-19	22
1566	Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion. <b>2014</b> , 20, 1322-8	11
1565	Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. <b>2014</b> , 20, 370-4	37
1564	Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. <b>2014</b> , 20, 402-408.e1	79
1563	Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. <b>2014</b> , 20, 1363-8	47
1562	Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. <b>2014</b> , 20, 1516-21	36
1561	Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. <b>2014</b> , 5, 238-44	14
1560	Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation. <b>2014</b> , 20, 66-72	34
1559	Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic. <b>2014</b> , 12, 128-36	36

1558	Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <b>2014</b> , 99, 916-21		49
1557	Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. <b>2014</b> , 99, 1095-100		74
1556	A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. <b>2014</b> , 99, 1624-31		32
1555	Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. <b>2014</b> , 99, 1373-9		157
1554	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. <i>Blood</i> , <b>2014</b> , 123, 2333-42	2.2	119
1553	Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. <i>Blood</i> , <b>2014</b> , 123, 3664-71	2.2	528
1552	The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , <b>2014</b> , 124, 1174-82	2.2	531
1551	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. <i>Blood</i> , <b>2014</b> , 124, 3841-9	2.2	158
1550	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. <i>Blood</i> , <b>2014</b> , 124, 3817-27	2.2	128
1549	Building the graph of medicine from millions of clinical narratives. <b>2014</b> , 1, 140032		43
1548	Stem cell transplants for myelodysplastic syndromes: refining the outcome predictions. <b>2014</b> , 99, 1536-7		
1547	Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell Transplantation. <b>2015</b> , 20, 1290-7		29
1546	Spanning the canyon between stem cell transplantation and palliative care. <b>2015</b> , 2015, 484-9		17
1545	Use of transplantation in lymphoma. <b>2015</b> , 23-29		
1544	Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. <i>Blood</i> , <b>2015</b> , 125, 1333-8	2.2	298
1543	A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. <i>Blood</i> , <b>2015</b> , 126, 478-85	2.2	33
1542	[Comprehensive assessment of comorbidity in the elderly]. <b>2015</b> , 13 Suppl 1, 7-12		3
1541	Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. <b>2015</b> , 100, 269-74		22

1540	New diagnostic method for lysosomal acid lipase deficiency and the need to recognize its manifestation in infants (Wolman disease). <b>2015</b> , 60, e22-4	10
1539	Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. <b>2015</b> , 8, 85	29
1538	Haploidentical stem cell transplantation in patients aged 50 yr and older with leukemia: similar outcomes compared to younger adults. <b>2015</b> , 29, 523-30	11
1537	Instability of HCT-CI scoring system caused by the different equation for hemoglobin correction of diffusion capacity of carbon monoxide. <b>2015</b> , 4, 108-114	
1536	Atypical manifestation of carnitine palmitoyltransferase 1A deficiency: hepatosplenomegaly and nephromegaly. <b>2015</b> , 60, e19-22	6
1535	Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. <b>2015</b> , 170, 574-83	29
1534	Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <b>2015</b> , 121, 3709-16	22
1533	Validating the allogeneic stem cell transplantation disease risk index: sample size, follow-up, and local data are important. <b>2015</b> , 99, 128-32	10
1532	Effects of physical exercise on survival after allogeneic stem cell transplantation. <b>2015</b> , 137, 2749-56	59
1531	Pretransplant metabolic distress predicts relapse of acute myeloid leukemia after allogeneic stem cell transplantation. <b>2015</b> , 99, 1065-71	17
1530	Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease. <b>2015</b> , 171, 411-6	9
1529	Autologous Transplant in Lymphoma: Experience in a Limited Resource Mexican Reference Center. <b>2015</b> , 06,	
1528	Enhanced International Prognostic Index (NCCN-IPI), Charlson Comorbidity Index and absolute lymphocyte count as predictors for survival of elderly patients with diffuse large B cell lymphoma treated by immunochemotherapy. <b>2015</b> , 62, 988-95	11
1527	Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation. <b>2015</b> , e398-412	8
1526	Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients. <b>2015</b> , 4, 488-503	14
1525	La maladie veino-occlusive ¶ syndrome d¶bstruction sinus¶ale Mise ¶jour 2014. <b>2015</b> , 21, 35-41	0
1524	Weight Loss and Decrease of Body Mass Index during Allogeneic Stem Cell Transplantation Are Common Events with Limited Clinical Impact. <b>2015</b> , 10, e0145445	18
1523	Successful Secondary Umbilical Cord Blood Transplantation for Graft Failure in Acute Myelogenous Leukemia, Treated with Modified One-Day Conditioning Regimen, and Graft-Versus-Host Disease Prophylaxis Consisting of Mycophenolate and Tacrolimus. <b>2015</b> , 55, 89-96	0

1522	Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms. <b>2015</b> , 22, 184-90	5
1521	Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. <b>2015</b> , 50, 1037-56	226
1520	Reduced-intensity conditioned allogeneic SCT in adults with AML. <b>2015</b> , 50, 759-69	28
1519	Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. <b>2015</b> , 21, 1074-82	11
1518	Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. <b>2015</b> , 15, 335-40	6
1517	Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. <i>Blood</i> , <b>2015</b> , 126, 415-22	2.2 37
1516	A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT. <b>2015</b> , 50, 601-3	7
1515	Prognostic understanding, quality of life and mood in patients undergoing hematopoietic stem cell transplantation. <b>2015</b> , 50, 1119-24	34
1514	Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. <b>2015</b> , 50, 1157-67	18
1513	Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. <b>2015</b> , 21, 1405-1412	20
1512	Isolated autoimmune enteropathy associated with autoantibodies to a novel 28-kDa duodenal antigen. <b>2015</b> , 60, e17-9	2
1511	Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. <b>2015</b> , 2, e427-36	61
1510	Estimating demand and unmet need for allogeneic hematopoietic cell transplantation in the United States using geographic information systems. <b>2015</b> , 11, e120-30	10
1509	Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics. <b>2015</b> , 8, 143-9	3
1508	Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. <b>2015</b> , 21, 1754-60	11
1507	Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. <b>2015</b> , 29, 396-405	98
1506	Blood and marrow transplant clinical trials network state of the Science Symposium 2014. <b>2015</b> , 21, 202-24	17
1505	Transplant for MDS: challenges and emerging strategies. <b>2015</b> , 28, 43-54	3

1504	Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities. <b>2015</b> , 21, 412-20	9
1503	Reprint of: Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. <b>2015</b> , 21, S3-10	4
1502	Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents. <b>2015</b> , 62, 883-9	12
1501	Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. <b>2015</b> , 21, 373-8	17
1500	Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done?. <b>2015</b> , 21, 300-4	21
1499	Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. <b>2015</b> , 94, 23-34	10
1498	High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. <b>2015</b> , 56, 2379-87	13
1497	Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. <b>2015</b> , 50, 679-84	13
1496	[Myelodysplastic syndromes]. <b>2015</b> , 56, 364-73	1
1495	Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study. <b>2015</b> , 29, 548-55	48
1494	Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. <b>2015</b> , 8, 4	29
1493	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. <b>2015</b> , 21, 2115-2122	21
1492	Intensive Care Utilization for Hematopoietic Cell Transplant Recipients. <b>2015</b> , 21, 2023-7	8
1491	Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. <b>2015</b> , 33, 3144-51	83
1490	Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation. <b>2015</b> , 21, 848-54	28
1489	Systematic Nutritional Support in Allogeneic Hematopoietic Stem Cell Transplant Recipients. <b>2015</b> , 21, 1707-13	47
1488	Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cyto-reductive Therapy Appropriate?. <b>2015</b> , 10, 329-33	3
1487	Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2. <b>2015</b> , 50, 1405-10	23

1486	Severe weight loss in 3 months after allogeneic hematopoietic SCT was associated with an increased risk of subsequent non-relapse mortality. <b>2015</b> , 50, 100-5	42
1485	Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged ≥60. <b>2015</b> , 50, 427-31	12
1484	Racial differences in allogeneic hematopoietic cell transplantation outcomes among African Americans and whites. <b>2015</b> , 50, 834-9	11
1483	Arrhythmias in the setting of hematopoietic cell transplants. <b>2015</b> , 50, 1212-6	30
1482	Mitigating Fear and Loathing in Managing Acute Myeloid Leukemia. <b>2015</b> , 52, 249-55	3
1481	Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes. <b>2015</b> , 39, 846-52	18
1480	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. <b>2015</b> , 21, 1479-87	113
1479	Interferon- $\alpha$ Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. <b>2015</b> , 21, 1939-47	44
1478	Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation. <b>2015</b> , 141, 2193-203	5
1477	Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota. <b>2015</b> , 94, 1667-75	7
1476	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. <b>2015</b> , 21, 1425-30	9
1475	Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT. <b>2015</b> , 50, 553-8	14
1474	Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. <b>2015</b> , 100, 842-8	52
1473	Which Acute Myeloid Leukemia Patients Should Be Offered Transplantation?. <b>2015</b> , 52, 223-31	7
1472	Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center. <b>2015</b> , 50, 954-60	5
1471	Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. <b>2015</b> , 26, 1058-1068	52
1470	Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation. <b>2015</b> , 121, 951-9	106
1469	Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation. <b>2015</b> , 50, 1180-6	13



1468	Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study. <b>2015</b> , 56, 2331-8		8
1467	Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. <b>2015</b> , 90, 144-8		22
1466	Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score. <b>2015</b> , 15, e73-81		10
1465	A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease. <b>2015</b> , 21, 646-52		36
1464	Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. <b>2015</b> , 21, 873-80		38
1463	Individual prediction of heart failure among childhood cancer survivors. <b>2015</b> , 33, 394-402		137
1462	Beta-2 microglobulin predicts the outcome after autologous stem cell transplantation in non-Hodgkin lymphoma. <b>2015</b> , 52, 65-71		2
1461	Predictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations. <b>2015</b> , 7, 47-56		3
1460	10th anniversary of the Austrian MDS Platform: aims and ongoing projects. <b>2015</b> , 127, 12-5		1
1459	How I treat refractory and early relapsed acute myeloid leukemia. <i>Blood</i> , <b>2015</b> , 126, 319-27	2.2	185
1458	Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societ		8
1457	ACUTE LEUKEMIAS XV. <b>2015</b> , 94, 1-102		12
1456	Sarcopenia is associated with autologous transplant-related outcomes in patients with lymphoma. <b>2015</b> , 56, 2855-62		20
1455	Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation. <b>2015</b> , 21, 926-33		33
1454	Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities. <b>2015</b> , 56, 2552-5		5
1453	Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. <b>2015</b> , 50, 307-9		1
1452	Elderly acute myeloid leukemia: assessing risk. <b>2015</b> , 10, 118-25		16
1451	[Allogeneic haematopoietic stem cell transplantation - an overview]. <b>2015</b> , 232, 641-6		2

1450	How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia. <b>2015</b> , 15, 646-54	8
1449	Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management. <b>2015</b> , 32, 891-905	13
1448	The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology. <b>2015</b> , 10, 213-24	14
1447	Defining vulnerability in allogeneic transplants is more complicated than the two numerical digits of age. <b>2015</b> , 56, 2235-6	
1446	Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. <b>2015</b> , 50, 106-12	12
1445	Baseline body mass index among children and adults undergoing allogeneic hematopoietic cell transplantation: clinical characteristics and outcomes. <b>2015</b> , 50, 402-10	25
1444	Impact of comorbidities on the treatment of non-Hodgkin's lymphoma: a systematic review. <b>2015</b> , 8, 329-41	14
1443	Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study. <b>2015</b> , 168, 463-6	10
1442	Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation. <b>2015</b> , 50, 1371-4	3
1441	Clinical comorbidity predictive measures in ex vivo T-cell-depleted allogeneic hematopoietic stem cell transplantation. <b>2015</b> , 50, 1138-40	3
1440	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <b>2015</b> , 16, 1506-1514	60
1439	Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen: Outcomes of patients admitted to intensive care unit. <b>2015</b> , 30, 1107-13	19
1438	Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients. <b>2015</b> , 50, 1235-40	17
1437	Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents. <b>2015</b> , 10, 318-28	5
1436	Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution. <b>2015</b> , 39, 693-9	17
1435	Early-onset acute kidney injury is a poor prognostic sign for allogeneic SCT recipients. <b>2015</b> , 50, 1557-62	23
1434	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. <b>2015</b> , 33, 3152-61	165
1433	Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study. <b>2015</b> , 70, 3146-53	33

1432	Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma. <b>2015</b> , 21, 1153-4	12
1431	A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies. <b>2015</b> , 50, 1519-25	8
1430	Autologous hematopoietic stem cell transplantation in elderly patients (≥70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study. <b>2015</b> , 6, 346-52	23
1429	Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis. <b>2015</b> , 15 Suppl, S34-42	
1428	Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. <b>2015</b> , 21, 1418-24	47
1427	Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. <b>2015</b> , 39, 1207-1207	7
1426	Implementation of an Advanced Practice Provider Service on an Allogeneic Stem Cell Transplant Unit: Impact on Patient Outcomes. <b>2015</b> , 21, 1692-8	3
1425	High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. <b>2015</b> , 21, 1985-93	35
1424	A model for the functional assessment of elderly with myeloid neoplasms. <b>2015</b> , 37, 109-14	2
1423	Limitations of performance status assessment in elderly with acute myeloid leukemia. <b>2015</b> , 37, 259-62	6
1422	Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant. <b>2015</b> , 56, 2392-7	4
1421	High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma. <b>2015</b> , 17, 42	9
1420	Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. <b>2015</b> , 94, 779-87	47
1419	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective. <b>2015</b> , 101, 243-54	18
1418	Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. <b>2015</b> , 29, 1041-50	100
1417	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. <b>2015</b> , 21, 8-15	36
1416	Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. <b>2015</b> , 21, 89-96	9
1415	Patient selection for allogeneic hematopoietic cell transplantation (HCT): the evolution of HCT risk assessment. <b>2015</b> , 10, 28-34	1

1414	Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. <b>2015</b> , 50, 127-33	25
1413	Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. <b>2015</b> , 56, 1626-35	
1412	Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: no difference in the high- and low-risk groups. <b>2015</b> , 136, 1697-707	33
1411	Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation. <b>2015</b> , 21, 281-7	16
1410	Management of Hematological Cancer in Older People. <b>2015</b> ,	
1409	Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. <b>2015</b> , 29, 143-52	8
1408	High-dose total body irradiation and myeloablative conditioning before allogeneic hematopoietic cell transplantation: time to rethink?. <b>2015</b> , 21, 620-4	30
1407	Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. <b>2015</b> , 29, 51-7	55
1406	Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. <b>2015</b> , 29, 137-44	142
1405	The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. <b>2015</b> , 29, 464-73	57
1404	Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia. <b>2015</b> , 168, 405-12	33
1403	Impact of donor age on outcome after allogeneic hematopoietic cell transplantation. <b>2015</b> , 21, 105-12	34
1402	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <b>2015</b> , 168, 361-70	40
1401	Pretherapy Cardiology Evaluation. <b>2016</b> , 345-378	1
1400	Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes. <b>2016</b> , 35, e337-44	9
1399	Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?. <b>2016</b> , 35, e302-12	6
1398	Donor and recipient sex in allogeneic stem cell transplantation: what really matters. <b>2016</b> , 101, 1260-1266	32
1397	Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments. <b>2016</b> , 7, 470	58

1396	Acute Myeloid Leukemia: A Concise Review. <b>2016</b> , 5,	161
1395	Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia. <b>2016</b> , 11, e0164587	23
1394	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. <b>2016</b> , 7, 43027-43038	29
1393	Late-onset severe pneumonia after allogeneic hematopoietic stem cell transplantation: prognostic factors and treatments. <b>2016</b> , 18, 492-503	9
1392	Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. <b>2016</b> , 91, 302-7	39
1391	Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation. <b>2016</b> , 91, E341-7	14
1390	Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1?. <b>2016</b> , 23, 95-101	0
1389	Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: <b>2016</b> , 91, E287-292	30
1388	The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease. <b>2016</b> , 97, 471-478	4
1387	Biosimilars G-CSF versus originator G-CSF in post allotransplant recovery. A case-control study. <b>2016</b> , 91, E7-8	1
1386	Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. <b>2016</b> , 91, E284-92	41
1385	Allogeneic hematopoietic cell transplantation in patients ≥70 years: which patients may benefit?. <b>2016</b> , 6, e443	3
1384	T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation. <b>2016</b> , 22, 1861-1866	9
1383	Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation. <b>2016</b> , 122, 806-12	63
1382	The Dinakara equation for adjusting DLCO for hemoglobin in the HCT-CI is superior to the Cotes equation for predicting high-risk patients in allogeneic hematopoietic stem cell transplantation. <b>2016</b> , 91, E296	1
1381	Splenomegaly and thrombosis risk in essential thrombocythemia: the Mayo Clinic experience. <b>2016</b> , 91, E296-7	6
1380	Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. <b>2016</b> , 91, 793-9	11
1379	FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission. <b>2016</b> , 96, 475-82	14

1378	Autologous stem cell transplantation in HIV-positive patients affected by relapsed/partially responding lymphoma: let it be. <b>2016</b> , 9, 617-9	1
1377	Treatment of thrombotic microangiopathy after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. <b>2016</b> , 56, 886-92	20
1376	Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD. <b>2016</b> , 101, e348-51	5
1375	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. <b>2016</b> , 101, 1426-1433	41
1374	Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction. <b>2016</b> , 2016, 339-347	22
1373	Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. <b>2016</b> , 2016, 478-484	25
1372	Biologic vs physiologic age in the transplant candidate. <b>2016</b> , 2016, 99-105	26
1371	Hematopoietic Cell Transplantation for Myelodysplastic Syndromes. <b>2016</b> , 12, 786-92	6
1370	Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults. <b>2016</b> , 101, 764-72	19
1369	How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT. <b>2016</b> , 51, 1041-9	19
1368	Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia. <b>2016</b> , 57, 2109-18	17
1367	Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis. <b>2016</b> , 95, 1315-21	9
1366	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <b>2016</b> , 22, 1493-1503	45
1365	Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review. <b>2016</b> , 22, 1696-1701	44
1364	Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. <b>2016</b> , 175, 103-115.e4	14
1363	Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis. <b>2016</b> , 51, 1050-61	33
1362	Pretransplant $\kappa$ -Microglobulin Is Associated with the Risk of Acute Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant. <b>2016</b> , 22, 1329-1332	2
1361	Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation. <b>2016</b> , 51, 949-54	16

1360	Successful second bone marrow transplantation in a Wiskott-Aldrich syndrome patient with systemic vasculitis. <b>2016</b> , 137, 1615-6	3
1359	Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience. <b>2016</b> , 95, 973-83	2
1358	Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center. <b>2016</b> , 22, 1403-1409	35
1357	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <b>2016</b> , 34, 1864-71	46
1356	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <b>2016</b> , 22, 1348-1356	51
1355	Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions. <b>2016</b> , 16, 304-10	9
1354	Myeloma Is Not a Single Disease. <b>2016</b> , 12, 287-92	9
1353	The Difficulties of Informed Consent in Stem Cell Transplant. <b>2016</b> , 11, 1-5	6
1352	How I treat acute myeloid leukemia presenting with preexisting comorbidities. <i>Blood</i> , <b>2016</b> , 128, 488-96 2.2	33
1351	Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. <b>2016</b> , 50, 385-393	13
1350	Improved reproducibility and quality of GvHD biomarker assay: application of multiplex microfluidic channel system. <b>2016</b> , 51, 1615-1616	1
1349	Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. <b>2016</b> , 22, 2256-2263	17
1348	An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices. <b>2016</b> , 16, 625-636.e3	23
1347	Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902 Data. <b>2016</b> , 22, 2077-2083	9
1346	Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation. <b>2016</b> , 16 Suppl, S49-52	2
1345	Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. <b>2016</b> , 18, 913-920	30
1344	Definition of Unfit for Standard Acute Myeloid Leukemia Therapy. <b>2016</b> , 11, 537-544	9
1343	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. <b>2016</b> , 22, 1582-1587	12

1342	A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies. <b>2016</b> , 22, 1844-1850	39
1341	Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. <b>2016</b> , 5, 3059-3067	14
1340	Novel therapeutic options in Acute Myeloid Leukemia. <b>2016</b> , 6, 39-49	25
1339	Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience. <b>2016</b> , 38, 314-319	1
1338	Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia. <b>2016</b> , 22, 1816-1822	21
1337	Reduced-intensity Allogeneic Transplantation Regimens. <b>2016</b> , 232-246	
1336	Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. <b>2016</b> , 613-627	
1335	Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians. <b>2016</b> , 22, 2092-2099	3
1334	Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. <b>2016</b> , 91, 1107-1112	7
1333	Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). <b>2016</b> , 122, 91-8	46
1332	Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation. <b>2016</b> , 16, 1361-1372	3
1331	Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. <b>2016</b> , 22, 2025-2030	18
1330	Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis. <b>2016</b> , 55, 1721-7	2
1329	Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. <b>2016</b> , 316, 2094-2103	198
1328	Management of Relapsed Diffuse Large B-cell Lymphoma. <b>2016</b> , 30, 1195-1213	17
1327	Basics of Hematopoietic Cell Transplantation for Primary Care Physicians and Internists. <b>2016</b> , 43, 693-701	4
1326	Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia. <b>2016</b> , 64, 1988-1995	50
1325	Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis. <b>2016</b> , 22, 2270-2275	11



1324	Acute myeloid leukemia in the older adults. <b>2016</b> , 6, 1-7	82
1323	The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial). <b>2016</b> , 51, 1404-1407	3
1322	Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. <b>2016</b> , 101, 1390-1397	51
1321	Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia. <b>2016</b> , 101, 20-5	40
1320	Pretransplant paranasal sinus disease is associated with a high incidence of transplant-related mortality in hematopoietic stem cell transplantation for children and adolescents. <b>2016</b> , 20, 1111-1116	1
1319	Stellenwert und Perspektiven der hämatopoetischen Stammzelltransplantation bei malignen hämatologischen Systemerkrankungen. <b>2016</b> , 22, 469-477	
1318	GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies. <b>2016</b> , 51, 1642-1643	5
1317	[Allogeneic stem cell transplantation : An option for autoimmune diseases?]. <b>2016</b> , 75, 780-785	1
1316	Comparative Evaluation of Common Comorbidity Scores and Freiburger Comorbidity Index as Prognostic Variables in a Real Life Multiple Myeloma Population. <b>2016</b> , 32, 424-430	2
1315	Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). <b>2016</b> , 101, 781-8	25
1314	Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. <b>2016</b> , 51, 1283-1300	51
1313	Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia. <b>2016</b> , 7, 131-41	14
1312	Risk Factors for Invasive Mold Infections and Implications for Choice of Prophylaxis after Allogeneic Stem Cell Transplantation. <b>2016</b> , 22, 1684-1689	8
1311	Treatment of elderly and very old patients with AML. <b>2016</b> , 9, 4-7	
1310	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. <b>2016</b> , 22, 1431-1439	18
1309	Survival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing Outcomes. <b>2016</b> , 22, 1525-1530	9
1308	Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. <b>2016</b> , 22, 1065-1072	14
1307	Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis. <b>2016</b> , 22, 1721-1724	9

1306	Glycemic Status and Infection Risk in Nondiabetic Autologous Hematopoietic Cell Transplantation Recipients. <b>2016</b> , 18, 344-50	5
1305	Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (>60 years). <b>2016</b> , 51, 1441-1448	26
1304	Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study. <b>2016</b> , 34, 17-21	4
1303	ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning. <b>2016</b> , 56, 518-27	12
1302	Comparable outcomes between younger (<40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning. <b>2016</b> , 51, 1456-1463	28
1301	Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. <b>2016</b> , 22, 1851-1860	91
1300	Infectious basophilia?. <b>2016</b> , 91, E8	2
1299	Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. <b>2016</b> , 34, 154-60	3
1298	Predicting early post-chemotherapy adverse events in patients with hematological malignancies: a retrospective study. <b>2016</b> , 24, 2727-33	
1297	Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. <b>2016</b> , 103, 444-52	6
1296	Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I. <b>2016</b> , 55, 525-50	20
1295	Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. <b>2016</b> , 22, 149-56	24
1294	Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. <b>2016</b> , 22, 862-8	26
1293	Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. <b>2016</b> , 51, 462-5	4
1292	Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma. <b>2016</b> , 11, 196-207	13
1291	Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil. <b>2016</b> , 22, 1037-1042	59
1290	A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation. <b>2016</b> , 51, 1010-2	6
1289	Clotrimazole troches induce suprathreshold blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. <b>2016</b> , 9, 157-161	13

1288	Pretransplantation Supportive and Palliative Care Consultation for High-Risk Hematopoietic Cell Transplantation Patients. <b>2016</b> , 22, 1299-1305	41
1287	Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?. <b>2016</b> , 110, 5-11	7
1286	Impact of pre-transplant diffusion lung capacity for nitric oxide (DLNO) and of DLNO/pre-transplant diffusion lung capacity for carbon monoxide (DLNO/DLCO) ratio on pulmonary outcomes in adults receiving allogeneic stem cell transplantation for hematological diseases. <b>2016</b> , 51, 589-92	3
1285	Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. <b>2016</b> , 22, 441-8	84
1284	The artful management of older patients with acute myeloid leukemia. <b>2016</b> , 9, 425-32	1
1283	Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. <b>2016</b> , 51, 799-806	10
1282	Retrospective analysis of adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation: A multicenter experience of daily practice. <b>2016</b> , 54, 41-7	4
1281	Acute kidney injury in HCT: an update. <b>2016</b> , 51, 755-62	22
1280	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. <b>2016</b> , 22, 432-40	95
1279	Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. <b>2016</b> , 22, 80-5	11
1278	Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation. <b>2016</b> , 22, 339-343	4
1277	Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT <b>2016</b> , 27, 1088-1094	25
1276	Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study. <b>2016</b> , 51, 1019-21	4
1275	Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. <b>2016</b> , 3, e119-27	199
1274	Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation. <b>2016</b> , 57, 2133-9	6
1273	Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation. <b>2016</b> , 51, 841-7	23
1272	Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index. <b>2016</b> , 51, 955-60	5
1271	Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase. <b>2016</b> , 33, 335-45	

1270	T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. <b>2016</b> , 51, 194-8	16
1269	Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia. <b>2016</b> , 22, 669-675	37
1268	Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. <b>2016</b> , 51, 553-9	45
1267	Comorbidity in older adults with cancer. <b>2016</b> , 7, 249-57	130
1266	Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation. <b>2016</b> , 51, 529-35	11
1265	New insights into transfusion-related iron toxicity: Implications for the oncologist. <b>2016</b> , 99, 261-71	39
1264	Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor. <b>2016</b> , 22, 119-24	74
1263	Current challenges and novel treatment strategies in double hit lymphomas. <b>2016</b> , 7, 52-64	19
1262	Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies. <b>2016</b> , 95, 115-124	8
1261	Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes. <b>2016</b> , 57, 76-80	10
1260	Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation. <b>2016</b> , 51, 96-102	15
1259	Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. <b>2016</b> , 57, 666-75	9
1258	CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission. <b>2016</b> , 57, 1375-81	8
1257	FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. <b>2016</b> , 51, 511-520	30
1256	Second allogeneic transplantation using unrelated cord blood for relapsed hematological malignancies after allogeneic transplantation. <b>2016</b> , 57, 103-9	5
1255	Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study. <b>2017</b> , 26, e12426	
1254	Different Impact of the Number of Organ Failures and Graft-Versus-Host Disease on the Outcome of Allogeneic Stem Cell Transplantation Recipients Requiring Intensive Care. <b>2017</b> , 101, 437-444	11
1253	Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome. <b>2017</b> , 23, 776-781	2

1252	Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation. <b>2017</b> , 23, 445-451		21
1251	Frontline treatment of acute myeloid leukemia in adults. <b>2017</b> , 110, 20-34		68
1250	Transforming growth factor- $\beta$ functional polymorphisms in myeloablative sibling hematopoietic stem cell transplantation. <b>2017</b> , 52, 739-744		6
1249	Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. <b>2017</b> , 52, 697-703		7
1248	Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions. <b>2017</b> , 23, 677-683		9
1247	T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. <b>2017</b> , 23, 648-653		28
1246	Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. <b>2017</b> , 52, 592-599		25
1245	Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. <b>2017</b> , 52, 683-688		32
1244	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. <b>2017</b> , 102, 391-400		119
1243	The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. <i>Blood</i> , <b>2017</b> , 129, 2316-2325	2.2	93
1242	Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. <i>Blood</i> , <b>2017</b> , 129, 2347-2358	2.2	184
1241	Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation. <b>2017</b> , 23, 654-658		13
1240	Myelodysplastic Syndromes: Updates and Nuances. <b>2017</b> , 101, 333-350		6
1239	Untreated donor specific antibodies against HLA are associated with poor outcomes in peripheral blood haploidentical hematopoietic cell transplantation. <b>2017</b> , 52, 898-901		6
1238	Pulmonary Function and Pretransplant Evaluation of the Hematopoietic Cell Transplant Candidate. <b>2017</b> , 38, 307-316		6
1237	Reprint of: Aging: Treating the Older Patient. <b>2017</b> , 23, S10-S17		4
1236	Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. <b>2017</b> , 49, 25-33		14
1235	Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study. <b>2017</b> , 52, 818-824		8

1234	Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML. <b>2017</b> , 96, 479-487	10
1233	A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. <b>2017</b> , 102, 910-921	132
1232	Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort. <b>2017</b> , 92, 429-434	23
1231	Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation. <b>2017</b> , 96, 817-827	13
1230	Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation. <b>2017</b> , 123, 1800-1809	11
1229	Viral encephalitis after haplo-identical hematopoietic stem cell transplantation: Causative viral spectrum, characteristics, and risk factors. <b>2017</b> , 98, 450-458	17
1228	Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases. <b>2017</b> , 96, 787-796	2
1227	Oral health of adult patients undergoing hematopoietic cell transplantation. Pre-transplant assessment and care. <b>2017</b> , 96, 1135-1145	15
1226	Cardio-Oncology. <b>2017</b> ,	1
1225	Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogeneic Transplant. <b>2017</b> , 23, 1208-1214	24
1224	Preoperative and Pre-transplant Cardiac Evaluation in the Cancer Patient. <b>2017</b> , 125-159	
1223	Allogeneic Stem Cell Transplantation in Myelofibrosis. <b>2017</b> , 23, 1429-1436	20
1222	Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies. <b>2017</b> , 10, 627-636	
1221	Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore. <b>2017</b> , 52, 1044-1046	10
1220	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. <b>2017</b> , 23, 1549-1554	21
1219	Nutritional status of allogeneic hematopoietic stem cell transplantation recipients: influencing risk factors and impact on survival. <b>2017</b> , 25, 3085-3093	13
1218	Association of hematopoietic cell transplantation-specific comorbidity index with resource utilization after allogeneic transplantation. <b>2017</b> , 52, 998-1002	5
1217	Vancomycin-Resistant Enterococcus Colonization and Bacteremia and Hematopoietic Stem Cell Transplantation Outcomes. <b>2017</b> , 23, 340-346	29

1216	Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome. <b>2017</b> , 52, 522-531	9
1215	Therapy of older persons with acute myeloid leukaemia. <b>2017</b> , 60, 1-10	9
1214	Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. <b>2017</b> , 96, 1361-1372	38
1213	Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients. <b>2017</b> , 92, E529-E533	5
1212	Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial. <b>2017</b> , 23, 1491-1497	8
1211	Metabolic Syndrome in Long-Term Survivors of Hematopoietic Stem-Cell Transplantation. <b>2017</b> , 17, 340-346	10
1210	Risk-benefit assessment in allogeneic hematopoietic transplant. <b>2017</b> , 19-35	
1209	Donor and recipient pre-transplant evaluation. <b>2017</b> , 36-44	
1208	FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients. <b>2017</b> , 17, 767-773	11
1207	Hematopoietic cell transplantation: Training challenges and potential opportunities through networking and integration of modern technologies to the practice setting. <b>2017</b> , 10, 184-188	2
1206	Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index. <b>2017</b> , 23, 1485-1490	7
1205	Patterns of Care and Survival for Elderly Acute Myeloid Leukemia-Challenges and Opportunities. <b>2017</b> , 12, 290-299	4
1204	Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate. <b>2017</b> , 23, 1498-1508	13
1203	Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide. <b>2017</b> , 10, 79-84	12
1202	Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. <b>2017</b> , 52, 1003-1009	12
1201	Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?. <b>2017</b> , 99, 60-69	5
1200	Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. <b>2017</b> , 123, 2661-2670	8
1199	Nutritional status and hyperglycemia in the peritransplant period: a review of associations with parenteral nutrition and clinical outcomes. <b>2017</b> , 39, 155-162	5

1198	Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. <b>2017</b> , 28, 1547-1553		36
1197	A systematic review of prognostic factors at the end of life for people with a hematological malignancy. <b>2017</b> , 17, 213		16
1196	Venous thromboembolism is associated with graft-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <b>2017</b> , 102, 1185-1191		18
1195	Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. <i>Blood</i> , <b>2017</b> , 129, 3031-3033	2.2	8
1194	Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. <b>2017</b> , 96, 829-838		28
1193	Predictive parameters for imatinib failure in patients with chronic myeloid leukemia. <b>2017</b> , 22, 460-466		2
1192	Haematopoietic Stem Cell Transplantation. <b>2017</b> , 466-476		
1191	Prognostic Index for Critically Ill Allogeneic Transplantation Patients. <b>2017</b> , 23, 991-996		10
1190	Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial. <b>2017</b> , 123, 2881-2892		35
1189	Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome. <b>2017</b> , 92, E117-E119		3
1188	Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation. <b>2017</b> , 23, 1064-1071		83
1187	Clinical impact of hyperglycemia on days 0-7 after allogeneic stem cell transplantation. <b>2017</b> , 52, 1156-1163		3
1186	Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes. <b>2017</b> , 23, 1078-1086		11
1185	Ex Vivo CD34-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. <b>2017</b> , 23, 452-458		25
1184	The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome. <b>2017</b> , 58, 1893-1902		6
1183	Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling. <b>2017</b> , 23, 529-532		13
1182	Significance of OCT1 Expression in Acute Myeloid Leukemia. <b>2017</b> , 23, 665-671		3
1181	Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. <b>2017</b> , 52, 580-587		38



1180	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <b>2017</b> , 179, 781-789		36
1179	Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). <b>2017</b> , 96, 1993-2003		79
1178	Delayed Development of Hemolytic Anemia with Fragmented Red Blood Cells and Cardiac and Renal Impairments after High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma. <b>2017</b> , 138, 152-161		2
1177	Toward Individualizing Conditioning Regimens in Reduced-Intensity Transplantation. <b>2017</b> , 23, 2019-2020		
1176	Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies. <b>2017</b> , 179, 790-801		6
1175	Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful. <b>2017</b> , 123, 4687-4700		33
1174	Allogeneic transplant: does age still matter?. <i>Blood</i> , <b>2017</b> , 130, 1079-1080	2.2	6
1173	Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. <b>2017</b> , 3, 1675-1682		78
1172	Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older. <b>2017</b> , 23, 2079-2087		26
1171	External Validation of the COmorbidity Test. <b>2017</b> , 14, 513-517		3
1170	Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. <b>2017</b> , 99, 532-535		16
1169	The management and treatment of acute leukemias in the elderly population. <b>2017</b> , 10, 975-985		4
1168	Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint. <b>2017</b> , 23, 2192-2198		14
1167	Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome. <b>2017</b> , 52, 1530-1536		15
1166	Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. <i>Blood</i> , <b>2017</b> , 130, 1327-1335	2.2	61
1165	Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation. <b>2017</b> , 96, 1517-1523		31
1164	How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?. <b>2017</b> , 30, 201-211		7
1163	Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes. <b>2017</b> , 23, 1714-1721		17

1162	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. <b>2017</b> , 23, 6478-6486		21
1161	The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years. <b>2017</b> , 31, 362-369		17
1160	Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. <i>Blood</i> , <b>2017</b> , 130, 1760-1767	2.2	44
1159	Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?. <b>2017</b> , 23, 1839-1846		17
1158	A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell Transplantation. <b>2017</b> , 23, 2151-2158		5
1157	The Role of Age in Neurocognitive Functioning among Adult Allogeneic Hematopoietic Cell Transplant Recipients. <b>2017</b> , 23, 1974-1979		19
1156	Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies. <b>2017</b> , 38, 575-593		7
1155	Autologous stem cell transplantation and stem cell mobilization kinetics in elderly patients with B cell non-Hodgkin lymphoma. <b>2017</b> , 56, 814-818		2
1154	High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission. <b>2017</b> , 63, 22-27		18
1153	History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. <b>2017</b> , 92, 1032-1036		9
1152	Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. <b>2017</b> , 23, 1736-1743		26
1151	Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation. <b>2017</b> , 23, 1646-1650		29
1150	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , <b>2017</b> , 130, 1156-1164	2.2	134
1149	Circulating Biomarkers to Identify Responders in Cardiac Cell therapy. <b>2017</b> , 7, 4419		14
1148	Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. <b>2017</b> , 23, 1744-1748		7
1147	Goodness-of-fit test for monotone proportional subdistribution hazards assumptions based on weighted residuals. <b>2017</b> , 36, 362-377		3
1146	An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication. <b>2017</b> , 52, 363-371		3
1145	Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. <b>2017</b> , 28, 218-227		44

1144	Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit. <b>2017</b> , 3, 374-381	42
1143	Aging: Treating the Older Patient. <b>2017</b> , 23, 193-200	21
1142	Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin's lymphoma in patients older than 50 years. <b>2017</b> , 96, 9-16	11
1141	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8. <b>2017</b> , 23, 75-80	2
1140	Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. <b>2017</b> , 52, 173-182	39
1139	Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation. <b>2017</b> , 58, 37-44	11
1138	Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation. <b>2017</b> , 98, 160-168	9
1137	Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma. <b>2017</b> , 58, 822-833	16
1136	Allogeneic Stem Cell Transplantation for Patients Age $\geq$ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. <b>2017</b> , 23, 44-52	36
1135	Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34 Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. <b>2017</b> , 23, 67-74	18
1134	Cell-based therapeutic strategies for multiple sclerosis. <b>2017</b> , 140, 2776-2796	102
1133	The Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation. <b>2017</b> , 31, e13103	4
1132	Hematopoietic Cell Transplants for Acute Myeloid Leukemia: Is There a Best Approach?. 316-327	
1131	Hematopoietic Cell Transplants for Chronic Myeloid Leukemia: Still a Role for Allogeneic Transplant?. 339-350	
1130	Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission.. <b>2017</b> , 1, 1-13	8
1129	How and when to decide between epigenetic therapy and chemotherapy in patients with AML. <b>2017</b> , 2017, 45-53	23
1128	Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. <b>2017</b> , 1, 652-661	55
1127	Clinical profile, biological markers, and comorbidity index as predictors of transplant-related mortality after allo-HSCT. <b>2017</b> , 1, 1409-1413	3

1126	Treatment of Elderly Patients With Aplastic Anemia. <b>2017</b> , 141-151	
1125	Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?. <b>2017</b> , 6,	24
1124	Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case. <b>2017</b> , 2017, 6167345	1
1123	Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. <b>2017</b> , 18,	30
1122	Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia. <b>2017</b> , 24, e123-e130	6
1121	Hematopoietic Cell Transplants for Children with Acute Lymphoblastic Leukemia. 291-297	
1120	Haploidentical hematopoietic stem cell transplantation in a myelofibrosis patient with primary graft failure. <b>2017</b> , 9, 7091	
1119	Conditioning Regimens: Do They Really Matter?. 247-257	
1118	Biology: Critical Components of Hematopoietic Cell Transplantation. 16-22	
1117	Recipient Selection for Hematopoietic Cell Transplantation. 23-42	
1116	Infectious Diseases: Evaluation and Implications of Results in Hematopoietic Cell Transplants. 43-50	
1115	Hematopoietic Cell Transplantation: Is There Any Age Limit?. 51-58	
1114	Allogeneic Hematopoietic Stem Cell Transplantation In Therapy-Related Myeloid Neoplasms (t-MN) of the Adult: Monocentric Observational Study and Review of the Literature. <b>2018</b> , 10, e2018005	7
1113	Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts. <b>2017</b> , 8, 12342-12354	17
1112	Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial. <b>2017</b> , 35, 3714-3721	99
1111	From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation. <b>2017</b> , 4, 39	4
1110	Refractory Graft-Versus-Host Disease-Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success. <b>2018</b> , 24, 1521-1526	7
1109	High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. <b>2018</b> , 180, 840-853	9

1108	Acquired long QT syndrome during conditioning for allogeneic stem cell transplantation-are we aware of this side effect?. <b>2018</b> , 97, 1111-1113	0
1107	Promising Outcome of Umbilical Cord Blood Transplantation in Patients with Multiple Comorbidities. <b>2018</b> , 24, 1455-1462	2
1106	Heart Rate Variability Markers as Correlates of Survival in Recipients of Hematopoietic Cell Transplantation. <b>2018</b> , 45, 250-259	2
1105	A Controlled Trial of Sheng-Yu-Tang for Post-Hematopoietic Stem Cell Transplantation Leukemia Patients: A Proposed Protocol and Insights From a Preliminary Pilot Study. <b>2018</b> , 17, 665-673	3
1104	Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort. <b>2018</b> , 11, 90-95	2
1103	Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy. <b>2018</b> , 24, 1237-1242	8
1102	Temporal trajectory of quality of life and its predictors in recipients of hematopoietic stem cell transplantation. <b>2018</b> , 97, 1407-1415	5
1101	Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting. <b>2018</b> , 53, 1304-1310	10
1100	Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. <b>2018</b> , 51,	33
1099	Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. <b>2018</b> , 24, 1029-1034	11
1098	Transplant-related mortality and survival in children with malignancies treated with allogeneic hematopoietic stem cell transplantation. A multicenter analysis. <b>2018</b> , 22, e13158	5
1097	Unmanipulated haploidentical transplantation conditioning with busulfan, cyclophosphamide and anti-thymoglobulin for adult severe aplastic anaemia. <b>2018</b> , 53, 188-192	19
1096	Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan. <b>2018</b> , 139, 35-44	5
1095	Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. <b>2018</b> , 124, 1733-1742	40
1094	Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations. <b>2018</b> , 100, 395-402	11
1093	Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency. <b>2018</b> , 103, e82-e86	27
1092	Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. <i>Blood</i> , <b>2018</b> , 131, 917-931	2.2 51
1091	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. <b>2018</b> , 24, 997-1004	12

1090	Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis. <b>2018</b> , 23, 624-630	12
1089	Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia. <b>2018</b> , 100, 198-205	8
1088	Perianal Infections in the Phase before Engraftment after Allogeneic Hematopoietic Stem Cell Transplantations: A Study of the Incidence, Risk Factors, and Clinical Outcomes. <b>2018</b> , 139, 19-27	6
1087	Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. <b>2018</b> , 27, 979-985	3
1086	Beneficial impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation: focusing on difference between stem cell sources. <b>2018</b> , 53, 634-639	10
1085	Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients. <b>2018</b> , 53, 576-583	8
1084	CD34 Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome . <b>2018</b> , 24, 964-972	15
1083	Management of older adults with myelodysplastic syndromes (MDS). <b>2018</b> , 9, 302-307	5
1082	Community Risk Score for Evaluating Health Care Disparities in Hematopoietic Cell Transplantation. <b>2018</b> , 24, 877-879	7
1081	Haploidentical Transplants for Acute Myeloid Leukemia in Adults. <b>2018</b> , 231-243	
1080	In-patient outcomes of Hematopoietic Stem Cell Transplantation in Patients with Immune Mediated Inflammatory Diseases: A Nationwide Study. <b>2018</b> , 8, 6825	4
1079	Hematopoietic stem cell transplantation in geriatric patients in Turkey. <b>2018</b> , 57, 159-162	
1078	Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. <b>2018</b> , 24, 1664-1670	27
1077	Applicability of and potential barriers preventing allogeneic stem cell transplant in sickle cell patients treated outside a sickle cell program. <b>2018</b> , 93, E150-E152	5
1076	Mild renal dysfunction defined by creatinine clearance rate has limited impact on clinical outcomes after allogeneic hematopoietic stem cell transplantation. <b>2018</b> , 107, 568-577	3
1075	Critically ill allogeneic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortality. <b>2018</b> , 53, 1233-1241	26
1074	CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. <b>2018</b> , 53, 1522-1531	13
1073	Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. <b>2018</b> , 53, 1541-1547	14

1072	Risk Factors Influencing Outcome of Acute Leukemia Patients Who Experience Relapse After Allogeneic Hematopoietic Stem-Cell Transplantation. <b>2018</b> , 18, e183-e190	2
1071	Successful outcomes of second hematopoietic stem cell transplantation with total nodal irradiation and ATG conditioning for graft failure in adult patients with severe aplastic anemia. <b>2018</b> , 53, 1270-1277	4
1070	The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis. <b>2018</b> , 20, 740-754	4
1069	Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. <b>2018</b> , 24, 2794-2803	23
1068	The European Blood and Marrow Transplantation Textbook for Nurses. <b>2018</b> ,	10
1067	Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients. <b>2018</b> , 551-571	
1066	A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. <b>2018</b> , 24, 1733-1740	11
1065	The current and future role of stem cells in myelodysplastic syndrome therapies. <b>2018</b> , 11, 411-422	5
1064	Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. <b>2018</b> , 53, 1096-1104	12
1063	Severity, course, and predictors of sleep disruption following hematopoietic cell transplantation: a secondary data analysis from the BMT CTN 0902 trial. <b>2018</b> , 53, 1038-1043	4
1062	Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids. <b>2018</b> , 97, 1209-1217	6
1061	Prognostic Prediction Model for Second Allogeneic Stem-Cell Transplantation in Patients With Relapsed Acute Myeloid Leukemia: Single-Center Report. <b>2018</b> , 18, e167-e182	1
1060	A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine. <b>2018</b> , 24, 290-298	4
1059	C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early- and long-term mortality. <b>2018</b> , 180, 889-892	5
1058	Initial therapy for acute myeloid leukemia in older patients: principles of care. <b>2018</b> , 59, 29-41	11
1057	Acute myeloid leukemia in the elderly: therapeutic options and choice. <b>2018</b> , 59, 274-287	34
1056	Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants. <b>2018</b> , 32, 492-498	32
1055	Pretransplant serum FT3 levels in recipients predict early non-relapse mortality after myeloablative allogeneic haematopoietic cell transplantation from matched sibling donors. <b>2018</b> , 23, 38-43	

1054	Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. <b>2018</b> , 24, 400-405	3
1053	Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. <b>2018</b> , 24, 343-352	46
1052	Impact of estimated glomerular filtration rate based on plasma cystatin C and serum creatinine levels before allogeneic hematopoietic cell transplantation. <b>2018</b> , 23, 271-276	1
1051	Kinetics of Double-Stranded DNA Viremia After Allogeneic Hematopoietic Cell Transplantation. <b>2018</b> , 66, 368-375	39
1050	Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients. <b>2018</b> , 24, 4-12	5
1049	Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia. <b>2018</b> , 124, 286-296	20
1048	Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. <b>2018</b> , 24, 386-392	41
1047	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. <b>2018</b> , 24, 581-586	3
1046	Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. <b>2018</b> , 107, 211-221	6
1045	Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <b>2018</b> , 24, 1232-1236	36
1044	IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. <b>2018</b> , 103, 531-539	20
1043	Donor/Recipient Selection, Work-Up, and Safety. <b>2018</b> , 141-154	
1042	Paving the Way to Hematopoietic Stem Transplantation Worldwide. <b>2018</b> , 287-296	
1041	Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment?. <b>2018</b> , 53, 3-10	17
1040	Frailty and the management of hematologic malignancies. <i>Blood</i> , <b>2018</b> , 131, 515-524	2.2 93
1039	Establishing a Hematopoietic Stem Cell Transplantation Unit. <b>2018</b> ,	1
1038	Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. <b>2018</b> , 24, 832-839	11
1037	Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities. <b>2018</b> , 97, 267-276	9



1036	Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation. <b>2018</b> , 53, 52-57	13
1035	Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. <b>2018</b> , 36, 3203-3210	18
1034	Advances and Perspective in Allogeneic Hematopoietic Cell Transplantation for Elderly Patients. <b>2018</b> , 7, 73-81	1
1033	Novel Health Information Technology Tool Use by Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: Longitudinal Quantitative and Qualitative Patient-Reported Outcomes. <b>2018</b> , 2, 1-12	9
1032	Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer. <b>2018</b> , 36, 44-52	54
1031	We do still transplant CML, don't we?. <b>2018</b> , 2018, 177-184	13
1030	Efficacy and Safety of Biosimilar Filgrastim for Cord Blood Transplantation: A Single-Institution Retrospective Analysis. <b>2018</b> , 50, 3804-3810	1
1029	The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era. <b>2018</b> , 53, 3-6	6
1028	Development and Applications of Prognostic Risk Models in the Management of Invasive Mold Disease. <b>2018</b> , 4,	5
1027	Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS. <b>2018</b> , 74, 21-41	13
1026	Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy. <b>2018</b> , 13, 484-493	5
1025	Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia. <b>2018</b> , 19, 67	20
1024	Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands. <b>2018</b> , 57, 90-96	8
1023	Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns. <b>2018</b> , 35, 1055-1064	4
1022	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome in Adults. <b>2018</b> , 970-980.e4	
1021	Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. <i>Blood</i> , <b>2018</b> , 132, 1703-1713	2.2 142
1020	Effects of individualized nutrition after allogeneic hematopoietic stem cell transplantation following myeloablative conditioning; a randomized controlled trial. <b>2018</b> , 28, 59-66	10
1019	Double-hit and double-expressor B-cell lymphomas: Current treatment strategies and impact of hematopoietic cell transplantation. <b>2018</b> , 1, e13	2

1018	Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. <b>2018</b> , 2, 909-922	39
1017	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <b>2018</b> , 2, 2922-2936	17
1016	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. <b>2018</b> , 2, 299-307	47
1015	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. <b>2018</b> , 2, 1180-1186	23
1014	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <b>2018</b> , 2, 933-940	23
1013	HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment. <b>2018</b> , 2, 3590-3601	10
1012	How I manage patients with relapsed/refractory diffuse large B cell lymphoma. <b>2018</b> , 182, 633-643	78
1011	Antibiotic Exposure Prior to Respiratory Viral Infection Is Associated with Progression to Lower Respiratory Tract Disease in Allogeneic Hematopoietic Cell Transplant Recipients. <b>2018</b> , 24, 2293-2301	19
1010	Guideline for the management of mantle cell lymphoma. <b>2018</b> , 182, 46-62	17
1009	Status of Natural Killer Cell Recovery in Day 21 Bone Marrow after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome. <b>2018</b> , 24, 1841-1847	16
1008	Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <b>2018</b> , 24, 1947-1951 <sup>3</sup>	
1007	Comparison of transplant-specific prognostic scoring systems in haploidentical transplantation for myelodysplastic syndrome. <b>2018</b> , 101, 200	
1006	How I treat older patients with acute myeloid leukemia. <b>2018</b> , 124, 2472-2483	5
1005	Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. <b>2018</b> , 24, 2047-2055	11
1004	Circulating CD3CD4CD161 Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma. <b>2018</b> , 2018, 5097325	2
1003	Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning. <b>2018</b> , 24, 2277-2284	11
1002	The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. <b>2018</b> , 32, 1787-1794	16
1001	What the internist should know about stem cell transplant in the elderly patient. <b>2018</b> , 58, 43-47	

1000	Impact of hospital length of stay on the risk of readmission and overall survival after allogeneic stem cell transplantation. <b>2018</b> , 108, 290-297		3
999	Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia. <b>2018</b> , 97, 2491-2500		13
998	Indications and Outcomes of Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies in Adults. <b>2018</b> , 1596-1607		
997	Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies. <b>2018</b> , 97, 1975-1985		3
996	Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia. <b>2018</b> , 10,		12
995	Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. <b>2018</b> , 24, 2501-2508		15
994	Timepoints of vancomycin-resistant Enterococcus colonization predict outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation. <b>2018</b> , 101, 620		
993	Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation. <b>2018</b> , 24, e20-e25		5
992	Higher Peak Tacrolimus Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation Increase the Risk of Endothelial Cell Damage Complications. <b>2018</b> , 24, 2509-2516		10
991	Bridging Strategies to Allogeneic Transplant for Older AML Patients. <b>2018</b> , 10,		4
990	Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease. <b>2018</b> , 24, 2190-2196		7
989	Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients. <b>2018</b> , 97, 2205-2215		3
988	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. <i>Blood</i> , <b>2018</b> , 132, 892-902	2.2	64
987	<i>Stenotrophomonas maltophilia</i> colonization during allogeneic hematopoietic stem cell transplantation is associated with impaired survival. <b>2018</b> , 13, e0201169		7
986	Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation. <b>2018</b> , 108, 282-289		3
985	Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <b>2018</b> , 24, 1828-1835		9
984	Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis. <i>Blood</i> , <b>2018</b> , 131, 2630-2639	2.2	7
983	Allogene Stammzelltransplantation. <b>2018</b> , 13, 128-136		

982	Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality. <b>2018</b> , 24, 1685-1691	10
981	Haploidentical Transplantation. <b>2018</b> ,	
980	Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes. <b>2018</b> , 11, 805-816	7
979	Myelodysplastic Syndromes. <b>2018</b> ,	
978	Allogeneic Stem Cell Transplantation for MDS. <b>2018</b> , 141-157	
977	Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients. <b>2019</b> , 54, 218-225	2
976	Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. <b>2019</b> , 60, 629-638	1
975	Whole-Body Lung Function Test-Derived Outcome Predictors in Allogeneic Stem Cell Transplantation. <b>2019</b> , 25, 129-136	4
974	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. <b>2019</b> , 25, 56-62	7
973	Low mean post-transplantation tacrolimus levels in weeks 2-3 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. <b>2019</b> , 54, 155-158	7
972	Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome. <b>2019</b> , 25, 63-72	11
971	Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. <b>2019</b> , 54, 432-441	39
970	Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables. <b>2019</b> , 54, 368-382	6
969	Miscellaneous Complications Related to Hematopoietic Cell Transplantation. <b>2019</b> , 335-348	
968	Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients. <b>2019</b> , 25, 2454-2460	15
967	Allogeneic stem cell transplantation for myelofibrosis patients aged ≥5 years. <b>2019</b> , 103, 370-378	4
966	Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. <i>Blood</i> , <b>2019</b> , 134, 924-934	2.2 98
965	Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas. <b>2019</b> , 110, 406-410	3

964	Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?. <b>2019</b> , 2019, 3914828	0
963	Clinical outcomes in allogeneic haematopoietic stem cell transplantation: A comparison between young and elderly patients. Observational study. <b>2019</b> , 28, e13122	1
962	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. <b>2019</b> , 12, 68	9
961	Impact of a Nutritional Risk Index on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation. <b>2019</b> , 25, 2287-2296	6
960	Outcomes of hematopoietic cell transplant recipients requiring invasive mechanical ventilation: a two-centre retrospective cohort study. <b>2019</b> , 66, 1450-1457	2
959	Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada. <b>2019</b> , 84, 106193	1
958	Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma. <b>2019</b> , 60, 3434-3441	3
957	Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach. <b>2019</b> , 8, 5058-5067	15
956	Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. <b>2019</b> , 103, 402-409	18
955	A general practitioner's guide to hematopoietic stem-cell transplantation. <b>2019</b> , 26, 187-191	22
954	Impact of hemoglobin levels on hemoglobin-adjusted carbon monoxide diffusion capacity after chemotherapy for testicular cancer. <b>2019</b> , 49, 1151-1156	0
953	Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?. <b>2019</b> , 10, 1-9	4
952	Allogeneic Hematopoietic Cell Transplantation in the Outpatient Setting. <b>2019</b> , 25, 2152-2159	11
951	Allogeneic stem cell transplant provides durable response in peripheral T-cell lymphoma. <b>2019</b> , 83, 106171	3
950	Acute myeloid leukemia: How to treat the fit patient over age 75?. <b>2019</b> , 32, 101105	2
949	Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease. <b>2019</b> , 8,	3
948	Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis. <b>2019</b> , 5, 1739-1748	41
947	The Presence of a CMV Immunodominant Allele in the Recipient Is Associated With Increased Survival in CMV Positive Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation. <b>2019</b> , 9, 888	5

946	Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma. <b>2019</b> , 10, 2235	16
945	Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. <b>2019</b> , 94, 1344-1352	4
944	Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation. <b>2019</b> , 98, 2579-2591	7
943	Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis. <b>2019</b> , 98, 753-762	4
942	Body weight, body composition and survival after 1 year: follow-up of a nutritional intervention trial in allo-HSCT recipients. <b>2019</b> , 54, 2102-2109	9
941	Identifying risk factors associated with worse outcomes in adolescents and young adults undergoing hematopoietic stem cell transplantation. <b>2019</b> , 66, e27940	4
940	A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors. <b>2019</b> , 32, 1322-1332	14
939	Renaissance of Modified Charlson Comorbidity Index in Prediction of Short- and Long-Term Survival After Liver Transplantation?. <b>2019</b> , 25, 4521-4526	
938	Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia. <b>2019</b> , 13, 667-679	0
937	Self-efficacy for symptom management in the acute phase of hematopoietic stem cell transplant: A pilot study. <b>2019</b> , 42, 21-27	3
936	No Evidence for Particular Association Between HLA-Haploidentical Hematopoietic Stem Cell Transplantation and Psychological Distress. <b>2019</b> , 51, 1990-1993	
935	Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. <b>2019</b> , 54, 1295-1303	5
934	Circadian Rhythmicity as a Predictor of Quality of Life in Allogeneic Hematopoietic Cell Transplant Patients. <b>2019</b> , 57, 952-960.e1	4
933	Psychosocial Assessment of Candidates for Transplant (PACT) as a tool for psychological and social evaluation of allogeneic hematopoietic cell transplantation recipients. <b>2019</b> , 54, 1443-1452	7
932	Second allogeneic hematopoietic cell transplantation for relapse after first allografts. <b>2019</b> , 60, 1758-1766	5
931	A post-transplant optimized transplant-specific risk score in myelodysplastic syndromes. <b>2019</b> , 104, 859-861	1
930	Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS. <b>2019</b> , 110, 347-354	3
929	Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. <b>2019</b> , 125, 3566-3573	12

928	High-grade B-cell lymphoma: how to diagnose and treat. <b>2019</b> , 12, 497-506	5
927	Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?. <b>2019</b> , 25, 2054-2060	7
926	Clinical Impacts of Using Serum IL-6 Level as an Indicator of Cytokine Release Syndrome after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <b>2019</b> , 25, 2061-2069	7
925	Moderate or severe valvular heart disease and outcomes in allogeneic stem cell transplantation. <b>2019</b> , 292, 166-170	2
924	Management of Newly Diagnosed Elderly Multiple Myeloma Patients. <b>2019</b> , 21, 64	7
923	Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. <b>2019</b> , 25, 1803-1809	11
922	Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis. <b>2019</b> , 33, 2610-2618	7
921	Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting. <b>2019</b> , 25, 1770-1778	13
920	Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation. <b>2019</b> , 25, 2024-2030	11
919	Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study. <b>2019</b> , 6, ofz173	20
918	Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome. <b>2019</b> , 60, 2762-2770	6
917	Patterns of onset and outcome of cryptogenic organizing pneumonia after allogeneic hematopoietic stem cell transplantation. <b>2019</b> , 109, 700-710	1
916	Geriatric nutritional risk index (GNRI) just before allogeneic hematopoietic stem cell transplantation predicts transplant outcomes in patients older than 50 years with acute myeloid leukemia in complete remission. <b>2019</b> , 98, 1799-1801	8
915	Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation. <b>2019</b> , 14, e0213913	7
914	Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. <b>2019</b> , 25, 1456-1464	13
913	Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients. <b>2019</b> , 54, 1730-1737	15
912	When to use stem cell transplant in mantle cell lymphoma. <b>2019</b> , 12, 207-210	3
911	G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients. <b>2019</b> , 186, 60-71	9

910	Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation. <b>2019</b> , 9, 31		3
909	Patient and Donor Selection and Workup for Hematopoietic Cell Transplantation. <b>2019</b> , 85-97		
908	VaccHemInf project: protocol for a prospective cohort study of efficacy, safety and characterisation of immune functional response to vaccinations in haematopoietic stem cell transplant recipients. <b>2019</b> , 9, e026093		6
907	Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. <b>2019</b> , 104, e555-e557		3
906	Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation. <b>2019</b> , 19, e343-e348		2
905	Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients. <b>2019</b> , 80, 33-39		5
904	Significance of Granulocyte Colony-Stimulating Factor-Combined High-Dose Cytarabine, Cyclophosphamide, and Total Body Irradiation in Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignant Neoplasms. <b>2019</b> , 51, 896-900		
903	Worsening cognitive performance is associated with increases in systemic inflammation following hematopoietic cell transplantation. <b>2019</b> , 80, 308-314		7
902	Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms. <b>2019</b> , 25, 1293-1303		11
901	Host and Graft Factors Impacting Infection Risk in Hematopoietic Cell Transplantation. <b>2019</b> , 33, 311-329		4
900	Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. <b>2019</b> , 19, 390-395		2
899	Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation. <b>2019</b> , 25, 1682-1688		3
898	Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. <i>Blood</i> , <b>2019</b> , 133, 2233-2242	2.2	60
897	Association of multidimensional comorbidities with survival, toxicity, and unplanned hospitalizations in older adults with metastatic colorectal cancer treated with chemotherapy. <b>2019</b> , 10, 733-741		7
896	New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications. <b>2019</b> , 25, 1225-1231		7
895	Predicting hepatic complications of allogeneic hematopoietic stem cell transplantation using liver stiffness measurement. <b>2019</b> , 54, 1738-1746		8
894	Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation. <b>2019</b> , 111, 837-844		18
893	Integrating patient-centered factors in the risk assessment of MDS. <b>2019</b> , 2019, 373-380		5



892	Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. <b>2019</b> , 3, 2764-2777	7
891	Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation. <b>2019</b> , 3, 230-236	11
890	Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. <b>2019</b> , 3, 1303-1317	24
889	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <b>2019</b> , 3, 1826-1836	50
888	BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient. <b>2019</b> , 3, 1750-1760	4
887	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. <b>2019</b> , 3, 2525-2536	8
886	Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. <b>2019</b> , 3, 2454-2464	6
885	Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years. <b>2019</b> , 3, 3070-3079	5
884	External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. <b>2019</b> , 3, 1881-1890	37
883	Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. <b>2019</b> , 3, 2608-2616	7
882	Refined Disease Risk Index for Hematological Malignancies, Including Rare Disorders, After Allogeneic Stem Cell Transplantation. <b>2019</b> , 51, 3437-3443	3
881	The Graft-Versus-Leukemia Effect in AML. <b>2019</b> , 9, 1217	23
880	Interleukin-18 and outcome after allogeneic stem cell transplantation: A retrospective cohort study. <b>2019</b> , 49, 202-212	7
879	Prognostic factors and outcome of adult allogeneic hematopoietic stem cell transplantation patients admitted to intensive care unit during transplant hospitalization. <b>2019</b> , 9, 19911	9
878	Clinical research in older adults with hematologic malignancies: Opportunities for alignment in the Veterans Affairs. <b>2019</b> , 46, 341-345	
877	What have we learned from transplanting older patients?. <b>2019</b> , 32, 101110	1
876	The Roles of Nurses in Hematopoietic Cell Transplantation for the Treatment of Leukemia in Older Adults. <b>2019</b> , 35, 150960	0
875	Pretransplant C-reactive protein as a prognostic marker in allogeneic stem cell transplantation: A PRISMA-compliant meta-analysis. <b>2019</b> , 98, e14474	7

874	Decrease in physical performance during the hospitalisation phase of haematopoietic stem cell transplantation. <b>2019</b> , 26, 1-12	1
873	Allogeneic transplantation in elderly patients $\geq 5$ years with non-Hodgkin lymphoma: a time-trend analysis. <b>2019</b> , 9, 97	6
872	Trajectories of Fasting Blood Glucose in Autologous Hematopoietic Cell Transplantation. <b>2019</b> , 42, 307-313	0
871	The Proportional Relationship Between Pretransplant WT1 mRNA Levels and Risk of Mortality After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission. <b>2019</b> , 103, 2201-2210	3
870	Differential impact of anti-thymocyte globulin dosing by disease risk index in alternative donor peripheral blood stem cell transplantation in patients with acute leukemia or myelodysplastic syndrome after reduced intensity conditioning. <b>2019</b> , 54, 290-295	
869	Fatigue predicts impaired social adjustment in survivors of allogeneic hematopoietic cell transplantation (HCT). <b>2019</b> , 27, 1355-1363	10
868	Fludarabine/Melphalan 100 mg/m Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis. <b>2019</b> , 25, 1116-1121	3
867	Sarcopenic obesity derived from PET/CT predicts mortality in lymphoma patients undergoing hematopoietic stem cell transplantation. <b>2019</b> , 67, 93-99	11
866	Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas. <b>2019</b> , 54, 1237-1244	5
865	Human Rhinovirus Infections in Hematopoietic Cell Transplant Recipients: Risk Score for Progression to Lower Respiratory Tract Infection. <b>2019</b> , 25, 1011-1021	18
864	Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission. <b>2019</b> , 285, 446-454	3
863	Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome. <b>2019</b> , 25, 921-931	15
862	Bayesian non-parametric survival regression for optimizing precision dosing of intravenous busulfan in allogeneic stem cell transplantation. <b>2019</b> , 68, 809-828	4
861	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. <b>2019</b> , 25, 1128-1135	21
860	Haematopoietic stem cell transplants: principles and indications. <b>2019</b> , 80, 33-39	15
859	Reduced-Toxicity Myeloablative Conditioning Consisting of Fludarabine/Busulfan/Low-Dose Total Body Irradiation/Granulocyte Colony-Stimulating Factor-Combined Cytarabine in Single Cord Blood Transplantation for Elderly Patients with Nonremission Myeloid Malignancies. <b>2019</b> , 25, 764-770	13
858	[Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]. <b>2019</b> , 106, S40-S51	0
857	Successful Cord Blood Transplantation in a Werner Syndrome Patient with High-risk Myelodysplastic Syndrome. <b>2019</b> , 58, 109-113	2

856	Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study. <b>2019</b> , 54, 1049-1057	14
855	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. <b>2019</b> , 25, 480-487	5
854	Elderly do benefit from induction chemotherapy: High dose mitoxantrone-based ("5 + 1") induction chemotherapy regimen in newly diagnosed acute myeloid leukemia. <b>2019</b> , 94, 209-215	5
853	Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. <b>2019</b> , 25, 466-473	3
852	Hematopoietic Cell Transplantation. <b>2019</b> , 487-502	0
851	Psychosocial Assessment of Candidates for Transplantation scale (PACT) and survival after allogeneic hematopoietic stem cell transplantation. <b>2019</b> , 54, 1013-1021	8
850	Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability. <b>2019</b> , 25, 1158-1163	12
849	Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease. <b>2019</b> , 79, 75-80	3
848	Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions. <b>2019</b> , 12, 99-106	4
847	Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. <b>2019</b> , 25, 861-867	21
846	Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. <b>2019</b> , 54, 601-606	18
845	Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR. <b>2019</b> , 56, 164-170	8
844	Expanding Therapeutic Opportunities for Hematopoietic Stem Cell Transplantation: T Cell Depletion as a Model for the Targeted Allograft. <b>2019</b> , 70, 381-393	4
843	Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal. <b>2019</b> , 25, 570-576	27
842	Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. <b>2019</b> , 54, 775-781	8
841	Impact of Body Mass Index on Outcomes of Hematopoietic Stem Cell Transplantation in Adults. <b>2019</b> , 25, 613-620	11
840	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. <b>2019</b> , 54, 867-876	4
839	Advances in T Cell Depletion - Where Do We Stand?. <b>2019</b> , 2, e29	1

838	Are We Choosing Wisely With Autologous Hematopoietic Cell Transplantation Screening? The Utility of Pulmonary Function Testing Prior to Autologous Hematopoietic Cell Transplantation. <b>2019</b> , 19, 68-72		
837	Reassessment of clinical implication of pretransplant surgical procedures for pulmonary invasive fungal lesions. <b>2019</b> , 21, e13023		1
836	The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. <i>Blood</i> , <b>2019</b> , 133, 754-762	2.2	25
835	Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis. <b>2019</b> , 98, 951-962		1
834	Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. <b>2019</b> , 25, 1045-1052		11
833	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. <b>2019</b> , 25, 505-514		9
832	The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation. <b>2019</b> , 25, 606-612		9
831	Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. <b>2019</b> , 25, 335-342		18
830	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. <b>2019</b> , 25, 301-306		14
829	Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. <b>2019</b> , 54, 839-848		18
828	Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. <b>2019</b> , 25, e33-e38		4
827	Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma. <b>2019</b> , 98, 465-471		16
826	Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality. <b>2019</b> , 54, 973-979		1
825	Impact of a health information technology tool addressing information needs of caregivers of adult and pediatric hematopoietic stem cell transplantation patients. <b>2019</b> , 27, 2103-2112		13
824	Pilot randomized trial of an electronic symptom monitoring and reporting intervention for hospitalized adults undergoing hematopoietic stem cell transplantation. <b>2020</b> , 28, 1223-1231		7
823	The use of comprehensive geriatric assessment in older patients before allogeneic hematopoietic stem cell transplantation: A cross-sectional study. <b>2020</b> , 11, 100-106		11
822	Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia. <b>2020</b> , 11, 410-416		4
821	Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis. <b>2020</b> , 55, 70-76		24

820	Excellent outcomes of hematopoietic stem cell transplantation with total nodal irradiation and antithymocyte globulin conditioning in severe aplastic anemia with advanced age and/or severe comorbidity. <b>2020</b> , 55, 1447-1450	1
819	Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma. <b>2020</b> , 26, 157-161	3
818	Does Resetting the Immune System Fix Multiple Sclerosis?. <b>2020</b> , 47, 1-10	4
817	Acute respiratory failure and the kinetics of neutrophil recovery in pediatric hematopoietic cell transplantation: a multicenter study. <b>2020</b> , 55, 341-348	5
816	Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. <b>2020</b> , 55, 349-355	8
815	Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients. <b>2020</b> , 26, 189-196	20
814	Presalvage International Staging System Stage and Other Important Outcome Associations in CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <b>2020</b> , 26, 58-65	7
813	Comparative evaluation of biological human leukocyte antigen DPB1 mismatch models for survival and graft–host disease prediction after unrelated donor hematopoietic cell transplantation. <b>2020</b> , 105, e186-e189	7
812	Prospective Phase 2 Study of Umbilical Cord Blood Transplantation in Adult Acute Leukemia and Myelodysplastic Syndrome. <b>2020</b> , 26, 139-144	3
811	The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review. <b>2020</b> , 55, 708-716	11
810	Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia. <b>2020</b> , 55, 452-460	9
809	Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. <b>2020</b> , 6, e192974	9
808	Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. <b>2020</b> , 13, 160-165	3
807	Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease. <b>2020</b> , 26, 323-332	9
806	Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia. <b>2020</b> , 95, 48-56	1
805	Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <b>2020</b> , 26, 451-457	8
804	Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission. <b>2020</b> , 26, 463-471	8
803	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. <b>2020</b> , 26, 76-82	11

802	Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. <b>2020</b> , 55, 157-164	23
801	Pretransplant body mass index on outcomes of allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 55, 1175-1177	1
800	R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma. <b>2020</b> , 26, 683-690	5
799	Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. <b>2020</b> , 9, 52-61	10
798	The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. <b>2020</b> , 40, 100639	11
797	The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <b>2020</b> , 26, 123-131	4
796	Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. <b>2020</b> , 7, e134-e145	67
795	Intestinal pathophysiological and microbial changes in sickle cell disease: Potential targets for therapeutic intervention. <b>2020</b> , 188, 488-493	9
794	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <b>2020</b> , 26, 358-366	20
793	Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness. <b>2020</b> , 12,	17
792	Changes in body weight and serum liver tests associated with parenteral nutrition compared with no parenteral nutrition in patients with acute myeloid leukemia during remission induction treatment. <b>2020</b> , 28, 4381-4393	3
791	Arsenic-Containing Qinghuang Powder () is an Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy. <b>2020</b> , 26, 339-344	1
790	Role of Transplant Conditioning Regimen Intensity in High-Risk Acute Myelogenous Leukemia. <b>2020</b> , 26, e51-e52	
789	Contemporary treatment approaches to CMML - Is allogeneic HCT the only cure?. <b>2020</b> , 33, 101138	1
788	Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. <b>2020</b> , 13, 32-39	5
787	Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial. <b>2020</b> , 26, 316-322	1
786	Prognostic significance of low pre-transplant skeletal muscle mass on survival outcomes in patients undergoing hematopoietic stem cell transplantation. <b>2020</b> , 111, 267-277	6
785	Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation. <b>2020</b> , 26, 519-528	13

784	Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). <b>2020</b> , 11, 107-113	25
783	Comparative Study of Tacrolimus and Short-Term Methotrexate: 2-Day versus 3-Day Methotrexate as Graft-versus-Host-Disease Prophylaxis after Umbilical Cord Blood Transplantation in Adults. <b>2020</b> , 26, 367-372	1
782	Hematopoietic Stem Cell Transplantation. <b>2020</b> , 461-469.e3	1
781	Pretransplant serum beta-2 microglobulin level is a potential novel prognostic marker of overall survival after allogeneic hematopoietic cell transplantation - a retrospective observational study. <b>2020</b> , 33, 391-401	0
780	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. <b>2020</b> , 6, 486-493	19
779	Improvement of early mortality in single-unit cord blood transplantation for Japanese adults from 1998 to 2017. <b>2020</b> , 95, 343-353	15
778	The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. <b>2020</b> , 188, 129-146	29
777	Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases. <b>2020</b> , 55, 758-762	3
776	Early Post-Transplantation Spirometry Is Associated with the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. <b>2020</b> , 26, 943-948	5
775	Predictors of the trajectory of cognitive functioning in the first 6 months after allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 55, 918-928	4
774	Use of geriatric assessment in hematopoietic cell transplant. <b>2020</b> , 11, 225-236	15
773	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. <b>2020</b> , 26, 1077-1083	0
772	Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. <b>2020</b> , 55, 906-917	15
771	Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. <b>2020</b> , 61, 799-807	8
770	Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome. <b>2020</b> , 59, 1081-1086	2
769	Donor KIR2DS1-Mediated Decreased Relapse and Improved Survival Depending on Remission Status at HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <b>2020</b> , 26, 723-733	3
768	Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible. <b>2020</b> , 10, 1746	1
767	Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. <b>2020</b> , 26, e328-e332	4

766	Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status. <b>2020</b> , 68, 131-137	1
765	Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. <b>2020</b> , 26, 2229-2236	0
764	Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia. <b>2020</b> , 20, 836-842	2
763	Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. <b>2020</b> , 26, 2252-2261	1
762	Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. <b>2020</b> , 68, 159-170	8
761	The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 4, 4812-4821	4
760	Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single-center retrospective study. <b>2020</b> , 9, 6244-6255	5
759	Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?. <b>2020</b> , 34, 2552-2560	2
758	Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. <b>2020</b> , 61, 2839-2849	10
757	Novel Approach for Bone Marrow Transplantation Conditioning in Acute Myelogenous Leukemia not Responding to the Induction Therapy Using Etoposide Carried in Lipid Core Nanoparticles: A Pilot Clinical Study. <b>2020</b> , 26, 2027-2033	1
756	Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 99, 1655-1665	6
755	Comparison of outcomes of two non-BCNU-containing conditioning regimens used in autologous stem cell transplantation for relapsed/refractory lymphoma. <b>2020</b> , 13, 294-300	
754	Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <b>2020</b> , 10, 596134	8
753	Development and validation of a prognostic model for adult patients with acute myeloid leukaemia. <b>2020</b> , 62, 103126	2
752	Pre-Hematopoietic Stem Cell Transplantation Lung Computed Tomography as an Alternative to the Pulmonary Function Test during the COVID-19 Pandemic. <b>2020</b> , 26, 2318-2322	1
751	Feasibility and safety of exercise training and nutritional support prior to haematopoietic stem cell transplantation in patients with haematologic malignancies. <b>2020</b> , 20, 1142	4
750	A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. <b>2020</b> , 4, 5580-5588	42
749	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia of the Elderly: Review of Literature and New Perspectives. <b>2020</b> , 12, e2020081	4



748	Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia. <b>2020</b> , 20, 804-812.e8	7
747	Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. <b>2020</b> , 26, 2237-2244	5
746	Hematopoietic Cell Transplantation for Chronic Granulomatous Disease in Japan. <b>2020</b> , 11, 1617	2
745	Sarcopenia and low muscle radiodensity associate with impaired FEV in allogeneic haematopoietic stem cell transplant recipients. <b>2020</b> , 11, 1570-1579	10
744	Improving the accuracy of prognostication in chronic myelomonocytic leukemia. <b>2020</b> , 20, 703-714	2
743	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <b>2020</b> , 61, 1823-1832	1
742	Successful Matched Related Bone Marrow Transplantation in a Patient with Autosomal Dominant Interferon Gamma Receptor 1 Deficiency. <b>2020</b> , 40, 1045-1047	1
741	Clinical usefulness of diagnostic criteria for transplant-associated thrombotic microangiopathy. <b>2020</b> , 112, 697-706	2
740	Splenomegaly Negatively Impacts Neutrophil Engraftment in Cord Blood Transplantation. <b>2020</b> , 26, 1689-1696	3
739	Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies. <b>2020</b> , 112, 510-523	6
738	Impact of Clostridioides difficile infection on the outcome of patients receiving a hematopoietic stem cell transplantation. <b>2020</b> , 99, 428-436	2
737	Interleukin-18 and Hematopoietic Recovery after Allogeneic Stem Cell Transplantation. <b>2020</b> , 12,	2
736	Supportive Care Strategies. <b>2020</b> ,	
735	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. <b>2020</b> , 4, 5078-5088	6
734	Pre-transplant depression decreased overall survival of patients receiving allogeneic hematopoietic stem cell transplantation: a nationwide cohort study. <b>2020</b> , 10, 15265	3
733	Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20 B Cell Malignancies. <b>2020</b> , 26, 1811-1818	3
732	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <b>2020</b> , 4, 4113-4123	13
731	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <b>2020</b> , 12,	12

730	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <b>2020</b> , 4, 3977-3989	30
729	Guideline-based indicators for adult patients with myelodysplastic syndromes. <b>2020</b> , 4, 4029-4044	2
728	Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. <b>2020</b> , 4, 3900-3912	12
727	Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. <b>2020</b> , 15, e0238824	1
726	Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study. <b>2020</b> , 4, 3822-3828	1
725	Absolute lymphocyte count on the first day of thymoglobulin predicts relapse-free survival in matched unrelated peripheral blood stem cell transplantation. <b>2020</b> , 61, 3137-3145	6
724	CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison. <b>2020</b> , 4, 6157-6168	9
723	High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. <b>2020</b> , 4, 6064-6076	7
722	New-onset post-transplant diabetes mellitus after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide. <b>2020</b> , 1, 576-580	0
721	Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. <b>2020</b> , 10, 599933	4
720	Machine Learning Algorithms to Differentiate Among Pulmonary Complications After Hematopoietic Cell Transplant. <b>2020</b> , 158, 1090-1103	5
719	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <b>2020</b> , 38, 2062-2076	19
718	Does Desire to Pursue Pleasurable Activities Matter? The Impact of Pretransplantation Anhedonia on Quality of Life and Fatigue in Hematopoietic Stem Cell Transplantation. <b>2020</b> , 26, 1477-1481	3
717	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. <b>2020</b> , 26, 1439-1445	8
716	Onkologische Kardiologie. <b>2020</b> , 14, 267-293	1
715	Multidimensional geriatric assessment for elderly hematological patients (≥80 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients. <b>2020</b> , 55, 2224-2233	11
714	Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. <b>2020</b> , 109, 1197-1222	27
713	Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. <b>2020</b> , 79, 1084-1089	14

712	The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant - a retrospective study. <b>2020</b> , 33, 1089-1098		
711	Quality of Life following Allogeneic Stem Cell Transplantation for Patients Age >60 Years with Acute Myelogenous Leukemia. <b>2020</b> , 26, 1527-1533		3
710	Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. <b>2020</b> , 4, 2317-2324		
709	Pre-transplant testosterone and outcome of men after allogeneic stem cell transplantation. <b>2020</b> , 105, 1454-1464		1
708	Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. <i>Blood</i> , <b>2020</b> , 136, 823-830	2.2	35
707	Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. <b>2020</b> , 34, 2285-2294		28
706	Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial. <b>2021</b> , 106, 1867-1875		3
705	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. <b>2020</b> , 10, 36		6
704	European Group for Blood and Marrow Transplantation score correlates with outcomes of older patients undergoing allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 83, 238-244		0
703	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. <b>2020</b> , 105, 47-55		1
702	Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia. <b>2020</b> , 61, 1678-1687		3
701	Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome. <b>2020</b> , 55, 1399-1409		6
700	Low-intensity regimens standard-intensity induction strategies in acute myeloid leukemia. <b>2020</b> , 11, 2040620720913010		8
699	Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer. <b>2020</b> , 6, 315-322		11
698	Allogeneic hematopoietic stem-cell transplantation for myelofibrosis. <b>2020</b> , 11, 2040620720906002		3
697	Autologous stem cell transplantation for lymphoma in HIV+ patients: higher rate of infections compared with non-HIV lymphoma. <b>2020</b> , 55, 1716-1725		1
696	Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. <b>2020</b> , 26, 1670-1678		6
695	Predominant low Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) score in a Mexican referral center: a selection bias caused by limited-resources?. <b>2021</b> , 43, 249-255		

694	Management of newly diagnosed transplant ineligible multiple myeloma. <b>2020</b> , 61, 2549-2560	2
693	Outcomes of Haploidentical Stem Cell Transplantation using Total Body Irradiation (600 cGy) and Fludarabine with Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia: A Prospective Phase II Study. <b>2020</b> , 26, 1906-1914	1
692	Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG. <b>2020</b> , 26, 1868-1875	4
691	Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin. <b>2020</b> , 34, e14018	2
690	Performance Status in Cancer: Not Broken, But Time for an Upgrade?. <b>2020</b> , 38, 2824-2829	18
689	Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score. <b>2020</b> , 26, 1828-1832	3
688	Comparison of HLA-matched sibling and unrelated donor transplantation in adult patients with acquired severe aplastic anemia. <b>2020</b> , 55, 1570-1579	3
687	High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience. <b>2020</b> , 99, 855-866	0
686	Permanent Impairment-Free, Relapse-Free Survival: A Novel Composite Endpoint to Evaluate Long-Term Success in Allogeneic Transplantation. <b>2020</b> , 26, 1005-1012	0
685	Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. <b>2020</b> , 382, 822-834	204
684	Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis. <b>2020</b> , 55, 1264-1271	5
683	Matched-Pair Analysis of Transplant from Haploidentical, Unmanipulated Bone Marrow Donor versus HLA Identical Sibling for Patients with Hematologic Malignancies. <b>2020</b> , 26, 1113-1118	3
682	Validation of a Hematopoietic Cell Transplant-Composite Risk (HCT-CR) Model for Post-Transplant Survival Prediction in Patients with Hematologic Malignancies. <b>2020</b> , 26, 2404-2410	5
681	Improved Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes. <b>2020</b> , 26, 1091-1098	3
680	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. <b>2020</b> , 34, 2451-2459	9
679	Stem cell transplant for the treatment of myelofibrosis. <b>2020</b> , 13, 363-374	4
678	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. <b>2020</b> , 126, 2193-2205	17
677	Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. <b>2020</b> , 15, 268-275	3

676	Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia harboring t(1;19)(q23;p13.3); comparison with normal karyotype. <b>2020</b> , 55, 1337-1346	4
675	Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes?. <b>2020</b> , 22, 158-165	8
674	A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe. <b>2020</b> , 55, 965-973	6
673	Role of pretransplant anti-thymocyte globulin in matched sibling donor stem cell transplantation after reduced intensity conditioning for myelodysplastic syndrome. <b>2020</b> , 104, 459-468	1
672	NFKB1 gene single-nucleotide polymorphisms: implications for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 99, 609-618	1
671	The Glasgow prognostic score divides high-risk hematopoietic cell transplantation-specific comorbidity index patients into stratified subgroups in allogeneic hematopoietic cell transplantation. <b>2020</b> , 99, 671-673	
670	Clinical research in older adults with hematologic malignancies: Opportunities for alignment in the Veterans Affairs. <b>2020</b> , 47, 94-101	
669	Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years. <b>2020</b> , 95, 759-765	7
668	Effectiveness and Cost-Effectiveness of Prophylactic Voriconazole and Fluconazole Regarding Prevention of Post-hematopoietic Stem Cell Transplantation Invasive Fungal Infection and Its Related Death: A Single Center Experience. <b>2020</b> , 36, 680-689	1
667	Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study. <b>2020</b> , 22, e13289	6
666	Non-cryopreserved peripheral blood stem cells autologous transplantation in multiple myeloma: Bicentric study. <b>2020</b> , 27, 152-156	2
665	Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia. <b>2020</b> , 21, 34	2
664	Infectious Complications in Patients With Multiple Myeloma After High-Dose Chemotherapy Followed by Autologous Stem Cell Transplant: Nationwide Study of the Infectious Complications Study Group of the Polish Adult Leukemia Group. <b>2020</b> , 52, 2178-2185	5
663	Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study. <b>2020</b> , 95, 927-936	16
662	Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper. <b>2020</b> , 4, 762-775	13
661	Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation. <b>2020</b> , 4, 408-419	10
660	Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. <b>2020</b> , 4, 1242-1249	10
659	The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent. <b>2020</b> , 9,	0

658	Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome. <b>2020</b> , 55, 27-34	1
657	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <b>2021</b> , 35, 215-224	15
656	Hematological malignancies in Polish population: what are the predictors of outcome in patients admitted to Intensive Care Unit?. <b>2021</b> , 29, 323-330	1
655	Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin. <b>2021</b> , 35, 850-862	2
654	Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study. <b>2021</b> , 192, 474-483	4
653	Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. <b>2021</b> , 106, 1599-1607	6
652	Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation. <b>2021</b> , 56, 110-120	3
651	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. <b>2021</b> , 56, 60-69	10
650	Autologous stem cell transplantation in light-chain amyloidosis. <b>2021</b> , 14, 111-114	
649	Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. <b>2021</b> , 27, 46-52	8
648	Evaluation of Disease Risk Comorbidity Index after Allogeneic Stem Cell Transplantation in a Cohort with Patients Undergoing Transplantation with In Vitro Partially T Cell Depleted Grafts. <b>2021</b> , 27, 67.e1-67.e7	0
647	Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study. <b>2021</b> , 100, 197-208	1
646	Limitations of Applying the Hematopoietic Cell Transplantation Comorbidity Index in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation. <b>2021</b> , 27, 74.e1-74.e9	2
645	Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. <b>2021</b> , 56, 368-375	1
644	Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. <b>2021</b> , 56, 101-109	7
643	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <b>2021</b> , 127, 609-618	4
642	How I treat adult T-cell leukemia/lymphoma. <i>Blood</i> , <b>2021</b> , 137, 459-470	2.2 10
641	Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis. <b>2021</b> , 27, 70.e1-70.e8	

640	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <b>2021</b> , 96, 69-79	11
639	Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2021</b> , 32, 23-33	92
638	WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience. <b>2021</b> , 21, e145-e151	2
637	Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 106, 114-125	1
636	Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation. <b>2021</b> , 51, 854-869	5
635	Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS. <b>2021</b> , 62, 944-951	0
634	The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell Transplantation Compared to Inpatient Transplantation. <b>2021</b> , 21, e402-e409	2
633	Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). <b>2021</b> , 10, 23-33	2
632	Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation. <b>2021</b> , 106, 205-212	
631	Exacerbated hemodynamic response during exercise in cancer patients prior to autologous hematopoietic stem cell transplantation. <b>2021</b> , 29, 3831-3838	0
630	Hepatic dysfunction impairs prognosis in critically ill patients with hematological malignancies: A post-hoc analysis of a prospective multicenter multinational dataset. <b>2021</b> , 62, 88-93	0
629	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. <b>2021</b> , 27, 165.e1-165.e11	4
628	A Question of Beneficence: Comorbidity Assessment to Ascertain Potential Benefit of CD19 Chimeric Antigen Receptor T Cells for Patients with Diffuse Large B Cell Lymphoma. <b>2021</b> , 27, 2-3	
627	Combining the disease risk index and hematopoietic cell transplant co-morbidity index provides a comprehensive prognostic model for CD34 + -selected allogeneic transplantation. <b>2021</b> , 4,	
626	Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study. <b>2021</b> , 100, 1579-1591	3
625	An Examination of Cytomegalovirus, Socioeconomic Status, Race, and Ethnicity on Outcomes after Haploidentical Hematopoietic Transplantation. <b>2021</b> , 27, 327.e1-327.e11	
624	Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. <b>2021</b> , 27, 406.e1-406.e11	1
623	Prognostic Biomarkers for Thrombotic Microangiopathy after Acute Graft-versus-Host Disease: A Nested Case-Control Study. <b>2021</b> , 27, 308.e1-308.e8	4

- 622 Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. **2021**, 56, 917-927 2
- 621 CELL THERAPY IN INFLAMMATORY BOWEL DISEASE. **2021**, 163, 105247 5
- 620 Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. **2021**, 56, 387-394 4
- 619 Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT. **2021**, 56, 461-469 1
- 618 History of drug use in allogeneic hematopoietic cell transplant recipients. **2021**, 56, 581-585
- 617 Collaborative care for depression and anxiety in the bone marrow transplant population: A pilot feasibility study. **2021**, 30, 118-122 1
- 616 Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT. **2021**, 56, 709-712
- 615 How to select older patients with acute myeloid leukemia fit for intensive treatment?. **2021**, 39, 151-161
- 614 Cognitive function in patients prior to undergoing allogeneic hematopoietic stem cell transplantation. **2021**, 29, 2007-2014 1
- 613 Inpatient variability in concentration/dose ratio of tacrolimus predicts transplant-associated thrombotic microangiopathy. **2021**, 113, 63-72 2
- 612 Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. **2021**, 56, 243-256 3
- 611 Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia - results from a retrospective Belgian registry study. **2021**, 76, 98-105 1
- 610 Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study. **2021**, 100, 799-808 1
- 609 Diagnostik und Therapie der chronischen myelomonozytären Leukämie im Jahr 2020. **2021**, 16, 20-28
- 608 Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation. **2021**, 56, 1364-1372 2
- 607 Transplant Pharmacology and Conditioning Therapy. **2021**, 315-346
- 606 Cardiac Risk Assessment Prior to Hematopoietic Stem Cell Transplantation: Cases and Management Strategies. **2021**, 87-96
- 605 HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment. **2021**, 5, 167-175 3



604	Prognostic Factors in AML. <b>2021</b> , 127-175	1
603	The Future of Transplantation: Hope, Investigative Discipline, and Fairness. <b>2021</b> , 733-740	
602	Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance. <b>2021</b> , 23, e13548	3
601	Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients - results of the PALG study 'PoLAZA'. <b>2021</b> , 26, 556-564	1
600	Clinical Manifestation and Diagnostic Workup. <b>2021</b> , 119-126	
599	Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. <b>2021</b> , 120, 2144-2152	4
598	The Role of Hematopoietic Stem Cell Transplantation in CML. <b>2021</b> , 159-178	
597	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. <b>2021</b> , 127, 1598-1605	3
596	A case of carcinoma of the buccal mucosa with the development of therapy-related myelodysplastic syndrome. <b>2021</b> , 33, 19-27	
595	Determination of fitness and therapeutic options in older patients with acute myeloid leukemia. <b>2021</b> , 96, 493-507	10
594	Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy. <b>2021</b> , 113, 765-769	0
593	Harmonization, biomarkers, disease risk index. <i>Blood</i> , <b>2021</b> , 137, 874-875	2.2
592	Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care. <b>2021</b> , 113, 712-722	1
591	Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan. <b>2021</b> , 100, 1849-1861	1
590	Otolog Hematopoetik Kll Hare Nakli Yaplan Hastalarda Komorbidite Bdekslerinin Sakalın Deİsinin Deİlendirilmesi.	
589	Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study. <b>2021</b> , 11, 639502	2
588	The clinical and functional effects of TERT variants in myelodysplastic syndrome.	
587	CPX-351 (Vyxeos) can cause severe rash in acute myeloid leukemia-A case report. <b>2021</b> , 9, 1933-1936	1

586	Disease Risk Comorbidity Index for Patients Receiving Haploidentical Allogeneic Hematopoietic Transplantation. <b>2021</b> , 7, 162-169	6
585	Comparison of the effect of different methods of cyclosporine infusion on transplant-related outcomes in allogeneic transplant recipients. <b>2021</b> , 27, 778-779	
584	Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation. <b>2021</b> , 5, e532	1
583	Pretransplant plasma brain natriuretic peptide and N-terminal probrain natriuretic peptide are more useful prognostic markers of overall survival after allogeneic hematopoietic cell transplantation than echocardiography. <b>2021</b> , 56, 1467-1470	0
582	Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis. <b>2021</b> , 100, 969-978	
581	Sharing and caring: The impact of social support on quality of life and health outcomes in hematopoietic stem cell transplantation. <b>2021</b> , 127, 1260-1265	2
580	A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. <b>2021</b> , 5, 1154-1163	5
579	Gastrointestinal complications. <b>2021</b> , 260-270	
578	Treatment of AML in Older Patients.	
577	Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes. <b>2021</b> , 5, 1352-1359	2
576	When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis. <b>2021</b> , 10,	2
575	Future perspective: precision medicine to improve treatment results in the settings of allogeneic stem cell transplantation for acute myelogenous leukemia. <b>2021</b> , 6, 151-155	1
574	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <b>2021</b> , 39, 409-418	3
573	Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?. <b>2021</b> , 106, 1794-1804	7
572	The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. <b>2021</b> , 27, 233-240	7
571	Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. <b>2021</b> , 5, 1360-1368	7
570	The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia. <b>2021</b> , 56, 1257-1265	4
569	Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases. <b>2021</b> , 27, 492.e1-492.e6	2

568	ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <b>2021</b> , 27, 256.e1-256.e7	2
567	Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. <b>2021</b> , 5, 1199-1208	11
566	A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. <b>2021</b> , 33, 100787	2
565	Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. <b>2021</b> , 56, 1919-1928	1
564	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. <b>2021</b> , 2, 236-248	1
563	Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. <b>2021</b> , 56, 1683-1690	1
562	New Treatment Options for Older Patients with Acute Myeloid Leukemia. <b>2021</b> , 22, 39	2
561	Hb-adjusted DLCO with GLI reference predicts long-term survival after HSCT in children. <b>2021</b> , 56, 1929-1936	1
560	Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. <b>2021</b> , 62, 2177-2183	
559	The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor-risk cytogenetic abnormalities. <b>2021</b> , 2, 249-256	1
558	Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. <b>2021</b> , 27, 2712-2722	5
557	Feasibility of an intensified myeloablative conditioning regimen consisting of busulfan, fludarabine, cytarabine, and total body irradiation before single cord blood transplantation in elderly patients. <b>2021</b> , 114, 85-93	3
556	A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. <b>2021</b> , 5, 1760-1769	6
555	Does one model fit all? Predicting non-relapse mortality after allogeneic hematopoietic cell transplantation. <b>2021</b> , 56, 1720-1722	0
554	Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status. <b>2021</b> , 106, 859-867	0
553	Sleep Disruption, Fatigue, and Depression as Predictors of 6-Year Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation. <b>2021</b> , 113, 1405-1414	1
552	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <b>2021</b> , 193, 592-601	3
551	Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 56, 2183-2193	0

550	Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia. <b>2021</b> , 11, 666091	4
549	Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. <b>2021</b> , 27, 334.e1-334.e11	6
548	Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study. <b>2021</b> , 27, 311.e1-311.e10	0
547	Sarcopenia Screening Allows Identifying High-Risk Patients for Allogenic Stem Cell Transplantation. <b>2021</b> , 13,	3
546	Allogene Blutstammzelltransplantation: Etabliertes und Neues. <b>2021</b> , 24, 10-15	
545	Late-occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors. <b>2021</b> , 10, 2956-2966	1
544	Body Weight Loss Before Allogeneic Hematopoietic Stem Cell Transplantation Predicts Survival Outcomes in Acute Leukemia Patients. <b>2021</b> , 27, 340.e1-340.e6	2
543	Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival. <b>2021</b> , 103, 106533	
542	Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy. <b>2021</b> , 30, 1294-1301	1
541	Discharge Disposition Following Hematopoietic Cell Transplantation: Predicting the Need for Rehabilitation and Association with Survival. <b>2021</b> , 27, 337.e1-337.e7	1
540	Cardiovascular Issues in Hematopoietic Stem Cell Transplantation (HSCT). <b>2021</b> , 22, 51	1
539	Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review. <b>2021</b> , 100, 1359-1376	1
538	Application of Stem Cell Therapy in Myelofibrosis. <b>2021</b> , 35, 391-407	2
537	Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy. <b>2021</b> , 27, 342.e1-342.e10	0
536	De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. <b>2021</b> , 127, 2049-2061	18
535	Pre-transplant Dementia is Associated with Poor Survival After Hematopoietic Stem Cell Transplantation: A Nationwide Cohort Study with Propensity Score Matched Control. <b>2021</b> , 19, 294-302	1
534	Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). <b>2021</b> , 56, 2533-2543	1
533	Frailty in Patients With Hematologic Malignancies and Those Undergoing Transplantation: A Scoping Review. <b>2021</b> , 48, 291-307	0

532	Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. <b>2021</b> , 12, 585-591	6
531	Current challenges and unmet medical needs in myelodysplastic syndromes. <b>2021</b> , 35, 2182-2198	6
530	Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with MDS-EB-1 or MDS-EB-2. <b>2021</b> , 149, 1109-1120	1
529	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?. <b>2021</b> , 12, 659595	6
528	International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. <b>2021</b> ,	9
527	Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study. <b>2021</b> , 62, 2514-2520	
526	High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. <b>2021</b> , 11, 96	3
525	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <b>2021</b> , 27, 410-422	4
524	Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant. <b>2021</b> , 11, 92	1
523	Functional capacity, lung function, and muscle strength in patients undergoing hematopoietic stem cell transplantation: A prospective cohort study. <b>2021</b> , 14, 126-133	0
522	Allogeneic hematopoietic stem cell transplantation in an adolescent with Prader-Willi syndrome - unique considerations. <b>2021</b> , 1-7	1
521	Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort. <b>2021</b> , 127, 3422-3436	4
520	High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma. <b>2021</b> , 56, 2690-2696	0
519	Parental limited English proficiency in pediatric stem cell transplantation: Clinical impact and health care utilization. <b>2021</b> , 68, e29174	0
518	Acute Kidney Injury in the Modern Era of Allogeneic Hematopoietic Stem Cell Transplantation. <b>2021</b> , 16, 1318-1327	1
517	Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT. <b>2021</b> , 56, 2651-2655	0
516	Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. <b>2021</b> , 38, 138-144	
515	Treatment for Relapsed/Refractory Acute Myeloid Leukemia. <b>2021</b> , 5, e572	4

514	Applicability of the acute leukemia (AL) - EBMT score as a prognostic model for allogeneic hematopoietic stem cell transplantation: a single-center, prospective, cohort study at a reference transplant center in Brazil. <b>2021</b> ,	
513	Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. <b>2021</b> , 5, 2608-2618	2
512	Impact of acute kidney injury on overall survival in children and young adults undergoing allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 68, e29167	1
511	Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT. <b>2021</b> , 10, 4250-4268	1
510	Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review. <b>2021</b> , 16, e0252925	
509	Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. <b>2021</b> , 56, 2664-2671	1
508	Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. <b>2021</b> , 66, 2498-2498	15
507	Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. <b>2021</b> , 13,	0
506	Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. <b>2021</b> , 107, 354-363	0
505	Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. <b>2021</b> , 3, 250-259	6
504	Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor. <b>2021</b> , 8, 604085	2
503	Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia. <b>2021</b> , 21, e559-e568	1
502	Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. <b>2021</b> , 5, 2650-2659	2
501	Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study. <b>2021</b> , 194, 557-567	0
500	Hematopoietic Cell Transplant-Composite Risk (HCT-CR): A Novel Predictor of Prognosis in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <b>2021</b> , 53, 2013-2020	
499	Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal. <b>2021</b> , 23, 635-640	3
498	Free of malignancy but not of fears: A closer look at Damocles syndrome in survivors of hematologic malignancies. <b>2021</b> , 48, 100783	1
497	ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- and Long-term Outcomes. <b>2021</b> , 7, e724	0

496	Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. <b>2021</b> , 27, 617.e1-617.e7	3
495	Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations. <b>2021</b> , 107, 489-496	0
494	FLAMSA-Busulfan-Melphalan as a Sequential Conditioning Regimen in HLA-Matched or Haploidentical Hematopoietic Stem Cell Transplantation for High-Risk Myeloid Diseases. <b>2021</b> , 27, 915.e1-915.e8	0
493	Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. <b>2021</b> , 96, 1186-1194	1
492	Intestinal fungal dynamics and linkage to hematopoietic cell transplantation outcomes.	
491	Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. <b>2021</b> , 1	0
490	Survival Advantage of Treosulfan Plus Fludarabine Before Allogeneic Hematopoietic Cell Transplantation for Older or Comorbid Patients With Myeloid Malignancies. <b>2021</b> , 27, 916.e1-916.e6	0
489	Increased Infections and Delayed CD4 T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. <b>2021</b> , 27, 940-948	1
488	The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant. <b>2021</b> , 56, 2749-2754	
487	Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients. <b>2021</b> , 11, 705568	0
486	A randomized double-blind placebo-controlled trial of intravenous thiamine for prevention of delirium following allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 146, 110503	2
485	Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?. <b>2021</b> , 106, 2544-2554	1
484	Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. <b>2021</b> , 27, 600.e1-600.e8	2
483	Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML. <b>2021</b> , 56, 2834-2841	2
482	Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. <b>2021</b> , 56, 2763-2770	4
481	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. <b>2021</b> , 27, 913.e1-913.e12	0
480	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. <b>2021</b> , 39, 2397-2409	7
479	Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. <b>2021</b> , 27, 689-695	2

478	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <b>2021</b> , 127, 4421-4431	1
477	Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma. <b>2021</b> , 56, 2964-2974	0
476	A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin. <b>2021</b> , 23, 1007-1016	0
475	Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. <b>2021</b> , 56, 2897-2903	4
474	Cardiac complications associated with hematopoietic stem-cell transplantation. <b>2021</b> , 56, 2637-2643	0
473	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <b>2021</b> , 27, 921.e1-921.e10	2
472	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <b>2021</b> , 27, 917.e1-917.e9	0
471	Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancies. <b>2021</b> , 27, 912.e1-912.e6	0
470	Allogeneic Stem Cell Transplantation for MDS. <b>2021</b> , 2, 545-555	2
469	Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. <b>2021</b> , 107, 573-582	1
468	Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant. <b>2021</b> , 96, 1275-1286	1
467	"I took the road less traveled, and that has made all the difference": Making a case for high-dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma. <b>2021</b> , 127, 4133-4136	1
466	Outcomes of Fludarabine, Melphalan and Total Body Irradiation as a Reduced Intensity Conditioning Regimen in Matched Donor Allogeneic Peripheral Blood Stem Cell Transplantation. <b>2021</b> , 27, 665.e1-665.e7	0
465	Investigation of demographic features, performance, comorbidity status and mortality causes among multiple myeloma patients: real-life data. <b>2021</b> , 1-7	
464	Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis. <b>2021</b> , 100, 2763-2771	0
463	Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant. <b>2021</b> ,	1
462	Pretransplantation Red Blood Cell and Platelet Transfusion Burden in De Novo Myelodysplastic Syndrome Undergoing Allogeneic Transplantation. <b>2021</b> , 27, 671-678	1
461	Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies. <b>2021</b> , 27, 669.e1-669.e8	1



460	Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes. <b>2021</b> , 1-9	
459	The Simplified Comorbidity Index (SCI) - a new tool for prediction of non-relapse mortality in allogeneic HCT. <b>2021</b> ,	0
458	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <b>2021</b> , 56, 3068-3077	3
457	Development and validation of a comorbidity index for predicting survival outcomes after allogeneic stem cell transplantation in adult patients with acute leukemia: a Korean nationwide cohort study. <b>2021</b> , 56, 184-196	0
456	Comorbidities and frailty predict outcome of patients with myelodysplastic syndromes. Should we integrate them in novel prognostic scoring systems?. <b>2021</b> , 12, 1122-1129	2
455	The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia. <b>2021</b> , 100, 3017-3027	
454	Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis. <b>2021</b> , 56, 3008-3015	0
453	Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. <b>2021</b> , 27, 796.e1-796.e7	6
452	Beyond steroids: A systematic review and proposed solutions to managing acute graft-versus-host disease in adolescents and young adults. <b>2021</b> , 52, 100886	1
451	Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis. <b>2021</b> , 27, 1005.e1-1005.e1	0
450	The anemia-independent impact of myelodysplastic syndromes on health-related quality of life. <b>2021</b> , 100, 2921-2932	0
449	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma. <b>2021</b> , 13,	2
448	Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience. <b>2021</b> , 1-7	
447	Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis. <b>2021</b> , 11, 159	
446	Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide. <b>2021</b> , 10, 7194-7202	1
445	Outcomes of pediatric patients with therapy-related myeloid neoplasms. <b>2021</b> , 56, 2997-3007	1
444	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. <b>2021</b> , 137, 31-44	3
443	Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial. <b>2021</b> , 11, 731478	0

442	Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases. <b>2021</b> , 11, 737645	0
441	Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies. <b>2021</b> , 1	1
440	Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients. <b>2021</b> , 27, 774.e1-774.e12	3
439	Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation. <b>2021</b> , 5, 3418-3426	1
438	Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <b>2021</b> , 27, 760-767	6
437	Echocardiographic predictors of new-onset atrial arrhythmias in patients undergoing hematopoietic stem cell transplantation. <b>2021</b> , 339, 225-231	0
436	Donor clonal hematopoiesis and recipient outcomes after transplantation.	
435	Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <b>2021</b> ,	3
434	The Addition of Sirolimus to GVHD Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis of Efficacy and Safety. <b>2021</b> , 11, 683263	1
433	A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. <b>2021</b> ,	1
432	Cardiac Toxicity after Matched Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era. <b>2021</b> ,	2
431	Early Post-Transplantation Serum Ferritin Level Predicts Survival in Recipients of Haploidentical Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis. <b>2021</b> , 27, 861.e1-861.e7	
430	Sequential Organ Failure Assessment Score and the Need for Organ Support Predict Mortality in Allogeneic Stem Cell Transplant Patients Admitted to the Intensive Care Unit. <b>2021</b> , 27, 865.e1-865.e7	2
429	Effect of Donor NKG2D Polymorphism on Relapse after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <b>2021</b> ,	1
428	Replicated Risk Index of Patient Functional Status Prior to Allogeneic Hematopoietic Cell Transplantation Predicts Healthcare Utilization and Survival. <b>2021</b> , 27, 875.e1-875.e9	
427	Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma. <b>2021</b> , 110, 106700	
426	Pretransplant Assessment for Hematopoietic Cell Transplantation Recipients and Donors. <b>2021</b> , 55-72	
425	Hematopoietic Stem Cell Donor and Recipient Evaluation. <b>2021</b> , 421-442	

424	Characteristics and predictors of post-transplant-associated hemophagocytic lymphohistiocytosis in adults. <b>2021</b> , 113, 693-702	1
423	Cardiopulmonary performance in allogeneic hematopoietic cell transplantation recipients-evaluation of pre-transplant risk assessments. <b>2021</b> , 56, 1325-1334	
422	Conditioning Regimens for Frail Patients with Acute Leukemia Undergoing Allogeneic Stem Cell Transplant: How to Strike Gently.. <b>2021</b> , 3, 153-160	0
421	History of Bone Marrow Transplantation. <b>2021</b> , 3-26	
420	The NICE COVID-19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact. <b>2021</b> , 192, 467-473	9
419	Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation. <b>2021</b> , 9, 2050313X20988413	
418	Treatment of Newly Diagnosed AML in Unfit Patients. <b>2021</b> , 215-231	
417	Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease. <b>2021</b> , 384, 11-19	18
416	Disseminated intravascular coagulopathy in non-promyelocytic acute myeloid leukemia: Incidence, clinical and laboratory features and prognostic significance. <b>2021</b> , 2, 99-109	
415	Reduced-intensity and nonmyeloablative conditioning regimens. <b>2009</b> , 144, 209-32	2
414	Nonmyeloablative Transplantation. <b>2008</b> , 349-374	2
413	Allogeneic Hematopoietic Cell Transplantation for Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders. <b>2008</b> , 167-182	2
412	Evaluation and Counseling of Candidates. <b>2019</b> , 77-86	3
411	Acute Myeloid Leukemia in Adults. <b>2019</b> , 507-521	3
410	Myelodysplastic/Myeloproliferative Neoplasms. <b>2019</b> , 561-568	1
409	Diffuse Large B-Cell Lymphomas in Older Adults. <b>2020</b> , 583-612	1
408	Toxicity of Conditioning Regimens in Haploidentical SCT. <b>2017</b> , 43-56	1
407	Komorbidity unter geriatrischen Aspekten. <b>2018</b> , 27-36	1

406	Prognostic Scoring in MDS. <b>2011</b> , 103-120	2
405	Myelodysplastic Syndromes. <b>2008</b> , 2235-2259	1
404	Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome. <b>2017</b> , 23, 2143-2150	13
403	Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. <b>2019</b> , 25, 1218-1224	19
402	Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion. <b>2020</b> , 26, 1492-1496	5
401	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <b>2020</b> , 26, 1459-1468	14
400	Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function. <b>2020</b> , 26, 1597-1606	3
399	Prognostic Impact of Cytogenetic Evolution on the Outcome of Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Nonremission: A Single-Institute Analysis of 212 Recipients. <b>2020</b> , 26, 2262-2270	1
398	Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. <b>2021</b> , 56, 596-604	3
397	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <b>2020</b> , 55, 1114-1125	28
396	Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. <b>2020</b> , 55, 1317-1325	6
395	Comorbidities cluster with impaired functional capacities and depressive mood and predict adverse outcome in older patients with hematological malignancies. <b>2020</b> , 61, 1954-1964	1
394	Interactive Web Application for Plotting Personalized Prognosis Prediction Curves in Allogeneic Hematopoietic Cell Transplantation Using Machine Learning. <b>2021</b> , 105, 1090-1096	3
393	Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models. <b>2018</b> , 3,	11
392	Older patients/older donors: choosing wisely. <b>2013</b> , 2013, 70-75	1
391	Chemotherapy-induced cognitive impairment in hematological malignancies. <b>2019</b> , 55,	2
390	Liver disease during and after hematopoietic stem cell transplantation in adults: a single-center Egyptian experience. <b>2020</b> , 32, 11	2
389	Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country. <b>2015</b> , 10, e0137390	7

388	What is the role of transplantation for indolent lymphoma?. <b>2012</b> , 494-500	1
387	Predictive Role of Circulating Immune Cell Subtypes Early after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia. <b>2018</b> , 12, 73-83	13
386	Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. <b>2017</b> , 8, 112972-112979	13
385	Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy. <b>2018</b> , 9, 5823-5833	1
384	Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. <b>2018</b> , 9, 33528-33535	10
383	Comorbidity and Personalized Treatment of Multiple Myeloma in Real Clinical Practice. <b>2020</b> , 13, 322-334	1
382	Promoting Health and Well-Being Through Mobile Health Technology (Roadmap 2.0) in Family Caregivers and Patients Undergoing Hematopoietic Stem Cell Transplantation: Protocol for the Development of a Mobile Randomized Controlled Trial. <b>2020</b> , 9, e19288	5
381	Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Elderly. <b>2019</b> , 17, eAE4340	2
380	The treatment of elderly patients with acute myeloid leukemia. <b>2011</b> , 108, 863-70	38
379	The indications for allogeneic stem cell transplantation in myeloid malignancies. <b>2015</b> , 112, 262-70	9
378	History of hematopoietic cell transplantation: challenges and progress. <b>2020</b> , 105, 2716-2729	12
377	Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of -ITD in Mutated AML, Irrespectively of -ITD Allelic Burden. <b>2020</b> , 13,	3
376	Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement. <b>2020</b> , 17,	0
375	Effects of total body irradiation-based conditioning on allogeneic stem cell transplantation for pediatric acute leukemia: a single-institution study. <b>2014</b> , 32, 198-207	9
374	Is immunological recovery clinically relevant at 100 days after allogeneic transplantation?. <b>2020</b> , 35, 957-969	3
373	A case of hepatosplenic T-cell lymphoma successfully treated by HLA haploidentical stem cell transplantation. <b>2020</b> , 60, 55-59	2
372	Impact of comorbidity on waiting list and post-transplant outcomes in patients undergoing liver retransplantation. <b>2017</b> , 9, 884-895	6
371	Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study. <b>2019</b> , 36, 88-96	3

370	Lymphocyte recovery is an independent predictor of relapse in allogeneic hematopoietic cell transplantation recipients for acute leukemia. <b>2017</b> , 7, 235-242	2
369	Graft host disease impacts overall survival post allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia/lymphoma. <b>2018</b> , 8, 252-261	3
368	Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <b>2020</b> , 18, 599-634	11
367	Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT. <b>2021</b> , 56, 3084-3087	
366	The effect of comorbidity on survival and collected CD34 + cell counts in autologous hematopoietic stem cell transplant patients. <b>2021</b> , 103296	
365	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. <b>2021</b> , 1	1
364	Psychosocial Pre-Transplant Screening With the Transplant Evaluation Rating Scale Contributes to Prediction of Survival After Hematopoietic Stem Cell Transplantation. <b>2021</b> , 12, 741438	0
363	Decrease in Mortality from Sepsis: Impact of the Multidisciplinary Program for the Hematologic Patient at Very High Risk. 1	
362	Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. <b>2021</b> , 1	0
361	Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. <b>2022</b> , 108, 61-72	1
360	Toward a pathophysiology inspired treatment of VEXAS syndrome. <b>2021</b> , 58, 239-246	7
359	Single-Nucleotide Polymorphisms in MICA and MICB Genes Could Play a Role in the Outcome in AML Patients after HSCT. <b>2021</b> , 10,	
358	Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI. <b>2021</b> , 1	
357	Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant. <b>2021</b> ,	
356	Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021. <b>2021</b> , 13,	5
355	Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi. <b>2021</b> , 1-10	1
354	Efficacy of expressive helping in adult hematologic cancer patients undergoing stem cell transplant: protocol for the Writing for Insight, Strength, and Ease (WISE) study's two-arm randomized controlled trial. <b>2021</b> , 22, 722	0
353	The impact of pulmonary function in patients undergoing autologous stem cell transplantation. <b>2021</b> , 5, 4327-4337	0

- 352 Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care. **2021**, 8, e853-e861 4
- 351 Hematopoietic Stem Cell Transplantation. **2008**, 501-512 1
- 350 Assessment and Impact of Comorbidity in Older Adults with Cancer. **2009**, 95-111
- 349 Therapy of acute myelogenous leukemia in adults. **2010**, 145, 257-71
- 348 The Role of Allogeneic Transplantation for Multiple Myeloma in Older Adults. **2010**, 127-142
- 347 Functional Assessment Tools and Co-morbidity Scoring in Hematopoietic Progenitor Cell Transplantation. **2010**, 687-694
- 346 Retrospective Analysis of 50 Cases of First Allogeneic Transplantation for Acute Myelogenous Leukemia and High Risk Myelodysplastic Syndrome. **2010**, 59, 105-113
- 345 Retrospective Analysis of Reduced Intensity Conditioning Stem Cell Transplantation for Hematological Malignancies. **2010**, 59, 63-70
- 344 Pre-transplant Evaluation. **2010**, 27-37
- 343 Primary Myelofibrosis (PMF) [Previously Chronic Idiopathic Myelofibrosid (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)]. **2010**, 81-116
- 342 Stem Cell Transplantation. 722-745
- 341 Haematopoietic Stem Cell Transplantation in MDS for Adults. **2011**, 239-252
- 340 Hematopoietic Stem-Cell Transplantation for Acute Myelogenous Leukemia. 148-160
- 339 Quality of Life after the Diagnosis of Hematological Malignancies. 384-397
- 338 Reduced-Intensity and Non-Myeloablative Conditioning Followed by Hematopoietic Cell Transplantation. **2012**, 187-217
- 337 Stem cell transplantation. **2012**, 54-64
- 336 Outcome of second/third allogeneic hematopoietic stem cell transplantations for a relapse of acute leukemia after the first transplantation. **2013**, 16, 17-24
- 335 Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation. **2013**, 5, 174-84 11

- 334 Hematopoietic Cell Transplantation (HCT). **2013**, 211-228
- 333 Haemopoietic Stem Cell Transplantation. 455-463
- 332 Preparative Regimens. **2014**, 41-56
- 331 Geriatric Assessment. **2015**, 219-237
- 330 Pre-transplant Medical Evaluation. **2015**, 43-54
- 329 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79
- 328 Preparative regimens for lymphoma. 57-67
- 327 Allogene Stammzelltransplantation bei älteren komorbiden Patienten. **2016**, 1-11
- 326 Conditioning Regimens for Cord Blood Transplantation. **2017**, 87-107
- 325 Komorbidität unter geriatrischen Aspekten. **2017**, 1-11
- 324 Stammzelltransplantation (SZT). **2017**, 211-231
- 323 Akute myeloische Leukämie beim alten und geriatrischen Patienten. **2017**, 1-16
- 322 Hematopoietic Stem Cell Transplantation. **2017**,
- 321 Special Care of Blood and Marrow Hematopoietic Cell Transplant Recipient. **2018**, 1211-1245
- 320 Role of Hematopoietic Cell Transplantation for Myeloma. **2018**, 573-583
- 319 Transplantation Through the Generations. **2018**, 135-161
- 318 The Evolving Role of Transplant for Older Adults. **2018**, 1-17
- 317 Transplant Preparation. **2018**, 45-69



316 Diffuse Large B-Cell Lymphomas in Older Adults. **2018**, 1-31

315 Allogene Stammzelltransplantation bei älteren komorbiden Patienten. **2018**, 113-123

314 Efficacy and safety of allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning in patients under 55 years old. **2018**, 7, 82-89

313 Comorbidity in Aging and Cancer. **2018**, 1-29

312 Akute myeloische Leukämie beim alten und geriatrischen Patienten. **2018**, 213-228

311 Graft vs host disease impacts overall survival post allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia/lymphoma. **2018**, 8, 252-261

310 Znaczenie badań molekularnych dla oceny ryzyka i rokowania u chorych na pierwotne włóknienie szpiku w oparciu o wskaźniki prognostyczne IPSS, DIPSS oraz MIPSS. **2018**, 49, 140-146

309 HSCT in Elderly Patients. **2019**, 499-503

1

308 Follicular Lymphoma. **2019**, 621-626

307 What the Intensivist Needs to Know About Hematopoietic Stem Cell Transplantation?. **2019**, 1-16

306 Allogeneic Stem Cell Transplantation with CD34+ Cell Selection. **2019**, 1, 154-160

3

305 Allogeneic hematopoietic stem cell transplantation in a 76-year-old woman with relapsed acute myeloid leukemia. **2019**, 6, 193

304 Progressive Hepatic Cirrhosis Early After Allogeneic Hematopoietic Stem Cell Transplantation in a Patient with Chronic Hepatitis C Infection. **2019**, 36, 130-133

303 What the Intensivist Needs to Know About Hematopoietic Stem Cell Transplantation?. **2020**, 1531-1546

1

302 Haploidentical Related Donor versus Matched Sibling Donor Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome Aged Over 50 Years: A Single-Center Retrospective Study..

301 Interactive web application for plotting personalized prognosis prediction curves in allogeneic hematopoietic cell transplantation using machine learning.

0

300 Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. **2020**, 18, 635-643

2

299 Comparable Outcomes Between Unrelated and Haploidentical Stem Cell Transplantation in Adult Patients With Severe Aplastic Anemia. **2021**, 105, 1097-1105

2

- 298 Pediatric hematopoietic cell transplantation: Longitudinal trends in body mass index and outcomes. **2020**, 24, e13844 ○
- 297 Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. **2021**, ○
- 296 The Future of Transplantation: Hope, Investigative Discipline, and Fairness. **2020**, 1-8
- 295 Impact of a prior history of cancer on prognosis after myeloablative single-unit cord blood transplantation. **2021**, 51, 657-660
- 294 Outcomes of Non-Cryopreserved Versus Cryopreserved Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma. **2020**, 25, e927084 4
- 293 Allogeneic haematopoietic stem cell transplantation with reduced-intensity conditioning in chronic myeloid leukaemia. **2020**, 65, 386-402
- 292 Hematopoietic Stem Cell Donor and Recipient Evaluation. **2020**, 1-22
- 291 Hematopoietic Cell Transplantation for MDS Patients. **2020**, 165-173
- 290 Comorbidity in Aging and Cancer. **2020**, 365-393
- 289 The Evolving Role of Transplant for Older Adults. **2020**, 613-629
- 288 Pre-transplant Comorbidities: Influence on Decision-Making and Outcomes. **2020**, 57-85
- 287 Transplant Pharmacology and Conditioning Therapy. **2020**, 1-32
- 286 History of Bone Marrow Transplantation. **2020**, 1-24
- 285 Hypomethylating Agents Use in Acute Myeloid Leukemia: A Single-Center Experience. **2020**, 41, 202-208
- 284 Is heart rate in post-hematopoietic stem cell transplant patients clinically relevant?. **2021**, 1-4
- 283 Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?. **2021**, 34, 101335 ○
- 282 Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation. **2021**, ○
- 281 The Role of Stem Cell Transplant in the Therapy of Acute Myeloid Leukemia (AML). **2021**, 111-131

- 280 Prognostic value of the modified multiple myeloma comorbidity index in real clinical practice. **2020**, 15, 51-62
- 279 Mental adjustment to cancer and survival of patients admitted for allogeneic hemopoietic stem cell transplantation - a prospective cohort study. **2006**, 3, Doc04 2
- 278 Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus. **2013**, 3, 141-64 10
- 277 To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision. **2012**, 10, 655-62
- 276 Risk factors for delirium in patients undergoing hematopoietic stem cell transplantation. **2012**, 24, 204-14 13
- 275 Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review. **2014**, 7, 4357-68 15
- 274 Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions. **2017**, 17, 398-404 21
- 273 The Confirmation of Safety for the Intensified Conditioning Regimens: A Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Non-Remission Hematological Malignant Diseases. **2018**, 12, 123-131
- 272 A Comparison of Inpatient and Outpatient-Based Chemotherapy Regimens for the Treatment of Acute Myeloid Leukaemia In The Elderly. **2019**, 88, 25-29 1
- 271 Management of thrombocytopenia in a patient with a mechanical mitral valve undergoing autologous hematopoietic stem cell transplantation: case report and review of literature. **2020**, 10, 11-14
- 270 Pre-transplant cytoreductive therapy can improve overall survival of patients with MDS-AML but not MDS-EB2 receiving HLA-matched sibling donor peripheral blood stem cell transplantation. **2020**, 10, 1218-1228 1
- 269 [Safety and efficacy of chimeric antigen receptor T cell in the treatment of elderly patients with hematological malignancies]. **2018**, 39, 952-955
- 268 [Prognostic evaluation of comorbidities in patients with myelodysplastic syndrome]. **2015**, 36, 196-201
- 267 [Treatment of 30 elderly patients with advanced myeloid neoplasm by allogeneic hematopoietic stem cell transplantation]. **2018**, 39, 629-633
- 266 [Focusing the application of hematopoietic stem cell transplantation in elderly acute myeloid leukemia]. **2018**, 39, 1043-1046
- 265 [A pilot study of ten-day decitabine regimen as initial therapy for newly diagnosed elderly patients with acute myeloid leukemia]. **2016**, 37, 993-995
- 264 [Clinical studies of myeloablative dose conditioning prior to allogeneic hematopoietic stem cell transplantation for treatment of 12 patients over 55 years with high- risk malignant blood diseases]. **2016**, 37, 708-11
- 263 Impact of gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes. **2021**, 11, 955-967

262	Salvage Cord Blood Transplantation Using a Short-term Reduced-intensity Conditioning Regimen for Graft Failure. <b>2021</b> ,	1
261	Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease. <b>2021</b> ,	0
260	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. <b>2021</b> , JCO2102286	5
259	Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study. <b>2021</b> ,	1
258	Hematopoietic Cell Transplant-Comorbidity Index Score is Correlated with Treatment Related Mortality and Overall Survival following Second Allogeneic Hematopoietic Cell Transplant in Children. <b>2021</b> ,	0
257	GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS. <b>2021</b> , 28, 96.e1-96.e1	0
256	A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. <b>2021</b> , 11, 183	
255	Haematopoietic cell transplantation outcomes are linked to intestinal mycobiota dynamics and an expansion of <i>Candida parapsilosis</i> complex species. <b>2021</b> , 6, 1505-1515	3
254	Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen. <b>2021</b> ,	1
253	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. <b>2021</b> , 28, 83.e1-83.e1 <sup>1</sup>	
252	Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. <b>2021</b> ,	1
251	Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. <b>2021</b> ,	0
250	Real-world Experience of Improvement in the Survival of Lymphoma and Myeloma Patients with Autologous Stem Cell Transplantation over a 25-year Period. <b>2021</b> , 96, 501-511	1
249	A New Prognostic Scoring System (BRIGHT) Predicts Mortality of Septic Shock after Allogeneic Hematopoietic Stem Cell Transplantation.	
248	Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.. <b>2021</b> , 11, 805514	2
247	Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes-results of a retrospective analysis from a German university hospital. <b>2021</b> , 101, 389	1
246	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.. <b>2022</b> ,	2
245	Preliminary Report for the Development of a Multiparameter Protocol for the Identification of Sinusoidal Obstruction Syndrome including Abdominal Ultrasound before and after Allogeneic Stem Cell Transplantation. <b>2022</b> , 12, 829	0

244	Geriatric assessment predicts non-fatal toxicities and survival for intensively treated older adults with AML.. <i>Blood</i> , <b>2022</b> ,	2.2	6
243	Duration of sweat cyclophosphamide excretion in patients undergoing a conditioning regimen of high-dose cyclophosphamide for hematopoietic stem-cell transplantation.. <b>2022</b> , 10781552221077035		1
242	Conditioning Intensity and Peri-Transplant Flow Cytometric MRD Dynamics in Adult AML.. <i>Blood</i> , <b>2022</b> ,	2.2	2
241	Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience.. <b>2022</b> ,		0
240	Short-term methotrexate plus cyclosporine for graft-versus-host disease prophylaxis after single-unit cord blood transplantation following reduced-intensity conditioning. <b>2022</b> , 11, 64-71		
239	What are the risks and benefit of a transplant for elderly patients?. <b>2022</b> , 11, 22-35		
238	Pitfalls and Successes in Trials in Older Transplant Patients with Hematologic Malignancies.. <b>2022</b> , 24, 125		
237	Evaluation of indices for predicting recovery of exercise tolerance in patients surviving allogeneic hematopoietic stem cell transplantation.. <b>2022</b> , 30, 4027		0
236	Incidence and Risk Factors for Acute Kidney Injury after Allogeneic Stem Cell Transplantation: A Prospective Study.. <b>2022</b> , 10,		0
235	Risk and predictive factors for candidemia after allogeneic hematopoietic cell transplantation: JSTCT Transplant Complications Working Group.. <b>2022</b> ,		2
234	Allogeneic Stem Cell Transplantation Combined With Transfusion of Mesenchymal Stem Cells in Primary Myelofibrosis: A Multicenter Retrospective Study.. <b>2021</b> , 11, 792142		0
233	Defibrotide combined with triple therapy including posttransplant cyclophosphamide, low dose rabbit anti-t-lymphocyte globulin and cyclosporine is effective in prevention of graft versus host disease after allogeneic peripheral blood stem cell transplantation for hematologic malignancies.. <b>2022</b> , 103367		1
232	Hematopoietic cell transplantation for myelodysplastic syndromes. <b>2022</b> , 11, 43-52		
231	Effectiveness of defibrotide in the prevention of hepatic venoocclusive disease among adult patients receiving allogeneic hematopoietic cell transplantation: A retrospective single center experience.. <b>2022</b> , 103369		0
230	Failure to reach hematopoietic allogeneic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study.. <b>2022</b> ,		1
229	Deletion of Y-chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors.. <b>2022</b> ,		
228	Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study.. <b>2022</b> ,		1
227	Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia.. <b>2022</b> , 12, 781479		

- 226 The Prognostic Value of Sarcopenia in Acute Myeloid Leukemia Patients and the Development and Validation of a Novel Nomogram for Predicting Survival.. **2022**, 12, 828939
- 225 How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.. **2022**, 11, 0
- 224 Delayed kidney transplantation after HLA-haploidentical hematopoietic cell transplantation in a young woman with myelodysplastic syndrome with renal failure.. **2022**, 17, 100302 0
- 223 Comorbidity and Polypharmacy in Older Adults with Cancer and Frailty. **2022**, 93-112
- 222 Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia.. **2022**, 0
- 221 Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population.. **2022**, 31, 9636897221080385 1
- 220 Hemorrhagic cystitis in allogeneic stem cell transplantation: a role for age and prostatic hyperplasia.. **2022**, 1
- 219 Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma.. **2022**,
- 218 The Two-Step Allogeneic Stem Cell Transplant Approach Results in Rapid Engraftment and Excellent Outcomes in Patients with Lymphoid Malignancies.. **2021**,
- 217 Non-infectious pulmonary toxicity after allogeneic hematopoietic cell transplantation.. **2022**, 1
- 216 Allogeneic hematopoietic stem cell transplantation for adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in second complete remission.. **2022**, 1
- 215 Myeloablative versus reduced-intensity conditioning with fludarabine/busulfan for myelodysplastic syndrome: A propensity score-matched analysis.. **2022**, 0
- 214 Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. **2022**, 0
- 213 Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities.. **2022**, 12, 805702 1
- 212 Predicting Long-term Survival After Allogeneic Hematopoietic Cell Transplantation in Patients With Hematologic Malignancies: Machine Learning-Based Model Development and Validation.. **2022**, 10, e32313 0
- 211 Patterns and predictors of functional decline after alloHCT in older adults.. **2022**,
- 210 External Validation of the Revised Pretransplant Assessment of Mortality Score in Allogeneic Hematopoietic Cell Transplantation: A Cohort Study.. **2022**, 6, e704
- 209 Unrelated bone marrow transplantation improves Crohn's disease in a patient with myelodysplastic syndrome that developed from aplastic anemia: A case report. **2022**, 4,

208	Risk Factors for early CMV reactivation and Impact of early CMV reactivation on Clinical Outcomes after T Cell-replete Haploidentical Transplantation with Post-transplant Cyclophosphamide.. <b>2021,</b>	0
207	Day100 Score predicts moderate-severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation.. <b>2021,</b>	0
206	The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis.. <b>2022, 12,</b>	
205	Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.. <b>2022,</b>	
204	Impact of serum insulin-like growth factor-1 on HSCT outcome in pediatric cancer patients.. <b>2022,</b>	
203	Immune reconstitution and survival of patients with parvovirus B19 related pure red cell aplasia after haplo-PBSCT.. <b>2022, 1</b>	
202	Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma.. <b>2022, 1</b>	0
201	Predicting Long-term Survival After Allogeneic Hematopoietic Cell Transplantation in Patients With Hematologic Malignancies: Machine LearningBased Model Development and Validation (Preprint).	
200	Establishment of a Predictive Model for GvHD-free, Relapse-free Survival after Allogeneic HSCT using Ensemble Learning.. <b>2021,</b>	3
199	Allogeneic haematopoietic stem cell transplantation-clinical outcomes: impact of leg muscle strength.. <b>2021,</b>	2
198	Room for Improvement: A 20-Year Single Center Experience with Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. 1	
197	Total body irradiation-based versus busulfan-based myeloablative conditioning for single-unit cord blood transplantation in adults.. <b>2021, 1-11</b>	
196	Case Report: Graft Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome.. <b>2021, 11, 749691</b>	
195	Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors.. <b>2021,</b>	0
194	Cachectic muscle wasting in acute myeloid leukaemia: a sleeping giant with dire clinical consequences. <b>2021,</b>	1
193	Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation.. <b>2021, 101, 681</b>	0
192	Intestinal Blautia may protect against neutropenic fever in allogeneic transplant patients by augmenting the intestinal epithelium.. <b>2022,</b>	0
191	Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.. <b>2022,</b>	0

- 190 Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant.. **2022,**
- 189 Targeted Marrow Irradiation Intensification of Reduced Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation.. **2022,** 0
- 188 Proteomic approaches for untangling pharmacological targets in acute myelogenous leukemia.. **2022,**
- 187 Geriatric assessment for older adults receiving less intensive therapy for acute myeloid leukemia: Report of CALGB 361101.. **2022,** 1
- 186 Data\_Sheet\_1.zip. **2020,**
- 185 Table\_1.docx. **2019,**
- 184 Table\_2.docx. **2019,**
- 183 Impact of CDC warning on co-prescribing of opioids and benzodiazepines in older allogeneic hematopoietic cell transplant recipients.. **2022,**
- 182 Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT.. **2022,** 0
- 181 Respiratory viruses in hematopoietic cell transplant candidates: impact of preexisting lower tract disease on outcomes.. **2022,** 0
- 180 CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis.. **2022,**
- 179 Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplant.. **2022,**
- 178 Successful neutrophil engraftment supported by granulocyte transfusion in adult allogeneic transplant patients with peri-transplant active infection.. **2022,** 103453
- 177 Ideal body weight is useful for predicting neutrophil engraftment and platelet recovery for overweight and obese recipients in single-unit cord blood transplantation.. **2022,** 0
- 176 Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning.. **2022,**
- 175 Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.. **2022** 6
- 174 Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma.. **2022,** 0
- 173 Oncology and Hematology in the ICU. **2022,** 473-513



172	The limited use of autologous hematopoietic stem cell transplant for fit older patients with multiple myeloma in India: a retrospective analysis.. <b>2022</b> , 34, 21	0
171	Change in patients' perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma.. <b>2022</b> ,	0
170	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.. <b>2022</b> ,	8
169	Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians.. <b>2022</b> , 1-4	0
168	Treosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized Trial.	0
167	Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative study.	
166	Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. <b>2022</b> , 1-16	1
165	Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan.	0
164	Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation. <b>2022</b> , 27, 620-628	
163	Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia. <b>2022</b> , 12,	1
162	MAIT and V $\alpha$ unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. <b>2022</b> , 14,	3
161	Real-world Evidence of Axicabtagene Ciloleucel for the Treatment of Large B-Cell Lymphoma in the United States. <b>2022</b> ,	1
160	Haematopoietic Cell Transplantation. <b>2022</b> , 531-542	
159	Critical Care Issues in Post Stem Cell Transplant Patient. <b>2022</b> , 217-231	
158	Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: A single-center retrospective analysis. <b>2022</b> ,	1
157	Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients $\geq$ 5 years of age.	0
156	Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation. <b>2022</b> ,	
155	Comparison of two spirometry reference equations in predicted FEV1 quantification and its effects on hematopoietic cell transplantation-specific comorbidity index (HCT-CI). <b>2022</b> , 5,	

- 154 Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients. **2022**, 14, 2910 0
- 153 Predictors and Outcomes of Dose Reduction of Methotrexate and Cyclosporin Graft-Versus-Host-Disease Prophylaxis Following Allogeneic Haematopoietic Cell Transplantation.
- 152 Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. 1
- 151 Successful outcomes of second hematopoietic stem cell transplantation for graft failure in pediatric patients with severe aplastic anemia. **2022**, 12,
- 150 Pre-transplantation vitamin E levels and acute graft-versus-host disease after non-myeloablative allogeneic hematopoietic cell transplantation. **2022**, 74, 101650
- 149 Hematopoietic stem cell transplantation for myeloproliferative neoplasms. **2022**, 11, 148-160
- 148 Kidney Disease Following Hematopoietic Stem Cell Transplantation. **2022**, 29, 103-115.e1 0
- 147 Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant. **2022**, 158, 451-457
- 146 Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation.
- 145 Acute kidney injury within 100 days post allogeneic hematopoietic cell transplantation is associated with increased risk of post-transplant complications and poor transplant outcomes. 1
- 144 Stroke before a haematopoietic stem cell transplantation is a potential risk factor for poor response to therapy in patients with blood cancer. **2022**, 16, 36-43 0
- 143 Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Haematopoietic Stem Cell Transplant Recipients: A Cohort Study. **2022**, 0
- 142 Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. **2022**, 4
- 141 Role of the intensive care in allogeneic hematopoietic stem cell transplantation. **2022**, 67, 216-239 1
- 140 Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups. 13, 0
- 139 Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. *Blood*, 2.2 60
- 138 Erstlinientherapie intensiv-therapierbarer AML-Patient\*innen. **2022**, 25, 16-21
- 137 Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy. **2022**, 1

- 136 A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies. **2022**, 31, 096368972211120
- 135 Curative allogeneic hematopoietic stem cell transplantation following reduced toxicity conditioning in adults with primary immunodeficiency. ○
- 134 Impact of Pre-transplant Individual Comorbidities on Risk of ICU Admission and Survival Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation.
- 133 Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups. ○
- 132 Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper.
- 131 Social vulnerability and risk of non-relapse mortality after allogeneic hematopoietic cell transplantation. ○
- 130 Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—Grand Ouest Against Leukemia (GOAL) study.
- 129 Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies.
- 128 Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia. ○
- 127 Higher cryopreserved CD34+ cell dose is associated with decreased hepatic veno-occlusive disease/sinusoidal obstruction syndrome after single-unit cord blood transplantation in adults given prophylactic ursodeoxycholic acid and intravenous heparin. **2022**, ○
- 126 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). 4
- 125 Impact of lung function impairment after allogeneic hematopoietic stem cell transplantation. **2022**, 12,
- 124 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). 39
- 123 Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia. ○
- 122 Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial.
- 121 Reducing mortality of single-unit unrelated cord blood transplantation for relapsed acute myeloid leukemia after a previous allogeneic transplantation: a real-world retrospective study over the past 19 years in Japan. **2022**, 1
- 120 Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease. **2022**, ○
- 119 Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant. ○

- 118 Weight-adjusted urinary creatinine excretion predicts transplant outcomes in adult patients with acute myeloid leukemia in complete remission. 1-11 ○
- 117 Incidence and therapy of relapse after allogeneic hematopoietic stem cell transplantation. **2022**, 3, 334-345 ○
- 116 Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia. **2022**, 62, 175-180 ○
- 115 Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology. **2022**, 29, 6245-6259 ○
- 114 Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity. 1
- 113 Overall Survival Rate in Allogeneic Stem Cell Transplanted Patients Requiring Intensive Care Can Be Predicted by the Prognostic Index for Critically Ill Allogeneic Transplantation Patients (PICAT) and the Sequential Organ Failure Assessment (SOFA) Scores. **2022**, 14, 4266 ○
- 112 Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease among diabetes mellitus patients undergoing allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective study. ○
- 111 Outcomes of CD19 targeted CAR T-cell Therapy for Patients with Reduced Renal Function Including Dialysis. **2022**, ○
- 110 Allogeneic hematopoietic cell transplantation for patients with relapsed acute promyelocytic leukemia. **2022**, 1
- 109 Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities. ○
- 108 Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). ○
- 107 Intensity of Induction Regimen and Outcomes Among Adults with Ph+ ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. ○
- 106 Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study. 1-8 ○
- 105 Relationship Between Pre-Transplant Nutritional Status and Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. **2022**, ○
- 104 Pulmonary Function is a Strong Predictor of 2-year Overall Survival and Non-relapse Mortality after Allogeneic Hematopoietic Cell Transplantation. ○
- 103 Allogeneic haematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukaemia: A single-centre experience. **2022**, ○
- 102 A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older. 1
- 101 Is comprehensive geriatric testing guiding in the identification of multiple myeloma patients who are candidates for autologous stem cell transplantation? A prospective analysis. ○

100	Treatment of patients with acute lymphoblastic leukemia who are not suitable for high-dose chemotherapy and hematopoietic stem cell transplantation. <b>2022</b> , 75, 19-23	0
99	Hematopoietic Cell Transplantation. 1-13	0
98	Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non-remission acute myeloid leukaemia: A nationwide retrospective study.	1
97	Impact of Implementing a Bendamustine-based Conditioning Regimen on outcomes of Autologous Stem Cell Transplant in Lymphoma while Novel Cellular Therapies Emerge. <b>2022</b> ,	0
96	Stellenwert der allogenen Stammzelltransplantation bei AML. <b>2022</b> , 25, 10-17	0
95	Use of CD122+ natural killer cell precursors for superior anti-leukemia responses.	0
94	Cardiovascular screening prior to stem cell transplantation in the United Kingdom.	0
93	Bortezomib maintenance after allogeneic transplantation in newly diagnosed myeloma patients results in decreased incidence and severity of chronic GVHD. <b>2022</b> ,	0
92	Hematopoietic Stem Cell Transplantation in Refractory Crohn's Disease: Should It Be Considered?. <b>2022</b> , 11, 3463	0
91	Planning Your Next Move in Philadelphia Chromosome Positive Leukaemias. 36-43	0
90	Allogeneic stem cell transplantation in patients with a prior history of prostate cancer.	0
89	Clinical Dilemmas in the Treatment of Elderly Patients Suffering from Hodgkin Lymphoma: A Review. <b>2022</b> , 10, 2917	0
88	Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia.	0
87	Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation. <b>2022</b> , 12,	0
86	Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.	0
85	Optimizing antifungal prophylaxis in allogeneic stem cell transplantation: A cohort study of two different approaches.	0
84	Identifying the optimal conditioning intensity for stem cell transplantation in patients with myelodysplastic syndrome: a machine learning analysis.	0
83	Pre-Transplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation. <b>2022</b> ,	0

- 82 Risk stratification system for skin and soft tissue infections after allogeneic hematopoietic stem cell transplantation: PAH risk score. ○
- 81 Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience. **2022**, 14, 5587 ○
- 80 Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysis. ○
- 79 Referral to and receipt of allogeneic hematopoietic stem cell transplantation in older adults with acute myeloid leukemia. **2022**, ○
- 78 Cardiopulmonary Exercise Test With Comorbidity Index Before Allogeneic Hematopoietic Stem Cell Transplantation. **2022**, 21, 153473542211342 ○
- 77 Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. **2023**, 10, e59-e70 1
- 76 Infectious diarrhea after allogeneic hematopoietic cell transplantation assessed by a multiplex polymerase chain reaction assay. **2023**, 127, 17-22 ○
- 75 Management of Adult Patients with Myelodysplastic Syndromes. 104-112 ○
- 74 Levofloxacin prophylaxis vs no prophylaxis in neutropenic patients within an endemic country for carbapenem-resistant GNB. ○
- 73 Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review From the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. **2022**, ○
- 72 Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups. **2022**, 14, 5670 ○
- 71 Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases. **2022**, ○
- 70 Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation. **2022**, 17, ○
- 69 Old age: the crown of life, our play's last act. Question and answers on older patients undergoing allogeneic hematopoietic cell transplantation. **2023**, 30, 14-21 ○
- 68 Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation. **2022**, ○
- 67 EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide. ○
- 66 Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome. 1-10 ○
- 65 Impact of pre-transplant individual comorbidities on risk of ICU admission and survival outcomes following allogeneic hematopoietic stem cell transplantation. ○

- 64 Fitness and frailty in myeloma. **2022**, 2022, 337-348 ○
- 63 Newly diagnosed multiple myeloma: making sense of the menu. **2022**, 2022, 539-550 ○
- 62 Immune Response Serves as a Bridge between Abnormal Lipid and Bone Metabolism: A Differential Expression Genes Profile Analysis Based on Clinical Data-mining. ○
- 61 Outcomes of older adults with non-Hodgkin lymphoma undergoing autologous stem cell transplantation: a Mayo Clinic Cohort Analysis. **2022**, ○
- 60 Effect of the COVID-19 pandemic on allogeneic stem cell transplantation in Japan. ○
- 59 Lower probability of relapse after myeloablative cord blood transplantation for patients with refractory AML. ○
- 58 Impact of hematopoietic cell transplant frailty scale on transplant outcome in adults. ○
- 57 Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML. **2023**, 55, 388-400 ○
- 56 Exercise Therapy on Muscle Mass and Physical Function in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. **2022**, 163-190 ○
- 55 Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome-positive acute myeloid leukemia: A case report. **2023**, 11, ○
- 54 Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study. 13, ○
- 53 Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis. ○
- 52 IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. **2023**, ○
- 51 Peritransplant glucocorticoid haploidentical stem cell transplantation is a promising strategy for AML patients with high leukemic burden: Comparison with transplants using other donor types. **2023**, ○
- 50 N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia. **2023**, 98, 290-299 ○
- 49 Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia. **2023**, 15, 352 ○
- 48 Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation. **2023**, 125, 107004 ○
- 47 Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. ○

- 46 Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission. ○
- 45 Allogeneic Hematopoietic Stem Cell Transplantation in the Outpatient Setting: The Mayo Clinic Experience. **2022**, ○
- 44 Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥5 Years. **2022**, ○
- 43 T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia. **2023**, ○
- 42 Sarcopenia Predicts Inferior Progression Free Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation. **2023**, ○
- 41 The role of transplantation in Hodgkin lymphoma. 12, 1
- 40 Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis. **2023**, 7, e846 ○
- 39 Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores. ○
- 38 Deuxième allogreffe (mise à jour). Recommandations de la Société francophone de greffe de moelle osseuse et de thérapie cellulaire (SFGM-TC). **2023**, ○
- 37 Allogeneic hematopoietic cell transplantation in acute myeloid leukemia. **2023**, 36, 101466 ○
- 36 Cardio-oncology and transplantation for acute myeloid leukemia. **2023**, 101465 ○
- 35 Clinical Benefit of Low-Dose Antithymocyte Globulin-Thymoglobulin as Graft-versus-Host Disease Prophylaxis in Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation from HLA-Identical Donors. **2023**, ○
- 34 Screening Chest CT Prior to Allogeneic Hematopoietic Stem Cell Transplantation. **2023**, ○
- 33 Combining the HCT-CI, G8, and AML-Score for Fitness Evaluation of Elderly Patients with Acute Myeloid Leukemia: A Single Center Analysis. **2023**, 15, 1002 ○
- 32 Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. **2023**, ○
- 31 Unique Reduced-Intensity Conditioning Haploidentical Peripheral Blood Stem Cell Transplantation Protocol for Patients with Hematologic Malignancy. **2023**, ○
- 30 Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel. ○
- 29 Pre-transplant CRP/albumin ratio as a biomarker in patients receiving haploidentical allogeneic hematopoietic transplantation: Developing a novel DRCI-based nomogram. 14, ○



- 28 Determinants of refined GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies. **2023**, 127, 107052 ○
- 27 Emergency Department Utilization Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Longitudinal Analysis of 557 Patients. **2023**, ○
- 26 Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Therapy-Related Acute Myeloid Leukemia: a Retrospective Multicentre Study on behalf of the SFGM-TC. ○
- 25 Acute kidney injury in autologous hematopoietic stem cell transplant for patients with lymphoma □ KDIGO classification with creatinine and urinary output criteria: a cohort analysis. **2023**, 45, ○
- 24 The prognostic value of patient-reported outcomes in allogeneic hematopoietic stem cell transplantation: exploratory analysis of a randomized nutrition intervention trial. **2023**, 102, 927-935 ○
- 23 Clinical trial participation predicts improved survival in older adults receiving allogeneic blood and marrow transplant. **2023**, 23, ○
- 22 Assessing eligibility for treatment in acute myeloid leukemia in 2023. **2023**, 16, 181-190 ○
- 21 Effect of Graft-versus-Host Disease on Post-Transplantation Outcomes following Single Cord Blood Transplantation Compared with Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Adult Acute Myeloid Leukemia. **2023**, ○
- 20 Long-term outcomes of corticosteroid graft versus host disease prophylaxis in peripheral blood allogeneic haemopoietic stem cell transplant: a comparative cohort analysis. ○
- 19 DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. **2023**, 329, 745 ○
- 18 Bacterial Bloodstream Infections after Allogeneic Hematopoietic Stem Cell Transplantation: Etiology, Risk Factors and Outcome in a Single-Center Study. **2023**, 11, 742 ○
- 17 Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database. **2023**, 102, 1215-1227 ○
- 16 The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation. **2023**, 24, 5764 ○
- 15 Autoimmune manifestations in VEXAS: Opportunities for integration and pitfalls to interpretation. **2023**, ○
- 14 Addition of ATG to non-myeloablative peripheral blood haploidentical transplant with PTCY decreases acute GVHD rates and improves GVHD-relapse free survival. ○
- 13 Association Between Candidemia and Noninfectious Interstitial Pneumonia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group. **2023**, 10, ○
- 12 HLA Class I genotype is associated with relapse risk after allogeneic stem cell transplantation for NPM1-mutated AML. **2023**, ○
- 11 A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease. **2023**, ○

- 10 The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study. ○
- 9 Incidence, Etiology, Risk Factors, and Outcomes of Bloodstream Infection after a Second Hematopoietic Stem Cell Transplantation. **2023**, ○
- 8 Validating the G8 screening tool for determining the need for hematopoietic stem cell transplantation in elderly patients. **2023**, 12, 110-116 ○
- 7 Transplantation Through the Generations. **2023**, 155-183 ○
- 6 Transplant Preparation. **2023**, 53-75 ○
- 5 Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: a 10-year experience. ○
- 4 Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide. ○
- 3 CAR T in patients with large B-cell lymphoma not fit for autologous transplant. ○
- 2 Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect<sup>®</sup> Myeloid Disease Registry: Potential Barriers to Care. **2023**, ○
- 1 A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. **2023**, 3, ○